primaryid,caseid,drug_seq,role_cod,drugname,prod_ai,val_vbm,route,dose_vbm,cum_dose_chr,cum_dose_unit,dechal,rechal,lot_num,exp_dt,nda_num,dose_amt,dose_unit,dose_form,dose_freq,year_x,quarter_x,pt,drug_rec_act,year_y,quarter_y,caseversion,i_f_code,event_dt,mfr_dt,init_fda_dt,fda_dt,rept_cod,auth_num,mfr_num,mfr_sndr,lit_ref,age,age_cod,age_grp,sex,e_sub,wt,wt_cod,rept_dt,to_mfr,occp_cod,reporter_country,occr_country,year,quarter,age_group
130741527,13074152,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,,2019,Q1,Influenza like illness,,2019,Q1,7,F,20161024.0,20181214.0,20161230,20190117,EXP,,US-ROCHE-1870521,ROCHE,,50.0,YR,,F,Y,111.7,KG,20190117.0,,MD,US,US,2019,Q1,Adult
143158452,14315845,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,,,,,,2019,Q1,Euglycaemic diabetic ketoacidosis,,2019,Q1,2,F,,20190304.0,20171221,20190315,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-116052,BRISTOL MYERS SQUIBB,,67.0,YR,,M,Y,,,20190315.0,,MD,JP,JP,2019,Q1,Elderly
146380552,14638055,2,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Unknown,"100 MG, UNK",,,U,,,,,100.0,MG,,,2019,Q1,Euglycaemic diabetic ketoacidosis,,2019,Q1,2,F,,20190131.0,20180314,20190211,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-022466,BRISTOL MYERS SQUIBB,KATO. A CASE OF EUGLYCAUMIC DIABETIC KETOACIDOSIS CAUSED BY SODIUM-GLUCOSE LINKED TRANSPORTER 2 (SGLT2) INHIBITOR THAT WAS USED DURING CARBOHYDRATE-RESTRICTED DIET THERAPY.. PROGRAMME AND ABSTRACTS OF THE PAPERS FOR THE 55TH LOCAL MEETING OF THE KANTO KO. 2018;82,44.0,YR,,M,Y,,,20190211.0,,OT,JP,JP,2019,Q1,Adult
154113132,15411313,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2019,Q1,Drug hypersensitivity,,2019,Q1,2,F,,20190104.0,20180921,20190109,PER,,US-PFIZER INC-2018380693,PFIZER,,62.0,YR,,M,Y,,,20190109.0,,MD,US,US,2019,Q1,Adult
155679855,15567985,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2019,Q1,Hypotension,,2019,Q1,5,F,20180725.0,20181119.0,20181030,20190205,EXP,,PHHY2018PT136253,NOVARTIS,,68.0,YR,,M,Y,,,20190205.0,,MD,PT,PT,2019,Q1,Elderly
155679855,15567985,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2019,Q1,Lower respiratory tract infection,,2019,Q1,5,F,20180725.0,20181119.0,20181030,20190205,EXP,,PHHY2018PT136253,NOVARTIS,,68.0,YR,,M,Y,,,20190205.0,,MD,PT,PT,2019,Q1,Elderly
155679855,15567985,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2019,Q1,Oedema peripheral,,2019,Q1,5,F,20180725.0,20181119.0,20181030,20190205,EXP,,PHHY2018PT136253,NOVARTIS,,68.0,YR,,M,Y,,,20190205.0,,MD,PT,PT,2019,Q1,Elderly
157593414,15759341,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"360 MG, UNK",,,U,,,,,360.0,MG,,,2019,Q1,Enterocolitis,,2019,Q1,4,F,20181013.0,20190116.0,20181226,20190117,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-096952,BRISTOL MYERS SQUIBB,,59.0,YR,,M,Y,91.0,KG,20190117.0,,OT,CA,CA,2019,Q1,Adult
157593414,15759341,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"360 MG, UNK",,,U,,,,,360.0,MG,,,2019,Q1,Gastritis,,2019,Q1,4,F,20181013.0,20190116.0,20181226,20190117,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-096952,BRISTOL MYERS SQUIBB,,59.0,YR,,M,Y,91.0,KG,20190117.0,,OT,CA,CA,2019,Q1,Adult
157862801,15786280,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,,,TABLET,,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,,20181226.0,20190103,20190103,EXP,,GB-JNJFOC-20181234075,JANSSEN,"SLOAN G, KAKOUDAKI T, RANJAN N. PROLONGED DIABETIC KETOACIDOSIS ASSOCIATED WITH CANAGLIFLOZIN. ENDOCRINOLOGY, DIABETES AND METABOLISM CASE REPORTS 2018;1.",63.0,YR,A,M,Y,,,20190103.0,,OT,GB,GB,2019,Q1,Adult
157943821,15794382,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,,20190104.0,20190107,20190107,EXP,GB-MHRA-EYC 00191397,GB-JNJFOC-20190104419,JANSSEN,,79.0,YR,E,M,Y,74.0,KG,20190107.0,,PH,GB,GB,2019,Q1,Elderly
157988951,15798895,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,150.0,MG,TABLET,,2019,Q1,Incorrect dose administered,,2019,Q1,1,I,,20190102.0,20190108,20190108,EXP,,US-JNJFOC-20190106514,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",26.0,YR,A,F,Y,,,20190108.0,,MD,US,US,2019,Q1,Young Adult
157988951,15798895,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,150.0,MG,TABLET,,2019,Q1,Ketoacidosis,,2019,Q1,1,I,,20190102.0,20190108,20190108,EXP,,US-JNJFOC-20190106514,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",26.0,YR,A,F,Y,,,20190108.0,,MD,US,US,2019,Q1,Young Adult
157988951,15798895,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,150.0,MG,TABLET,,2019,Q1,Off label use,,2019,Q1,1,I,,20190102.0,20190108,20190108,EXP,,US-JNJFOC-20190106514,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",26.0,YR,A,F,Y,,,20190108.0,,MD,US,US,2019,Q1,Young Adult
157988951,15798895,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,150.0,MG,TABLET,,2019,Q1,Product use in unapproved indication,,2019,Q1,1,I,,20190102.0,20190108,20190108,EXP,,US-JNJFOC-20190106514,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",26.0,YR,A,F,Y,,,20190108.0,,MD,US,US,2019,Q1,Young Adult
158009371,15800937,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,UNKNOWN,,2019,Q1,Hepatitis,,2019,Q1,1,I,20180823.0,20181023.0,20190109,20190109,EXP,ES-AEMPS-412098,ES-ZYDUS-029553,ZYDUS PHARM,,75.0,YR,E,F,Y,,,20190107.0,,MD,ES,ES,2019,Q1,Elderly
158079851,15807985,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,,20190108.0,20190110,20190110,EXP,GB-MHRA-EYC 00191848,GB-JNJFOC-20190109758,JANSSEN,,59.0,YR,A,M,Y,,,20190110.0,,OT,GB,GB,2019,Q1,Adult
158079861,15807986,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,,20190108.0,20190110,20190110,EXP,GB-MHRA-ADR 24367247,GB-JNJFOC-20190110045,JANSSEN,,62.0,YR,A,F,Y,,,20190110.0,,PH,GB,GB,2019,Q1,Adult
158079871,15807987,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,N,,,204042.0,,,TABLET,,2019,Q1,Vulval cancer,,2019,Q1,1,I,20180912.0,20190108.0,20190110,20190110,EXP,GB-MHRA-ADR 24366196,GB-JNJFOC-20190109846,JANSSEN,,56.0,YR,A,F,Y,,,20190110.0,,MD,GB,GB,2019,Q1,Adult
158079881,15807988,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,,,TABLET,,2019,Q1,Hallucination,,2019,Q1,1,I,20180417.0,20190108.0,20190110,20190110,EXP,GB-MHRA-EYC 00192281,GB-JNJFOC-20190110064,JANSSEN,,62.0,YR,A,F,Y,72.0,KG,20190110.0,,PH,GB,GB,2019,Q1,Adult
158079881,15807988,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,,,TABLET,,2019,Q1,Nervousness,,2019,Q1,1,I,20180417.0,20190108.0,20190110,20190110,EXP,GB-MHRA-EYC 00192281,GB-JNJFOC-20190110064,JANSSEN,,62.0,YR,A,F,Y,72.0,KG,20190110.0,,PH,GB,GB,2019,Q1,Adult
158079881,15807988,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,,,TABLET,,2019,Q1,Psychotic disorder,,2019,Q1,1,I,20180417.0,20190108.0,20190110,20190110,EXP,GB-MHRA-EYC 00192281,GB-JNJFOC-20190110064,JANSSEN,,62.0,YR,A,F,Y,72.0,KG,20190110.0,,PH,GB,GB,2019,Q1,Adult
158081111,15808111,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,300.0,MG,TABLET,,2019,Q1,Ketoacidosis,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106499,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",40.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Adult
158081111,15808111,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,300.0,MG,TABLET,,2019,Q1,Off label use,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106499,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",40.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Adult
158081111,15808111,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,300.0,MG,TABLET,,2019,Q1,Product use in unapproved indication,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106499,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",40.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Adult
158081121,15808112,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,300.0,MG,TABLET,,2019,Q1,Ketoacidosis,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106513,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",55.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Adult
158081121,15808112,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,300.0,MG,TABLET,,2019,Q1,Off label use,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106513,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",55.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Adult
158081121,15808112,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,300.0,MG,TABLET,,2019,Q1,Product use in unapproved indication,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106513,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",55.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Adult
158081131,15808113,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,300.0,MG,TABLET,,2019,Q1,Ketoacidosis,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106510,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",27.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Young Adult
158081131,15808113,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,300.0,MG,TABLET,,2019,Q1,Off label use,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106510,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",27.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Young Adult
158081131,15808113,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,300.0,MG,TABLET,,2019,Q1,Product use in unapproved indication,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106510,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",27.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Young Adult
158081131,15808113,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,100.0,MG,TABLET,,2019,Q1,Ketoacidosis,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106510,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",27.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Young Adult
158081131,15808113,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,100.0,MG,TABLET,,2019,Q1,Off label use,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106510,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",27.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Young Adult
158081131,15808113,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,100.0,MG,TABLET,,2019,Q1,Product use in unapproved indication,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106510,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",27.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Young Adult
158081141,15808114,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,300.0,MG,TABLET,,2019,Q1,Ketoacidosis,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106509,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",58.0,YR,A,M,Y,,,20190110.0,,MD,US,US,2019,Q1,Adult
158081151,15808115,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,,,TABLET,,2019,Q1,Ketoacidosis,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190105160,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",58.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Adult
158081161,15808116,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,300.0,MG,TABLET,,2019,Q1,Ketoacidosis,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106511,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",28.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Young Adult
158081161,15808116,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,300.0,MG,TABLET,,2019,Q1,Off label use,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106511,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",28.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Young Adult
158081161,15808116,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,300.0,MG,TABLET,,2019,Q1,Product use in unapproved indication,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106511,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",28.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Young Adult
158081161,15808116,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,100.0,MG,TABLET,,2019,Q1,Ketoacidosis,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106511,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",28.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Young Adult
158081161,15808116,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,100.0,MG,TABLET,,2019,Q1,Off label use,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106511,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",28.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Young Adult
158081161,15808116,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,100.0,MG,TABLET,,2019,Q1,Product use in unapproved indication,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106511,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",28.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Young Adult
158081171,15808117,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,300.0,MG,TABLET,,2019,Q1,Ketoacidosis,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106516,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",64.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Adult
158081181,15808118,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,300.0,MG,TABLET,,2019,Q1,Ketoacidosis,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106512,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",31.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Young Adult
158081181,15808118,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,300.0,MG,TABLET,,2019,Q1,Off label use,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106512,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",31.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Young Adult
158081181,15808118,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,300.0,MG,TABLET,,2019,Q1,Product use in unapproved indication,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106512,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",31.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Young Adult
158081191,15808119,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,300.0,MG,TABLET,,2019,Q1,Ketoacidosis,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106515,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",39.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Adult
158081191,15808119,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,300.0,MG,TABLET,,2019,Q1,Off label use,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106515,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",39.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Adult
158081191,15808119,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,300.0,MG,TABLET,,2019,Q1,Product use in unapproved indication,,2019,Q1,1,I,,20190102.0,20190110,20190110,EXP,,US-JNJFOC-20190106515,JANSSEN,"MASUTA P, JOHRI G, PAUL M. SGLT2 INHIBITORS AND EUGLYCEMIC KETOACIDOSIS. AMERICAN JOURNAL OF THERAPEUTICS 2018;25/4:E498-500.",39.0,YR,A,F,Y,,,20190110.0,,MD,US,US,2019,Q1,Adult
158204281,15820428,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2019,Q1,Peripheral ischaemia,,2019,Q1,1,I,20181102.0,20190110.0,20190114,20190114,EXP,GB-MHRA-EYC 00192602,GB-JNJFOC-20190112441,JANSSEN,,65.0,YR,A,M,Y,,,20190114.0,,MD,GB,GB,2019,Q1,Elderly
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Adverse drug reaction,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Arthralgia,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Arthritis,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Blood creatinine decreased,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Blood uric acid decreased,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Drug effect decreased,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Drug effect incomplete,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Drug ineffective,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Gastrointestinal haemorrhage,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Glycosylated haemoglobin increased,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Haemoglobin decreased,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Hepatic cirrhosis,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Hepatosplenomegaly,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Hypertrophy,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Inflammatory marker increased,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Joint effusion,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Joint swelling,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Liver disorder,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Low density lipoprotein increased,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Nausea,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Non-alcoholic fatty liver,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Pain in extremity,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Psoriasis,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Red blood cell sedimentation rate increased,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158468131,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q1,Varices oesophageal,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20190121.0,,MD,CA,CA,2019,Q1,Adult
158477571,15847757,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2019,Q1,Blood creatinine decreased,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001252,TEVA,,47.0,YR,,F,Y,,,20190121.0,,CN,CA,CA,2019,Q1,Adult
158477571,15847757,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2019,Q1,Blood uric acid decreased,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001252,TEVA,,47.0,YR,,F,Y,,,20190121.0,,CN,CA,CA,2019,Q1,Adult
158477571,15847757,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2019,Q1,Drug ineffective,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001252,TEVA,,47.0,YR,,F,Y,,,20190121.0,,CN,CA,CA,2019,Q1,Adult
158477571,15847757,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2019,Q1,Gastrointestinal haemorrhage,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001252,TEVA,,47.0,YR,,F,Y,,,20190121.0,,CN,CA,CA,2019,Q1,Adult
158477571,15847757,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2019,Q1,Hepatic cirrhosis,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001252,TEVA,,47.0,YR,,F,Y,,,20190121.0,,CN,CA,CA,2019,Q1,Adult
158477571,15847757,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2019,Q1,Hepatosplenomegaly,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001252,TEVA,,47.0,YR,,F,Y,,,20190121.0,,CN,CA,CA,2019,Q1,Adult
158477571,15847757,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2019,Q1,Liver disorder,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001252,TEVA,,47.0,YR,,F,Y,,,20190121.0,,CN,CA,CA,2019,Q1,Adult
158477571,15847757,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2019,Q1,Low density lipoprotein increased,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001252,TEVA,,47.0,YR,,F,Y,,,20190121.0,,CN,CA,CA,2019,Q1,Adult
158477571,15847757,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2019,Q1,Non-alcoholic fatty liver,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001252,TEVA,,47.0,YR,,F,Y,,,20190121.0,,CN,CA,CA,2019,Q1,Adult
158477571,15847757,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2019,Q1,Psoriasis,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001252,TEVA,,47.0,YR,,F,Y,,,20190121.0,,CN,CA,CA,2019,Q1,Adult
158477571,15847757,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2019,Q1,Psoriatic arthropathy,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001252,TEVA,,47.0,YR,,F,Y,,,20190121.0,,CN,CA,CA,2019,Q1,Adult
158477571,15847757,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2019,Q1,Rheumatoid arthritis,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001252,TEVA,,47.0,YR,,F,Y,,,20190121.0,,CN,CA,CA,2019,Q1,Adult
158477571,15847757,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2019,Q1,Type 2 diabetes mellitus,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001252,TEVA,,47.0,YR,,F,Y,,,20190121.0,,CN,CA,CA,2019,Q1,Adult
158477571,15847757,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2019,Q1,Varices oesophageal,,2019,Q1,1,I,,20190115.0,20190121,20190121,EXP,,CA-TEVA-2019-CA-1001252,TEVA,,47.0,YR,,F,Y,,,20190121.0,,CN,CA,CA,2019,Q1,Adult
158576651,15857665,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,,,TABLET,,2019,Q1,Euglycaemic diabetic ketoacidosis,,2019,Q1,1,I,,20190118.0,20190123,20190123,EXP,GB-MHRA-EYC 00193007,GB-JNJFOC-20190128056,JANSSEN,,57.0,YR,A,M,Y,90.0,KG,20190123.0,,MD,GB,GB,2019,Q1,Adult
158670231,15867023,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,PREFERABLY BEFORE BREAKFAST,,,,,,,,300.0,MG,TABLET,,2019,Q1,Constipation,,2019,Q1,1,I,,20190121.0,20190125,20190125,EXP,GB-MHRA-ADR 24307115,GB-ACCORD-103558,ACCORD,,56.0,YR,,M,Y,,,20190125.0,,PH,GB,GB,2019,Q1,Adult
158670231,15867023,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,PREFERABLY BEFORE BREAKFAST,,,,,,,,300.0,MG,TABLET,,2019,Q1,Epistaxis,,2019,Q1,1,I,,20190121.0,20190125,20190125,EXP,GB-MHRA-ADR 24307115,GB-ACCORD-103558,ACCORD,,56.0,YR,,M,Y,,,20190125.0,,PH,GB,GB,2019,Q1,Adult
158820503,15882050,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,, UNKNOWN,,,,,,,2019,Q1,Asthenia,,2019,Q1,3,F,20180719.0,20190128.0,20190128,20190201,EXP,,PHHY2019PT018602,NOVARTIS,,68.0,YR,,M,Y,80.0,KG,20190201.0,,OT,PT,PT,2019,Q1,Elderly
158820503,15882050,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,, UNKNOWN,,,,,,,2019,Q1,Decreased appetite,,2019,Q1,3,F,20180719.0,20190128.0,20190128,20190201,EXP,,PHHY2019PT018602,NOVARTIS,,68.0,YR,,M,Y,80.0,KG,20190201.0,,OT,PT,PT,2019,Q1,Elderly
158820503,15882050,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,, UNKNOWN,,,,,,,2019,Q1,Heart rate decreased,,2019,Q1,3,F,20180719.0,20190128.0,20190128,20190201,EXP,,PHHY2019PT018602,NOVARTIS,,68.0,YR,,M,Y,80.0,KG,20190201.0,,OT,PT,PT,2019,Q1,Elderly
158820503,15882050,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,, UNKNOWN,,,,,,,2019,Q1,Hypotension,,2019,Q1,3,F,20180719.0,20190128.0,20190128,20190201,EXP,,PHHY2019PT018602,NOVARTIS,,68.0,YR,,M,Y,80.0,KG,20190201.0,,OT,PT,PT,2019,Q1,Elderly
158820503,15882050,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,, UNKNOWN,,,,,,,2019,Q1,Medication error,,2019,Q1,3,F,20180719.0,20190128.0,20190128,20190201,EXP,,PHHY2019PT018602,NOVARTIS,,68.0,YR,,M,Y,80.0,KG,20190201.0,,OT,PT,PT,2019,Q1,Elderly
158820503,15882050,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,, UNKNOWN,,,,,,,2019,Q1,Oedema peripheral,,2019,Q1,3,F,20180719.0,20190128.0,20190128,20190201,EXP,,PHHY2019PT018602,NOVARTIS,,68.0,YR,,M,Y,80.0,KG,20190201.0,,OT,PT,PT,2019,Q1,Elderly
158853321,15885332,5,C,INVOKANA CANAGLIFLOZIN HEMIHYDRATE,,2,,UNK,,,,,,,,,,,,2019,Q1,Injury associated with device,,2019,Q1,1,I,20190123.0,20190124.0,20190129,20190129,PER,,US-ELI_LILLY_AND_COMPANY-US201901012599,ELI LILLY AND CO,,46.0,YR,,F,Y,,,20190129.0,,CN,US,US,2019,Q1,Adult
158853321,15885332,5,C,INVOKANA CANAGLIFLOZIN HEMIHYDRATE,,2,,UNK,,,,,,,,,,,,2019,Q1,Product dose omission,,2019,Q1,1,I,20190123.0,20190124.0,20190129,20190129,PER,,US-ELI_LILLY_AND_COMPANY-US201901012599,ELI LILLY AND CO,,46.0,YR,,F,Y,,,20190129.0,,CN,US,US,2019,Q1,Adult
158909841,15890984,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,,,TABLET,,2019,Q1,Ketoacidosis,,2019,Q1,1,I,20180829.0,20190128.0,20190130,20190130,EXP,GB-MHRA-EYC 00193329,GB-JNJFOC-20190137166,JANSSEN,,64.0,YR,A,F,Y,80.0,KG,20190130.0,,MD,GB,GB,2019,Q1,Adult
159076601,15907660,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2019,Q1,Euglycaemic diabetic ketoacidosis,,2019,Q1,1,I,,20190201.0,20190204,20190204,EXP,GB-MHRA-EYC 00193574,GB-JNJFOC-20190202178,JANSSEN,,39.0,YR,A,M,Y,,,20190204.0,,PH,GB,GB,2019,Q1,Adult
159209102,15920910,5,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,"100 MG, QD (AFTER BREAKFAST)",,,U,,,,,100.0,MG,TABLET,QD,2019,Q1,Atrial fibrillation,,2019,Q1,2,F,,20190206.0,20190205,20190210,EXP,,GXJP2019JP000510,SANDOZ,OGAWA RYUICHI. CARDIOVASCULAR DISEASE 5 CHRONIC CARDIAC FAILURE. THE PHARMACEUTICALS MONTHLY. 2018;60(14):2536-42,68.0,YR,,F,Y,65.0,KG,20190211.0,,OT,JP,JP,2019,Q1,Elderly
159209102,15920910,5,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,"100 MG, QD (AFTER BREAKFAST)",,,U,,,,,100.0,MG,TABLET,QD,2019,Q1,Cardiac failure,,2019,Q1,2,F,,20190206.0,20190205,20190210,EXP,,GXJP2019JP000510,SANDOZ,OGAWA RYUICHI. CARDIOVASCULAR DISEASE 5 CHRONIC CARDIAC FAILURE. THE PHARMACEUTICALS MONTHLY. 2018;60(14):2536-42,68.0,YR,,F,Y,65.0,KG,20190211.0,,OT,JP,JP,2019,Q1,Elderly
159209102,15920910,5,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,"100 MG, QD (AFTER BREAKFAST)",,,U,,,,,100.0,MG,TABLET,QD,2019,Q1,Dyspnoea,,2019,Q1,2,F,,20190206.0,20190205,20190210,EXP,,GXJP2019JP000510,SANDOZ,OGAWA RYUICHI. CARDIOVASCULAR DISEASE 5 CHRONIC CARDIAC FAILURE. THE PHARMACEUTICALS MONTHLY. 2018;60(14):2536-42,68.0,YR,,F,Y,65.0,KG,20190211.0,,OT,JP,JP,2019,Q1,Elderly
159209102,15920910,5,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,"100 MG, QD (AFTER BREAKFAST)",,,U,,,,,100.0,MG,TABLET,QD,2019,Q1,Left ventricular hypertrophy,,2019,Q1,2,F,,20190206.0,20190205,20190210,EXP,,GXJP2019JP000510,SANDOZ,OGAWA RYUICHI. CARDIOVASCULAR DISEASE 5 CHRONIC CARDIAC FAILURE. THE PHARMACEUTICALS MONTHLY. 2018;60(14):2536-42,68.0,YR,,F,Y,65.0,KG,20190211.0,,OT,JP,JP,2019,Q1,Elderly
159209102,15920910,5,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,"100 MG, QD (AFTER BREAKFAST)",,,U,,,,,100.0,MG,TABLET,QD,2019,Q1,Oedema peripheral,,2019,Q1,2,F,,20190206.0,20190205,20190210,EXP,,GXJP2019JP000510,SANDOZ,OGAWA RYUICHI. CARDIOVASCULAR DISEASE 5 CHRONIC CARDIAC FAILURE. THE PHARMACEUTICALS MONTHLY. 2018;60(14):2536-42,68.0,YR,,F,Y,65.0,KG,20190211.0,,OT,JP,JP,2019,Q1,Elderly
159209102,15920910,5,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,"100 MG, QD (AFTER BREAKFAST)",,,U,,,,,100.0,MG,TABLET,QD,2019,Q1,Pleural effusion,,2019,Q1,2,F,,20190206.0,20190205,20190210,EXP,,GXJP2019JP000510,SANDOZ,OGAWA RYUICHI. CARDIOVASCULAR DISEASE 5 CHRONIC CARDIAC FAILURE. THE PHARMACEUTICALS MONTHLY. 2018;60(14):2536-42,68.0,YR,,F,Y,65.0,KG,20190211.0,,OT,JP,JP,2019,Q1,Elderly
159457141,15945714,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,N,D,,,,300.0,MG,,QD,2019,Q1,Acute myocardial infarction,,2019,Q1,1,I,20190131.0,,20190212,20190212,DIR,,,FDA-CTU,,49.0,YR,,F,N,119.0,KG,20190212.0,N,PH,US,US,2019,Q1,Adult
159457141,15945714,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,N,D,,,,300.0,MG,,QD,2019,Q1,Cellulitis,,2019,Q1,1,I,20190131.0,,20190212,20190212,DIR,,,FDA-CTU,,49.0,YR,,F,N,119.0,KG,20190212.0,N,PH,US,US,2019,Q1,Adult
159457141,15945714,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,N,D,,,,300.0,MG,,QD,2019,Q1,Diabetic complication,,2019,Q1,1,I,20190131.0,,20190212,20190212,DIR,,,FDA-CTU,,49.0,YR,,F,N,119.0,KG,20190212.0,N,PH,US,US,2019,Q1,Adult
159457141,15945714,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,N,D,,,,300.0,MG,,QD,2019,Q1,Diabetic foot infection,,2019,Q1,1,I,20190131.0,,20190212,20190212,DIR,,,FDA-CTU,,49.0,YR,,F,N,119.0,KG,20190212.0,N,PH,US,US,2019,Q1,Adult
159457141,15945714,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,N,D,,,,300.0,MG,,QD,2019,Q1,Euglycaemic diabetic ketoacidosis,,2019,Q1,1,I,20190131.0,,20190212,20190212,DIR,,,FDA-CTU,,49.0,YR,,F,N,119.0,KG,20190212.0,N,PH,US,US,2019,Q1,Adult
159457141,15945714,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,N,D,,,,300.0,MG,,QD,2019,Q1,Leg amputation,,2019,Q1,1,I,20190131.0,,20190212,20190212,DIR,,,FDA-CTU,,49.0,YR,,F,N,119.0,KG,20190212.0,N,PH,US,US,2019,Q1,Adult
159457141,15945714,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,N,D,,,,300.0,MG,,QD,2019,Q1,Mental status changes,,2019,Q1,1,I,20190131.0,,20190212,20190212,DIR,,,FDA-CTU,,49.0,YR,,F,N,119.0,KG,20190212.0,N,PH,US,US,2019,Q1,Adult
159457141,15945714,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,N,D,,,,300.0,MG,,QD,2019,Q1,Necrotising fasciitis,,2019,Q1,1,I,20190131.0,,20190212,20190212,DIR,,,FDA-CTU,,49.0,YR,,F,N,119.0,KG,20190212.0,N,PH,US,US,2019,Q1,Adult
159457141,15945714,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,N,D,,,,300.0,MG,,QD,2019,Q1,Staphylococcal infection,,2019,Q1,1,I,20190131.0,,20190212,20190212,DIR,,,FDA-CTU,,49.0,YR,,F,N,119.0,KG,20190212.0,N,PH,US,US,2019,Q1,Adult
159526943,15952694,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q1,Alopecia,,2019,Q1,3,F,20180118.0,20190322.0,20190212,20190328,PER,,US-PFIZER INC-2019058581,PFIZER,,50.0,YR,,F,Y,,,20190328.0,,LW,US,US,2019,Q1,Adult
159526943,15952694,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q1,Hair colour changes,,2019,Q1,3,F,20180118.0,20190322.0,20190212,20190328,PER,,US-PFIZER INC-2019058581,PFIZER,,50.0,YR,,F,Y,,,20190328.0,,LW,US,US,2019,Q1,Adult
159526943,15952694,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q1,Hair disorder,,2019,Q1,3,F,20180118.0,20190322.0,20190212,20190328,PER,,US-PFIZER INC-2019058581,PFIZER,,50.0,YR,,F,Y,,,20190328.0,,LW,US,US,2019,Q1,Adult
159526943,15952694,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q1,Hair texture abnormal,,2019,Q1,3,F,20180118.0,20190322.0,20190212,20190328,PER,,US-PFIZER INC-2019058581,PFIZER,,50.0,YR,,F,Y,,,20190328.0,,LW,US,US,2019,Q1,Adult
159526943,15952694,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q1,Madarosis,,2019,Q1,3,F,20180118.0,20190322.0,20190212,20190328,PER,,US-PFIZER INC-2019058581,PFIZER,,50.0,YR,,F,Y,,,20190328.0,,LW,US,US,2019,Q1,Adult
159579701,15957970,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q1,Asthenia,,2019,Q1,1,I,20180719.0,20190207.0,20190213,20190213,EXP,PT-INFARMED-M201901-398,PT-PFIZER INC-2019059739,PFIZER,,68.0,YR,,M,Y,80.0,KG,20190213.0,,PH,PT,PT,2019,Q1,Elderly
159579701,15957970,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q1,Cardiac failure,,2019,Q1,1,I,20180719.0,20190207.0,20190213,20190213,EXP,PT-INFARMED-M201901-398,PT-PFIZER INC-2019059739,PFIZER,,68.0,YR,,M,Y,80.0,KG,20190213.0,,PH,PT,PT,2019,Q1,Elderly
159579701,15957970,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q1,Decreased appetite,,2019,Q1,1,I,20180719.0,20190207.0,20190213,20190213,EXP,PT-INFARMED-M201901-398,PT-PFIZER INC-2019059739,PFIZER,,68.0,YR,,M,Y,80.0,KG,20190213.0,,PH,PT,PT,2019,Q1,Elderly
159579701,15957970,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q1,Drug interaction,,2019,Q1,1,I,20180719.0,20190207.0,20190213,20190213,EXP,PT-INFARMED-M201901-398,PT-PFIZER INC-2019059739,PFIZER,,68.0,YR,,M,Y,80.0,KG,20190213.0,,PH,PT,PT,2019,Q1,Elderly
159579701,15957970,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q1,Heart rate decreased,,2019,Q1,1,I,20180719.0,20190207.0,20190213,20190213,EXP,PT-INFARMED-M201901-398,PT-PFIZER INC-2019059739,PFIZER,,68.0,YR,,M,Y,80.0,KG,20190213.0,,PH,PT,PT,2019,Q1,Elderly
159579701,15957970,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q1,Hypotension,,2019,Q1,1,I,20180719.0,20190207.0,20190213,20190213,EXP,PT-INFARMED-M201901-398,PT-PFIZER INC-2019059739,PFIZER,,68.0,YR,,M,Y,80.0,KG,20190213.0,,PH,PT,PT,2019,Q1,Elderly
159579701,15957970,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q1,Medication error,,2019,Q1,1,I,20180719.0,20190207.0,20190213,20190213,EXP,PT-INFARMED-M201901-398,PT-PFIZER INC-2019059739,PFIZER,,68.0,YR,,M,Y,80.0,KG,20190213.0,,PH,PT,PT,2019,Q1,Elderly
159579701,15957970,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q1,Oedema peripheral,,2019,Q1,1,I,20180719.0,20190207.0,20190213,20190213,EXP,PT-INFARMED-M201901-398,PT-PFIZER INC-2019059739,PFIZER,,68.0,YR,,M,Y,80.0,KG,20190213.0,,PH,PT,PT,2019,Q1,Elderly
159669681,15966968,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,MORNING PREFERABLY BEFORE BREAKFAST. TAKEN FOR ATLEAST 2 YEARS,,,,N,,,204042.0,100.0,MG,TABLET,,2019,Q1,Bladder cancer,,2019,Q1,1,I,,20190213.0,20190215,20190215,EXP,GB-MHRA-MIDB-52D193F3-6CA2-4844-92BE-C36E23A4D04B,GB-JNJFOC-20190218173,JANSSEN,,72.0,YR,E,M,Y,,,20190215.0,,PH,GB,GB,2019,Q1,Elderly
159874341,15987434,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2019,Q1,Euglycaemic diabetic ketoacidosis,,2019,Q1,1,I,20190131.0,20190218.0,20190220,20190220,EXP,GB-MHRA-EYC 00194432,GB-JNJFOC-20190224392,JANSSEN,,90.0,YR,E,F,Y,,,20190220.0,,MD,GB,GB,2019,Q1,Elderly
159920421,15992042,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,100.0,MG,TABLET,,2019,Q1,Bacteraemia,,2019,Q1,1,I,,20190219.0,20190221,20190221,EXP,,IN-JNJFOC-20190226451,JANSSEN,"GUPTA R, GHOSH A, MISRA A. CASE OF ACUTE UNILATERAL EMPHYSEMATOUS PYELONEPHRITIS AND BACTERAEMIA ON TREATMENT WITH CANAGLIFLOZIN. POSTGRADUATE MEDICAL JOURNAL 01-DEC-2018;94 (1118):714-715.",59.0,YR,A,F,Y,,,20190221.0,,MD,IN,IN,2019,Q1,Adult
159920421,15992042,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,100.0,MG,TABLET,,2019,Q1,Emphysematous pyelonephritis,,2019,Q1,1,I,,20190219.0,20190221,20190221,EXP,,IN-JNJFOC-20190226451,JANSSEN,"GUPTA R, GHOSH A, MISRA A. CASE OF ACUTE UNILATERAL EMPHYSEMATOUS PYELONEPHRITIS AND BACTERAEMIA ON TREATMENT WITH CANAGLIFLOZIN. POSTGRADUATE MEDICAL JOURNAL 01-DEC-2018;94 (1118):714-715.",59.0,YR,A,F,Y,,,20190221.0,,MD,IN,IN,2019,Q1,Adult
159970721,15997072,2,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q1,Glycosylated haemoglobin increased,,2019,Q1,1,I,201812.0,20190218.0,20190222,20190222,PER,,US-ELI_LILLY_AND_COMPANY-US201902008713,ELI LILLY AND CO,,50.0,YR,,M,Y,,,20190222.0,,CN,US,US,2019,Q1,Adult
159970721,15997072,2,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q1,Product dose omission,,2019,Q1,1,I,201812.0,20190218.0,20190222,20190222,PER,,US-ELI_LILLY_AND_COMPANY-US201902008713,ELI LILLY AND CO,,50.0,YR,,M,Y,,,20190222.0,,CN,US,US,2019,Q1,Adult
160196401,16019640,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,CUMULATIVE DOSE TO FIRST REACTION(NO.)??6000,,,Y,N,,,204042.0,100.0,MG,TABLET,,2019,Q1,Dry skin,,2019,Q1,1,I,20190101.0,20190227.0,20190228,20190228,EXP,GB-MHRA-TPP27888600C4549363YC1549887529993,GB-JNJFOC-20190240053,JANSSEN,,69.0,YR,E,F,Y,97.0,KG,20190228.0,,MD,GB,GB,2019,Q1,Elderly
160196401,16019640,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,CUMULATIVE DOSE TO FIRST REACTION(NO.)??6000,,,Y,N,,,204042.0,100.0,MG,TABLET,,2019,Q1,Pain in extremity,,2019,Q1,1,I,20190101.0,20190227.0,20190228,20190228,EXP,GB-MHRA-TPP27888600C4549363YC1549887529993,GB-JNJFOC-20190240053,JANSSEN,,69.0,YR,E,F,Y,97.0,KG,20190228.0,,MD,GB,GB,2019,Q1,Elderly
160232403,16023240,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q1,Acute myocardial infarction,,2019,Q1,3,F,,20190314.0,20190301,20190321,EXP,,JP-009507513-1902JPN011985,MERCK,"SHIMADA K, ET AL.. A CASE OF EUGLYCAEMIC DIABETIC KETOACIDOSIS THAT WAS TRIGGERED BY ACUTE MYOCARDIAL INFARCTION DURING THERAPY WITH SGLT2 INHIBITORS.. THE 56TH KANTO-KOSHINETSU REGIONAL MEETING OF THE JAPAN DIABETES SOCIETY. 2019;O-094",59.0,YR,,F,Y,,,20190321.0,,MD,JP,JP,2019,Q1,Adult
160232403,16023240,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q1,Euglycaemic diabetic ketoacidosis,,2019,Q1,3,F,,20190314.0,20190301,20190321,EXP,,JP-009507513-1902JPN011985,MERCK,"SHIMADA K, ET AL.. A CASE OF EUGLYCAEMIC DIABETIC KETOACIDOSIS THAT WAS TRIGGERED BY ACUTE MYOCARDIAL INFARCTION DURING THERAPY WITH SGLT2 INHIBITORS.. THE 56TH KANTO-KOSHINETSU REGIONAL MEETING OF THE JAPAN DIABETES SOCIETY. 2019;O-094",59.0,YR,,F,Y,,,20190321.0,,MD,JP,JP,2019,Q1,Adult
160235811,16023581,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,ON CANAGLIFLOZIN FOR 14 MONTHS PRIOR TO CURRENT PRESENTATION,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2019,Q1,Candiduria,,2019,Q1,1,I,,20190226.0,20190301,20190301,EXP,,US-JNJFOC-20190239029,JANSSEN,"RAJ R, HENDRIE J, JACOB A, ADAMS D. CANDIDEMIA FOLLOWING URETERIC STENT PLACEMENT IN A PATIENT WITH TYPE 2 DIABETES TREATED WITH CANAGLIFLOZIN. FRONTIERS IN ENDOCRINOLOGY 30-JAN-2019;10:1-5.",38.0,YR,A,F,Y,,,20190301.0,,MD,US,US,2019,Q1,Adult
160235811,16023581,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,ON CANAGLIFLOZIN FOR 14 MONTHS PRIOR TO CURRENT PRESENTATION,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2019,Q1,Systemic candida,,2019,Q1,1,I,,20190226.0,20190301,20190301,EXP,,US-JNJFOC-20190239029,JANSSEN,"RAJ R, HENDRIE J, JACOB A, ADAMS D. CANDIDEMIA FOLLOWING URETERIC STENT PLACEMENT IN A PATIENT WITH TYPE 2 DIABETES TREATED WITH CANAGLIFLOZIN. FRONTIERS IN ENDOCRINOLOGY 30-JAN-2019;10:1-5.",38.0,YR,A,F,Y,,,20190301.0,,MD,US,US,2019,Q1,Adult
160267551,16026755,5,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,100.0,MG,,QD,2019,Q1,Diarrhoea,,2019,Q1,1,I,,20190218.0,20190303,20190303,EXP,,US-TEVA-2019-US-1017208,TEVA,"BOWMAN C, ABRAMSON V, WELLONS M. KETOACIDOSIS WITH CANAGLIFLOZIN PRESCRIBED FOR PHOSPHOINOSITIDE 3-KINASE INHIBITOR-INDUCED HYPERGLYCEMIA: A CASE REPORT. J-INVESTIG-MED-HIGH-IMPACT-CASE-REP 2017;5:NO. 3.",69.0,YR,,F,Y,,,20190303.0,,MD,US,US,2019,Q1,Elderly
160267551,16026755,5,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,100.0,MG,,QD,2019,Q1,Dizziness,,2019,Q1,1,I,,20190218.0,20190303,20190303,EXP,,US-TEVA-2019-US-1017208,TEVA,"BOWMAN C, ABRAMSON V, WELLONS M. KETOACIDOSIS WITH CANAGLIFLOZIN PRESCRIBED FOR PHOSPHOINOSITIDE 3-KINASE INHIBITOR-INDUCED HYPERGLYCEMIA: A CASE REPORT. J-INVESTIG-MED-HIGH-IMPACT-CASE-REP 2017;5:NO. 3.",69.0,YR,,F,Y,,,20190303.0,,MD,US,US,2019,Q1,Elderly
160267551,16026755,5,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,100.0,MG,,QD,2019,Q1,Hyperglycaemia,,2019,Q1,1,I,,20190218.0,20190303,20190303,EXP,,US-TEVA-2019-US-1017208,TEVA,"BOWMAN C, ABRAMSON V, WELLONS M. KETOACIDOSIS WITH CANAGLIFLOZIN PRESCRIBED FOR PHOSPHOINOSITIDE 3-KINASE INHIBITOR-INDUCED HYPERGLYCEMIA: A CASE REPORT. J-INVESTIG-MED-HIGH-IMPACT-CASE-REP 2017;5:NO. 3.",69.0,YR,,F,Y,,,20190303.0,,MD,US,US,2019,Q1,Elderly
160267551,16026755,5,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,100.0,MG,,QD,2019,Q1,Ketoacidosis,,2019,Q1,1,I,,20190218.0,20190303,20190303,EXP,,US-TEVA-2019-US-1017208,TEVA,"BOWMAN C, ABRAMSON V, WELLONS M. KETOACIDOSIS WITH CANAGLIFLOZIN PRESCRIBED FOR PHOSPHOINOSITIDE 3-KINASE INHIBITOR-INDUCED HYPERGLYCEMIA: A CASE REPORT. J-INVESTIG-MED-HIGH-IMPACT-CASE-REP 2017;5:NO. 3.",69.0,YR,,F,Y,,,20190303.0,,MD,US,US,2019,Q1,Elderly
160267551,16026755,5,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,100.0,MG,,QD,2019,Q1,Nausea,,2019,Q1,1,I,,20190218.0,20190303,20190303,EXP,,US-TEVA-2019-US-1017208,TEVA,"BOWMAN C, ABRAMSON V, WELLONS M. KETOACIDOSIS WITH CANAGLIFLOZIN PRESCRIBED FOR PHOSPHOINOSITIDE 3-KINASE INHIBITOR-INDUCED HYPERGLYCEMIA: A CASE REPORT. J-INVESTIG-MED-HIGH-IMPACT-CASE-REP 2017;5:NO. 3.",69.0,YR,,F,Y,,,20190303.0,,MD,US,US,2019,Q1,Elderly
160267551,16026755,5,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,100.0,MG,,QD,2019,Q1,Vomiting,,2019,Q1,1,I,,20190218.0,20190303,20190303,EXP,,US-TEVA-2019-US-1017208,TEVA,"BOWMAN C, ABRAMSON V, WELLONS M. KETOACIDOSIS WITH CANAGLIFLOZIN PRESCRIBED FOR PHOSPHOINOSITIDE 3-KINASE INHIBITOR-INDUCED HYPERGLYCEMIA: A CASE REPORT. J-INVESTIG-MED-HIGH-IMPACT-CASE-REP 2017;5:NO. 3.",69.0,YR,,F,Y,,,20190303.0,,MD,US,US,2019,Q1,Elderly
160290291,16029029,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2019,Q1,Diabetic ketoacidosis,,2019,Q1,1,I,20181121.0,20190301.0,20190304,20190304,EXP,GB-MHRA-EYC 00195194,GB-JNJFOC-20190301750,JANSSEN,,46.0,YR,A,F,Y,96.0,KG,20190304.0,,MD,GB,GB,2019,Q1,Adult
160304811,16030481,2,SS,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2019,Q1,Euglycaemic diabetic ketoacidosis,,2019,Q1,1,I,,20190219.0,20190304,20190304,EXP,,AT-AMNEAL PHARMACEUTICALS-2019AMN00235,AMNEAL,,71.0,YR,,M,Y,,,20190304.0,,OT,AT,AT,2019,Q1,Elderly
160304811,16030481,2,SS,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2019,Q1,Lactic acidosis,,2019,Q1,1,I,,20190219.0,20190304,20190304,EXP,,AT-AMNEAL PHARMACEUTICALS-2019AMN00235,AMNEAL,,71.0,YR,,M,Y,,,20190304.0,,OT,AT,AT,2019,Q1,Elderly
160474231,16047423,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,N,N,,,204042.0,100.0,MG,TABLET,,2019,Q1,Candida infection,,2019,Q1,1,I,,20190305.0,20190307,20190307,EXP,GB-MHRA-TPP18185314C3262010YC1550487681749,GB-JNJFOC-20190305677,JANSSEN,,38.0,YR,A,F,Y,92.0,KG,20190307.0,,MD,GB,GB,2019,Q1,Adult
160830931,16083093,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,,,2019,Q1,Hepatitis,,2019,Q1,1,I,20180823.0,20190307.0,20190318,20190318,EXP,ES-AEMPS-412098,ES-ACCORD-113630,ACCORD,,75.0,YR,E,F,Y,,,20190318.0,,MD,ES,ES,2019,Q1,Elderly
160935511,16093551,1,PS,CANAGLIFLOZIN 300MG,CANAGLIFLOZIN,1,,,,,Y,D,,20191127,,,,,,2019,Q1,Ketoacidosis,,2019,Q1,1,I,20190127.0,,20190215,20190215,DIR,,,FDA-CTU,,54.0,YR,,M,N,93.5,KG,20190128.0,N,PH,US,US,2019,Q1,Adult
160935511,16093551,1,PS,CANAGLIFLOZIN 300MG,CANAGLIFLOZIN,1,,,,,Y,D,,20191127,,,,,,2019,Q1,Mental status changes,,2019,Q1,1,I,20190127.0,,20190215,20190215,DIR,,,FDA-CTU,,54.0,YR,,M,N,93.5,KG,20190128.0,N,PH,US,US,2019,Q1,Adult
160935511,16093551,1,PS,CANAGLIFLOZIN 300MG,CANAGLIFLOZIN,1,,,,,Y,D,,20191127,,,,,,2019,Q1,Metabolic acidosis,,2019,Q1,1,I,20190127.0,,20190215,20190215,DIR,,,FDA-CTU,,54.0,YR,,M,N,93.5,KG,20190128.0,N,PH,US,US,2019,Q1,Adult
161218811,16121881,5,C,INVOKANA CANAGLIFLOZIN HEMIHYDRATE,,2,,"300 MG, DAILY",,,,,,,,300.0,MG,,QD,2019,Q1,Decreased appetite,,2019,Q1,1,I,20190224.0,20190320.0,20190327,20190327,EXP,,US-ELI_LILLY_AND_COMPANY-US201903011804,ELI LILLY AND CO,,61.0,YR,,M,Y,,,20190327.0,,CN,US,US,2019,Q1,Adult
161218811,16121881,5,C,INVOKANA CANAGLIFLOZIN HEMIHYDRATE,,2,,"300 MG, DAILY",,,,,,,,300.0,MG,,QD,2019,Q1,Fatigue,,2019,Q1,1,I,20190224.0,20190320.0,20190327,20190327,EXP,,US-ELI_LILLY_AND_COMPANY-US201903011804,ELI LILLY AND CO,,61.0,YR,,M,Y,,,20190327.0,,CN,US,US,2019,Q1,Adult
161218811,16121881,5,C,INVOKANA CANAGLIFLOZIN HEMIHYDRATE,,2,,"300 MG, DAILY",,,,,,,,300.0,MG,,QD,2019,Q1,Lethargy,,2019,Q1,1,I,20190224.0,20190320.0,20190327,20190327,EXP,,US-ELI_LILLY_AND_COMPANY-US201903011804,ELI LILLY AND CO,,61.0,YR,,M,Y,,,20190327.0,,CN,US,US,2019,Q1,Adult
161218811,16121881,5,C,INVOKANA CANAGLIFLOZIN HEMIHYDRATE,,2,,"300 MG, DAILY",,,,,,,,300.0,MG,,QD,2019,Q1,Weight decreased,,2019,Q1,1,I,20190224.0,20190320.0,20190327,20190327,EXP,,US-ELI_LILLY_AND_COMPANY-US201903011804,ELI LILLY AND CO,,61.0,YR,,M,Y,,,20190327.0,,CN,US,US,2019,Q1,Adult
161237041,16123704,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2019,Q1,Colitis,,2019,Q1,1,I,20181221.0,20190314.0,20190327,20190327,EXP,,PHHO2019US003079,NOVARTIS,,50.0,YR,,F,Y,63.5,KG,20190327.0,,MD,US,US,2019,Q1,Adult
114588365,11458836,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,150-1000 TWO TIMES A DAY,,,,,,,,,,,,2019,Q2,Device issue,,2019,Q2,5,F,2014.0,20190417.0,20150904,20190517,PER,,US-ASTRAZENECA-2015SE82188,ASTRAZENECA,,54.0,YR,,M,Y,90.7,KG,20190517.0,,,US,US,2019,Q2,Adult
114588365,11458836,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,150-1000 TWO TIMES A DAY,,,,,,,,,,,,2019,Q2,Device leakage,,2019,Q2,5,F,2014.0,20190417.0,20150904,20190517,PER,,US-ASTRAZENECA-2015SE82188,ASTRAZENECA,,54.0,YR,,M,Y,90.7,KG,20190517.0,,,US,US,2019,Q2,Adult
114588365,11458836,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,150-1000 TWO TIMES A DAY,,,,,,,,,,,,2019,Q2,Incorrect dose administered by device,,2019,Q2,5,F,2014.0,20190417.0,20150904,20190517,PER,,US-ASTRAZENECA-2015SE82188,ASTRAZENECA,,54.0,YR,,M,Y,90.7,KG,20190517.0,,,US,US,2019,Q2,Adult
114588365,11458836,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,150-1000 TWO TIMES A DAY,,,,,,,,,,,,2019,Q2,Injection site extravasation,,2019,Q2,5,F,2014.0,20190417.0,20150904,20190517,PER,,US-ASTRAZENECA-2015SE82188,ASTRAZENECA,,54.0,YR,,M,Y,90.7,KG,20190517.0,,,US,US,2019,Q2,Adult
114588365,11458836,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,150-1000 TWO TIMES A DAY,,,,,,,,,,,,2019,Q2,Injection site haemorrhage,,2019,Q2,5,F,2014.0,20190417.0,20150904,20190517,PER,,US-ASTRAZENECA-2015SE82188,ASTRAZENECA,,54.0,YR,,M,Y,90.7,KG,20190517.0,,,US,US,2019,Q2,Adult
114588365,11458836,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,150-1000 TWO TIMES A DAY,,,,,,,,,,,,2019,Q2,Injection site mass,,2019,Q2,5,F,2014.0,20190417.0,20150904,20190517,PER,,US-ASTRAZENECA-2015SE82188,ASTRAZENECA,,54.0,YR,,M,Y,90.7,KG,20190517.0,,,US,US,2019,Q2,Adult
114588365,11458836,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,150-1000 TWO TIMES A DAY,,,,,,,,,,,,2019,Q2,Injection site pain,,2019,Q2,5,F,2014.0,20190417.0,20150904,20190517,PER,,US-ASTRAZENECA-2015SE82188,ASTRAZENECA,,54.0,YR,,M,Y,90.7,KG,20190517.0,,,US,US,2019,Q2,Adult
114588365,11458836,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,150-1000 TWO TIMES A DAY,,,,,,,,,,,,2019,Q2,Injection site urticaria,,2019,Q2,5,F,2014.0,20190417.0,20150904,20190517,PER,,US-ASTRAZENECA-2015SE82188,ASTRAZENECA,,54.0,YR,,M,Y,90.7,KG,20190517.0,,,US,US,2019,Q2,Adult
114588365,11458836,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,150-1000 TWO TIMES A DAY,,,,,,,,,,,,2019,Q2,Intentional product misuse,,2019,Q2,5,F,2014.0,20190417.0,20150904,20190517,PER,,US-ASTRAZENECA-2015SE82188,ASTRAZENECA,,54.0,YR,,M,Y,90.7,KG,20190517.0,,,US,US,2019,Q2,Adult
114588365,11458836,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,150-1000 TWO TIMES A DAY,,,,,,,,,,,,2019,Q2,Product dose omission,,2019,Q2,5,F,2014.0,20190417.0,20150904,20190517,PER,,US-ASTRAZENECA-2015SE82188,ASTRAZENECA,,54.0,YR,,M,Y,90.7,KG,20190517.0,,,US,US,2019,Q2,Adult
114588365,11458836,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,150-1000 TWO TIMES A DAY,,,,,,,,,,,,2019,Q2,Wrong technique in device usage process,,2019,Q2,5,F,2014.0,20190417.0,20150904,20190517,PER,,US-ASTRAZENECA-2015SE82188,ASTRAZENECA,,54.0,YR,,M,Y,90.7,KG,20190517.0,,,US,US,2019,Q2,Adult
127597975,12759797,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2019,Q2,Angina pectoris,,2019,Q2,5,F,20160312.0,20190404.0,20160919,20190415,EXP,,JP-JNJFOC-20160618215,JANSSEN,,65.0,YR,A,F,Y,66.0,KG,20190415.0,,MD,JP,JP,2019,Q2,Elderly
127597975,12759797,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2019,Q2,Autonomic nervous system imbalance,,2019,Q2,5,F,20160312.0,20190404.0,20160919,20190415,EXP,,JP-JNJFOC-20160618215,JANSSEN,,65.0,YR,A,F,Y,66.0,KG,20190415.0,,MD,JP,JP,2019,Q2,Elderly
127597975,12759797,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2019,Q2,Conjunctivitis allergic,,2019,Q2,5,F,20160312.0,20190404.0,20160919,20190415,EXP,,JP-JNJFOC-20160618215,JANSSEN,,65.0,YR,A,F,Y,66.0,KG,20190415.0,,MD,JP,JP,2019,Q2,Elderly
127597975,12759797,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2019,Q2,Diabetic retinopathy,,2019,Q2,5,F,20160312.0,20190404.0,20160919,20190415,EXP,,JP-JNJFOC-20160618215,JANSSEN,,65.0,YR,A,F,Y,66.0,KG,20190415.0,,MD,JP,JP,2019,Q2,Elderly
127597975,12759797,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2019,Q2,Hypertonic bladder,,2019,Q2,5,F,20160312.0,20190404.0,20160919,20190415,EXP,,JP-JNJFOC-20160618215,JANSSEN,,65.0,YR,A,F,Y,66.0,KG,20190415.0,,MD,JP,JP,2019,Q2,Elderly
127597975,12759797,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2019,Q2,Migraine,,2019,Q2,5,F,20160312.0,20190404.0,20160919,20190415,EXP,,JP-JNJFOC-20160618215,JANSSEN,,65.0,YR,A,F,Y,66.0,KG,20190415.0,,MD,JP,JP,2019,Q2,Elderly
129123033,12912303,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2019,Q2,Coronary artery stenosis,,2019,Q2,3,F,20160602.0,20190515.0,20161104,20190530,EXP,,JP-JNJFOC-20161102095,JANSSEN,,70.0,YR,E,M,Y,76.0,KG,20190530.0,,MD,JP,JP,2019,Q2,Elderly
129123033,12912303,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2019,Q2,Nasopharyngitis,,2019,Q2,3,F,20160602.0,20190515.0,20161104,20190530,EXP,,JP-JNJFOC-20161102095,JANSSEN,,70.0,YR,E,M,Y,76.0,KG,20190530.0,,MD,JP,JP,2019,Q2,Elderly
129123033,12912303,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2019,Q2,Urinary retention,,2019,Q2,3,F,20160602.0,20190515.0,20161104,20190530,EXP,,JP-JNJFOC-20161102095,JANSSEN,,70.0,YR,E,M,Y,76.0,KG,20190530.0,,MD,JP,JP,2019,Q2,Elderly
143158453,14315845,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,,,,,,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,3,F,,20190619.0,20171221,20190624,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-116052,BRISTOL MYERS SQUIBB,,67.0,YR,,M,Y,,,20190624.0,,MD,JP,JP,2019,Q2,Elderly
147086952,14708695,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Acute kidney injury,,2019,Q2,2,F,,20190325.0,20180403,20190402,EXP,,US-ASTRAZENECA-2018SE40300,ASTRAZENECA,,50.0,YR,,M,Y,125.0,KG,20190402.0,,,US,US,2019,Q2,Adult
147086952,14708695,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Chronic kidney disease,,2019,Q2,2,F,,20190325.0,20180403,20190402,EXP,,US-ASTRAZENECA-2018SE40300,ASTRAZENECA,,50.0,YR,,M,Y,125.0,KG,20190402.0,,,US,US,2019,Q2,Adult
147086952,14708695,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Renal failure,,2019,Q2,2,F,,20190325.0,20180403,20190402,EXP,,US-ASTRAZENECA-2018SE40300,ASTRAZENECA,,50.0,YR,,M,Y,125.0,KG,20190402.0,,,US,US,2019,Q2,Adult
147086952,14708695,14,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Renal injury,,2019,Q2,2,F,,20190325.0,20180403,20190402,EXP,,US-ASTRAZENECA-2018SE40300,ASTRAZENECA,,50.0,YR,,M,Y,125.0,KG,20190402.0,,,US,US,2019,Q2,Adult
147299375,14729937,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q2,Acute kidney injury,,2019,Q2,5,F,,20190430.0,20180406,20190507,EXP,,US-PFIZER INC-2018137097,PFIZER,,52.0,YR,,M,Y,125.0,KG,20190507.0,,LW,US,US,2019,Q2,Adult
147299375,14729937,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q2,Chronic kidney disease,,2019,Q2,5,F,,20190430.0,20180406,20190507,EXP,,US-PFIZER INC-2018137097,PFIZER,,52.0,YR,,M,Y,125.0,KG,20190507.0,,LW,US,US,2019,Q2,Adult
147299375,14729937,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q2,Renal failure,,2019,Q2,5,F,,20190430.0,20180406,20190507,EXP,,US-PFIZER INC-2018137097,PFIZER,,52.0,YR,,M,Y,125.0,KG,20190507.0,,LW,US,US,2019,Q2,Adult
147299375,14729937,24,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q2,Renal injury,,2019,Q2,5,F,,20190430.0,20180406,20190507,EXP,,US-PFIZER INC-2018137097,PFIZER,,52.0,YR,,M,Y,125.0,KG,20190507.0,,LW,US,US,2019,Q2,Adult
148419572,14841957,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2019,Q2,Otosclerosis,,2019,Q2,2,F,20170115.0,20190425.0,20180503,20190507,EXP,,JP-JNJFOC-20180502898,JANSSEN,,63.0,YR,A,F,Y,68.0,KG,20190507.0,,OT,JP,JP,2019,Q2,Adult
148501733,14850173,59,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Acute kidney injury,,2019,Q2,3,F,20160503.0,20190605.0,20180505,20190612,EXP,,US-ASTRAZENECA-2018SE57758,ASTRAZENECA,,27840.0,DY,,F,Y,77.1,KG,20190612.0,,,US,US,2019,Q2,Elderly
148501733,14850173,59,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Chronic kidney disease,,2019,Q2,3,F,20160503.0,20190605.0,20180505,20190612,EXP,,US-ASTRAZENECA-2018SE57758,ASTRAZENECA,,27840.0,DY,,F,Y,77.1,KG,20190612.0,,,US,US,2019,Q2,Elderly
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Adverse drug reaction,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Arthralgia,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Arthritis,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Blood creatinine decreased,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Blood uric acid decreased,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Drug ineffective,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Gastrointestinal haemorrhage,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Glycosylated haemoglobin increased,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Haemoglobin decreased,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Hepatic cirrhosis,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Hepatosplenomegaly,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Hypertrophy,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Inflammatory marker increased,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Joint effusion,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Joint swelling,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Liver disorder,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Low density lipoprotein increased,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Nausea,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Nonalcoholic fatty liver disease,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Pain in extremity,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Psoriasis,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Psoriatic arthropathy,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Red blood cell sedimentation rate increased,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Rheumatoid arthritis,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Therapeutic product effect decreased,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Therapeutic product effect incomplete,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Type 2 diabetes mellitus,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
148727573,14872757,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MILLIGRAM,,,,,,,,300.0,MG,TABLET,,2019,Q2,Varices oesophageal,,2019,Q2,3,F,2007.0,20190513.0,20180510,20190520,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20190520.0,,CN,CA,CA,2019,Q2,Adult
149021672,14902167,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q2,Acute kidney injury,,2019,Q2,2,F,,20190325.0,20180516,20190408,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,52.0,YR,,M,Y,125.0,KG,20190408.0,,LW,US,US,2019,Q2,Adult
149021672,14902167,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q2,Chronic kidney disease,,2019,Q2,2,F,,20190325.0,20180516,20190408,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,52.0,YR,,M,Y,125.0,KG,20190408.0,,LW,US,US,2019,Q2,Adult
149021672,14902167,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q2,Renal failure,,2019,Q2,2,F,,20190325.0,20180516,20190408,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,52.0,YR,,M,Y,125.0,KG,20190408.0,,LW,US,US,2019,Q2,Adult
149021672,14902167,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q2,Renal injury,,2019,Q2,2,F,,20190325.0,20180516,20190408,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,52.0,YR,,M,Y,125.0,KG,20190408.0,,LW,US,US,2019,Q2,Adult
154703312,15470331,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"UNK UNK, UNK",,,U,,,,,,,,,2019,Q2,Arthropathy,,2019,Q2,2,F,,20190503.0,20181005,20190510,EXP,,US-SA-2018SA272349,SANOFI AVENTIS,,65.0,YR,E,M,Y,,,20190510.0,,CN,US,US,2019,Q2,Elderly
154703312,15470331,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"UNK UNK, UNK",,,U,,,,,,,,,2019,Q2,Cardiac failure congestive,,2019,Q2,2,F,,20190503.0,20181005,20190510,EXP,,US-SA-2018SA272349,SANOFI AVENTIS,,65.0,YR,E,M,Y,,,20190510.0,,CN,US,US,2019,Q2,Elderly
154703312,15470331,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"UNK UNK, UNK",,,U,,,,,,,,,2019,Q2,Joint arthroplasty,,2019,Q2,2,F,,20190503.0,20181005,20190510,EXP,,US-SA-2018SA272349,SANOFI AVENTIS,,65.0,YR,E,M,Y,,,20190510.0,,CN,US,US,2019,Q2,Elderly
154703312,15470331,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"UNK UNK, UNK",,,U,,,,,,,,,2019,Q2,Malaise,,2019,Q2,2,F,,20190503.0,20181005,20190510,EXP,,US-SA-2018SA272349,SANOFI AVENTIS,,65.0,YR,E,M,Y,,,20190510.0,,CN,US,US,2019,Q2,Elderly
154703312,15470331,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"UNK UNK, UNK",,,U,,,,,,,,,2019,Q2,Nervous system disorder,,2019,Q2,2,F,,20190503.0,20181005,20190510,EXP,,US-SA-2018SA272349,SANOFI AVENTIS,,65.0,YR,E,M,Y,,,20190510.0,,CN,US,US,2019,Q2,Elderly
154703312,15470331,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"UNK UNK, UNK",,,U,,,,,,,,,2019,Q2,Product dose omission,,2019,Q2,2,F,,20190503.0,20181005,20190510,EXP,,US-SA-2018SA272349,SANOFI AVENTIS,,65.0,YR,E,M,Y,,,20190510.0,,CN,US,US,2019,Q2,Elderly
154703312,15470331,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"UNK UNK, UNK",,,U,,,,,,,,,2019,Q2,Product use issue,,2019,Q2,2,F,,20190503.0,20181005,20190510,EXP,,US-SA-2018SA272349,SANOFI AVENTIS,,65.0,YR,E,M,Y,,,20190510.0,,CN,US,US,2019,Q2,Elderly
154703312,15470331,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"UNK UNK, UNK",,,U,,,,,,,,,2019,Q2,Renal impairment,,2019,Q2,2,F,,20190503.0,20181005,20190510,EXP,,US-SA-2018SA272349,SANOFI AVENTIS,,65.0,YR,E,M,Y,,,20190510.0,,CN,US,US,2019,Q2,Elderly
154703312,15470331,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"UNK UNK, UNK",,,U,,,,,,,,,2019,Q2,Treatment noncompliance,,2019,Q2,2,F,,20190503.0,20181005,20190510,EXP,,US-SA-2018SA272349,SANOFI AVENTIS,,65.0,YR,E,M,Y,,,20190510.0,,CN,US,US,2019,Q2,Elderly
154745882,15474588,14,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2019,Q2,Depression,,2019,Q2,2,F,2017.0,20190528.0,20181008,20190607,EXP,,US-UCBSA-2018001276,UCB,,46.0,YR,,M,Y,106.0,KG,20190607.0,,CN,US,US,2019,Q2,Adult
154745882,15474588,14,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2019,Q2,Dry skin,,2019,Q2,2,F,2017.0,20190528.0,20181008,20190607,EXP,,US-UCBSA-2018001276,UCB,,46.0,YR,,M,Y,106.0,KG,20190607.0,,CN,US,US,2019,Q2,Adult
154745882,15474588,14,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2019,Q2,Knee arthroplasty,,2019,Q2,2,F,2017.0,20190528.0,20181008,20190607,EXP,,US-UCBSA-2018001276,UCB,,46.0,YR,,M,Y,106.0,KG,20190607.0,,CN,US,US,2019,Q2,Adult
154745882,15474588,14,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2019,Q2,Musculoskeletal stiffness,,2019,Q2,2,F,2017.0,20190528.0,20181008,20190607,EXP,,US-UCBSA-2018001276,UCB,,46.0,YR,,M,Y,106.0,KG,20190607.0,,CN,US,US,2019,Q2,Adult
154745882,15474588,14,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2019,Q2,Product dose omission,,2019,Q2,2,F,2017.0,20190528.0,20181008,20190607,EXP,,US-UCBSA-2018001276,UCB,,46.0,YR,,M,Y,106.0,KG,20190607.0,,CN,US,US,2019,Q2,Adult
154745882,15474588,14,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2019,Q2,Pruritus,,2019,Q2,2,F,2017.0,20190528.0,20181008,20190607,EXP,,US-UCBSA-2018001276,UCB,,46.0,YR,,M,Y,106.0,KG,20190607.0,,CN,US,US,2019,Q2,Adult
154745882,15474588,14,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2019,Q2,Psoriatic arthropathy,,2019,Q2,2,F,2017.0,20190528.0,20181008,20190607,EXP,,US-UCBSA-2018001276,UCB,,46.0,YR,,M,Y,106.0,KG,20190607.0,,CN,US,US,2019,Q2,Adult
154745882,15474588,14,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2019,Q2,Stress,,2019,Q2,2,F,2017.0,20190528.0,20181008,20190607,EXP,,US-UCBSA-2018001276,UCB,,46.0,YR,,M,Y,106.0,KG,20190607.0,,CN,US,US,2019,Q2,Adult
156038163,15603816,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,TABLET,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,3,F,,20190313.0,20181109,20190403,EXP,,JP-009507513-1811JPN000634J,MERCK,,48.0,YR,,F,Y,,,20190403.0,,CN,JP,JP,2019,Q2,Adult
158135894,15813589,1,PS,CANAGLIFLOZIN TABLET,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,50.0,MG,FILM-COATED TABLET,QD,2019,Q2,Acute myocardial infarction,,2019,Q2,4,F,20160419.0,20190611.0,20190111,20190626,EXP,,JP-JNJFOC-20190105468,JOHNSON AND JOHNSON,,73.0,YR,,M,Y,65.0,KG,20190626.0,,MD,JP,JP,2019,Q2,Elderly
158135894,15813589,1,PS,CANAGLIFLOZIN TABLET,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,50.0,MG,FILM-COATED TABLET,QD,2019,Q2,Diabetes mellitus inadequate control,,2019,Q2,4,F,20160419.0,20190611.0,20190111,20190626,EXP,,JP-JNJFOC-20190105468,JOHNSON AND JOHNSON,,73.0,YR,,M,Y,65.0,KG,20190626.0,,MD,JP,JP,2019,Q2,Elderly
158135894,15813589,1,PS,CANAGLIFLOZIN TABLET,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,50.0,MG,FILM-COATED TABLET,QD,2019,Q2,Incorrect dose administered,,2019,Q2,4,F,20160419.0,20190611.0,20190111,20190626,EXP,,JP-JNJFOC-20190105468,JOHNSON AND JOHNSON,,73.0,YR,,M,Y,65.0,KG,20190626.0,,MD,JP,JP,2019,Q2,Elderly
158135894,15813589,1,PS,CANAGLIFLOZIN TABLET,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,50.0,MG,FILM-COATED TABLET,QD,2019,Q2,Off label use,,2019,Q2,4,F,20160419.0,20190611.0,20190111,20190626,EXP,,JP-JNJFOC-20190105468,JOHNSON AND JOHNSON,,73.0,YR,,M,Y,65.0,KG,20190626.0,,MD,JP,JP,2019,Q2,Elderly
160650682,16065068,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q2,Blood lactic acid increased,,2019,Q2,2,F,20180829.0,20190313.0,20190313,20190410,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019208,BRISTOL MYERS SQUIBB,,56.0,YR,,M,Y,75.0,KG,20190410.0,,OT,JP,JP,2019,Q2,Adult
161237042,16123704,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,U,U,,,,300.0,MG,,QD,2019,Q2,Colitis,,2019,Q2,2,F,20181221.0,20190410.0,20190327,20190423,EXP,,PHHO2019US003079,NOVARTIS,,50.0,YR,,F,Y,63.5,KG,20190423.0,,MD,US,US,2019,Q2,Adult
161438421,16143842,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,20190311.0,20190328.0,20190401,20190401,EXP,GB-MHRA-TPP7612978C3787326YC1552330928908,GB-JNJFOC-20190342592,JANSSEN,,64.0,YR,A,M,Y,74.0,KG,20190401.0,,MD,GB,GB,2019,Q2,Adult
161483831,16148383,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,,2019,Q2,Fournier's gangrene,,2019,Q2,1,I,20180709.0,20190328.0,20190402,20190402,EXP,GB-MHRA-EYC 00196667,GB-JNJFOC-20190342411,JANSSEN,,64.0,YR,A,M,Y,,,20190402.0,,MD,GB,GB,2019,Q2,Adult
161697941,16169794,5,C,canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Cellulitis,,2019,Q2,1,I,20190221.0,,20190305,20190305,DIR,,,FDA-CTU,,70.0,YR,,M,N,140.4,KG,20190304.0,N,MD,US,US,2019,Q2,Elderly
161697941,16169794,5,C,canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Pneumonia,,2019,Q2,1,I,20190221.0,,20190305,20190305,DIR,,,FDA-CTU,,70.0,YR,,M,N,140.4,KG,20190304.0,N,MD,US,US,2019,Q2,Elderly
161697941,16169794,5,C,canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q2,Pyrexia,,2019,Q2,1,I,20190221.0,,20190305,20190305,DIR,,,FDA-CTU,,70.0,YR,,M,N,140.4,KG,20190304.0,N,MD,US,US,2019,Q2,Elderly
161852981,16185298,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,,,TABLET,,2019,Q2,Fournier's gangrene,,2019,Q2,1,I,20180709.0,20190404.0,20190411,20190411,EXP,GB-MHRA-ADR 24389929,GB-JNJFOC-20190413026,JANSSEN,,63.0,YR,A,M,Y,123.0,KG,20190411.0,,MD,GB,GB,2019,Q2,Adult
162066241,16206624,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,,,TABLET,,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,1,I,,20190409.0,20190417,20190417,EXP,,US-JNJFOC-20190422246,JANSSEN,"GYAWALI B, MARTINEZ F, MARTINEZ-BALZANO C. RAPID ONSET OF EUGLYCEMIC DIABETIC KETOACIDOSIS DUE TO CANAGLIFLOZIN IN A CASE OF NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS. J INVESTIG MED 2019;67 (2):401-402.",26.0,YR,A,M,Y,,,20190417.0,,OT,US,US,2019,Q2,Young Adult
162213541,16221354,6,C,INVOKANA CANAGLIFLOZIN HEMIHYDRATE,,2,,,,,,,,,,,,,,2019,Q2,Abdominal pain,,2019,Q2,1,I,,20190412.0,20190422,20190422,EXP,,US-ELI_LILLY_AND_COMPANY-US201904008343,ELI LILLY AND CO,,68.0,YR,,M,Y,,,20190422.0,,CN,US,US,2019,Q2,Elderly
162213541,16221354,6,C,INVOKANA CANAGLIFLOZIN HEMIHYDRATE,,2,,,,,,,,,,,,,,2019,Q2,Amylase increased,,2019,Q2,1,I,,20190412.0,20190422,20190422,EXP,,US-ELI_LILLY_AND_COMPANY-US201904008343,ELI LILLY AND CO,,68.0,YR,,M,Y,,,20190422.0,,CN,US,US,2019,Q2,Elderly
162213541,16221354,6,C,INVOKANA CANAGLIFLOZIN HEMIHYDRATE,,2,,,,,,,,,,,,,,2019,Q2,Lipase increased,,2019,Q2,1,I,,20190412.0,20190422,20190422,EXP,,US-ELI_LILLY_AND_COMPANY-US201904008343,ELI LILLY AND CO,,68.0,YR,,M,Y,,,20190422.0,,CN,US,US,2019,Q2,Elderly
162213541,16221354,6,C,INVOKANA CANAGLIFLOZIN HEMIHYDRATE,,2,,,,,,,,,,,,,,2019,Q2,Nausea,,2019,Q2,1,I,,20190412.0,20190422,20190422,EXP,,US-ELI_LILLY_AND_COMPANY-US201904008343,ELI LILLY AND CO,,68.0,YR,,M,Y,,,20190422.0,,CN,US,US,2019,Q2,Elderly
162213541,16221354,6,C,INVOKANA CANAGLIFLOZIN HEMIHYDRATE,,2,,,,,,,,,,,,,,2019,Q2,Pancreatitis,,2019,Q2,1,I,,20190412.0,20190422,20190422,EXP,,US-ELI_LILLY_AND_COMPANY-US201904008343,ELI LILLY AND CO,,68.0,YR,,M,Y,,,20190422.0,,CN,US,US,2019,Q2,Elderly
162277362,16227736,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, DAILY",,,,,,,,300.0,MG,TABLET,,2019,Q2,Intentional product misuse,,2019,Q2,2,F,20161205.0,20190531.0,20190423,20190611,EXP,,US-PFIZER INC-2016573618,PFIZER,,48.0,YR,,M,Y,95.25,KG,20190611.0,,MD,US,US,2019,Q2,Adult
162277362,16227736,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, DAILY",,,,,,,,300.0,MG,TABLET,,2019,Q2,Off label use,,2019,Q2,2,F,20161205.0,20190531.0,20190423,20190611,EXP,,US-PFIZER INC-2016573618,PFIZER,,48.0,YR,,M,Y,95.25,KG,20190611.0,,MD,US,US,2019,Q2,Adult
162277362,16227736,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, DAILY",,,,,,,,300.0,MG,TABLET,,2019,Q2,Osteonecrosis,,2019,Q2,2,F,20161205.0,20190531.0,20190423,20190611,EXP,,US-PFIZER INC-2016573618,PFIZER,,48.0,YR,,M,Y,95.25,KG,20190611.0,,MD,US,US,2019,Q2,Adult
162277362,16227736,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, DAILY",,,,,,,,300.0,MG,TABLET,,2019,Q2,Pain,,2019,Q2,2,F,20161205.0,20190531.0,20190423,20190611,EXP,,US-PFIZER INC-2016573618,PFIZER,,48.0,YR,,M,Y,95.25,KG,20190611.0,,MD,US,US,2019,Q2,Adult
162277362,16227736,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, DAILY",,,,,,,,300.0,MG,TABLET,,2019,Q2,Product use in unapproved indication,,2019,Q2,2,F,20161205.0,20190531.0,20190423,20190611,EXP,,US-PFIZER INC-2016573618,PFIZER,,48.0,YR,,M,Y,95.25,KG,20190611.0,,MD,US,US,2019,Q2,Adult
162330021,16233002,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,N,,,204042.0,100.0,MG,TABLET,,2019,Q2,Guttate psoriasis,,2019,Q2,1,I,20190321.0,20190419.0,20190424,20190424,EXP,GB-MHRA-EYC 00197689,GB-JNJFOC-20190433649,JANSSEN,,49.0,YR,A,F,Y,,,20190424.0,,MD,GB,GB,2019,Q2,Adult
162330021,16233002,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,N,,,204042.0,100.0,MG,TABLET,,2019,Q2,Skin disorder,,2019,Q2,1,I,20190321.0,20190419.0,20190424,20190424,EXP,GB-MHRA-EYC 00197689,GB-JNJFOC-20190433649,JANSSEN,,49.0,YR,A,F,Y,,,20190424.0,,MD,GB,GB,2019,Q2,Adult
162330021,16233002,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,N,,,204042.0,100.0,MG,TABLET,,2019,Q2,Skin plaque,,2019,Q2,1,I,20190321.0,20190419.0,20190424,20190424,EXP,GB-MHRA-EYC 00197689,GB-JNJFOC-20190433649,JANSSEN,,49.0,YR,A,F,Y,,,20190424.0,,MD,GB,GB,2019,Q2,Adult
162330021,16233002,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,N,,,204042.0,100.0,MG,TABLET,,2019,Q2,Superinfection,,2019,Q2,1,I,20190321.0,20190419.0,20190424,20190424,EXP,GB-MHRA-EYC 00197689,GB-JNJFOC-20190433649,JANSSEN,,49.0,YR,A,F,Y,,,20190424.0,,MD,GB,GB,2019,Q2,Adult
162569161,16256916,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,,20190423.0,20190430,20190430,EXP,,GB-JNJFOC-20190440099,JANSSEN,"KANDASWAMY L, AL?SALIHI A, SINGH PK, RANGAN S, MOULIK PK. KETOACIDOSIS IN PATIENTS ON SGLT2 INHIBITOR: EXPERIENCE FROM A DISTRICT GENERAL HOSPITAL. DIABETIC MEDICINE DIABETES UK PROFESSIONAL CONFERENCE 2019;36(SUPPLEMENT 1):174.",61.0,YR,A,F,Y,,,20190430.0,,OT,GB,GB,2019,Q2,Adult
162616921,16261692,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U,,,204353.0,,,TABLET,,2019,Q2,Dehydration,,2019,Q2,1,I,,20190425.0,20190501,20190501,EXP,US-MLMSERVICE-20190419-1710887-1,US-JNJFOC-20190443088,JANSSEN,DARWISH AM. METABOLIC ACIDOSIS IN POSTSURGICAL PATIENT ON CANAGLIFLOZIN AND METFORMIN: A CASE REPORT. A+A PRACTICE 2019;12(7):221-222.,38.0,YR,A,M,Y,,,20190501.0,,MD,US,US,2019,Q2,Adult
162616921,16261692,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U,,,204353.0,,,TABLET,,2019,Q2,Glycosuria,,2019,Q2,1,I,,20190425.0,20190501,20190501,EXP,US-MLMSERVICE-20190419-1710887-1,US-JNJFOC-20190443088,JANSSEN,DARWISH AM. METABOLIC ACIDOSIS IN POSTSURGICAL PATIENT ON CANAGLIFLOZIN AND METFORMIN: A CASE REPORT. A+A PRACTICE 2019;12(7):221-222.,38.0,YR,A,M,Y,,,20190501.0,,MD,US,US,2019,Q2,Adult
162616921,16261692,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U,,,204353.0,,,TABLET,,2019,Q2,Hypokalaemia,,2019,Q2,1,I,,20190425.0,20190501,20190501,EXP,US-MLMSERVICE-20190419-1710887-1,US-JNJFOC-20190443088,JANSSEN,DARWISH AM. METABOLIC ACIDOSIS IN POSTSURGICAL PATIENT ON CANAGLIFLOZIN AND METFORMIN: A CASE REPORT. A+A PRACTICE 2019;12(7):221-222.,38.0,YR,A,M,Y,,,20190501.0,,MD,US,US,2019,Q2,Adult
162616921,16261692,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U,,,204353.0,,,TABLET,,2019,Q2,Hypophosphataemia,,2019,Q2,1,I,,20190425.0,20190501,20190501,EXP,US-MLMSERVICE-20190419-1710887-1,US-JNJFOC-20190443088,JANSSEN,DARWISH AM. METABOLIC ACIDOSIS IN POSTSURGICAL PATIENT ON CANAGLIFLOZIN AND METFORMIN: A CASE REPORT. A+A PRACTICE 2019;12(7):221-222.,38.0,YR,A,M,Y,,,20190501.0,,MD,US,US,2019,Q2,Adult
162616921,16261692,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U,,,204353.0,,,TABLET,,2019,Q2,Ketoacidosis,,2019,Q2,1,I,,20190425.0,20190501,20190501,EXP,US-MLMSERVICE-20190419-1710887-1,US-JNJFOC-20190443088,JANSSEN,DARWISH AM. METABOLIC ACIDOSIS IN POSTSURGICAL PATIENT ON CANAGLIFLOZIN AND METFORMIN: A CASE REPORT. A+A PRACTICE 2019;12(7):221-222.,38.0,YR,A,M,Y,,,20190501.0,,MD,US,US,2019,Q2,Adult
162616921,16261692,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U,,,204353.0,,,TABLET,,2019,Q2,Metabolic acidosis,,2019,Q2,1,I,,20190425.0,20190501,20190501,EXP,US-MLMSERVICE-20190419-1710887-1,US-JNJFOC-20190443088,JANSSEN,DARWISH AM. METABOLIC ACIDOSIS IN POSTSURGICAL PATIENT ON CANAGLIFLOZIN AND METFORMIN: A CASE REPORT. A+A PRACTICE 2019;12(7):221-222.,38.0,YR,A,M,Y,,,20190501.0,,MD,US,US,2019,Q2,Adult
162698751,16269875,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,N,,,204353.0,,,TABLET,,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,1,I,,20190425.0,20190503,20190503,EXP,US-MLMSERVICE-20190419-1710887-2,US-JNJFOC-20190442292,JANSSEN,DARWISH AM. METABOLIC ACIDOSIS IN POSTSURGICAL PATIENT ON CANAGLIFLOZIN AND METFORMIN: A CASE REPORT. A+A PRACTICE 2019;12(7):221-222.,60.0,YR,A,M,Y,,,20190503.0,,MD,US,US,2019,Q2,Adult
162698751,16269875,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,N,,,204353.0,,,TABLET,,2019,Q2,Glycosuria,,2019,Q2,1,I,,20190425.0,20190503,20190503,EXP,US-MLMSERVICE-20190419-1710887-2,US-JNJFOC-20190442292,JANSSEN,DARWISH AM. METABOLIC ACIDOSIS IN POSTSURGICAL PATIENT ON CANAGLIFLOZIN AND METFORMIN: A CASE REPORT. A+A PRACTICE 2019;12(7):221-222.,60.0,YR,A,M,Y,,,20190503.0,,MD,US,US,2019,Q2,Adult
162698751,16269875,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,N,,,204353.0,,,TABLET,,2019,Q2,Metabolic acidosis,,2019,Q2,1,I,,20190425.0,20190503,20190503,EXP,US-MLMSERVICE-20190419-1710887-2,US-JNJFOC-20190442292,JANSSEN,DARWISH AM. METABOLIC ACIDOSIS IN POSTSURGICAL PATIENT ON CANAGLIFLOZIN AND METFORMIN: A CASE REPORT. A+A PRACTICE 2019;12(7):221-222.,60.0,YR,A,M,Y,,,20190503.0,,MD,US,US,2019,Q2,Adult
162783961,16278396,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,,,,,300.0,MG,,QD,2019,Q2,Rectal haemorrhage,,2019,Q2,1,I,20190308.0,20190425.0,20190506,20190506,EXP,CH-SM-2019-12857,CH-NOVOPROD-660301,NOVO NORDISK,,68.0,YR,,M,Y,107.0,KG,20190506.0,,MD,CH,CH,2019,Q2,Elderly
162809981,16280998,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,20190324.0,20190502.0,20190507,20190507,EXP,GB-MHRA-ADR 24395880,GB-JNJFOC-20190502840,JANSSEN,,29.0,YR,A,F,Y,80.0,KG,20190507.0,,OT,GB,GB,2019,Q2,Young Adult
162854941,16285494,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2019,Q2,Diabetic ketoacidosis,,2019,Q2,1,I,20190408.0,20190503.0,20190508,20190508,EXP,GB-MHRA-EYC 00198592,GB-JNJFOC-20190504913,JANSSEN,,65.0,YR,A,F,Y,,,20190508.0,,MD,GB,GB,2019,Q2,Elderly
162854941,16285494,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2019,Q2,Diarrhoea,,2019,Q2,1,I,20190408.0,20190503.0,20190508,20190508,EXP,GB-MHRA-EYC 00198592,GB-JNJFOC-20190504913,JANSSEN,,65.0,YR,A,F,Y,,,20190508.0,,MD,GB,GB,2019,Q2,Elderly
162899291,16289929,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2019,Q2,Necrotising fasciitis,,2019,Q2,1,I,20181224.0,20190501.0,20190509,20190509,EXP,GB-MHRA-ADR 24395731,GB-JNJFOC-20190501610,JANSSEN,,56.0,YR,A,F,Y,,,20190509.0,,OT,GB,GB,2019,Q2,Adult
162899291,16289929,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2019,Q2,Vulvovaginal swelling,,2019,Q2,1,I,20181224.0,20190501.0,20190509,20190509,EXP,GB-MHRA-ADR 24395731,GB-JNJFOC-20190501610,JANSSEN,,56.0,YR,A,F,Y,,,20190509.0,,OT,GB,GB,2019,Q2,Adult
163217901,16321790,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,,2019,Q2,Asthenia,,2019,Q2,1,I,2019.0,20190509.0,20190516,20190516,EXP,,CN-JNJFOC-20190515008,JANSSEN,,46.0,YR,A,M,Y,,,20190516.0,,CN,CN,CN,2019,Q2,Adult
163217901,16321790,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,,2019,Q2,Ketosis,,2019,Q2,1,I,2019.0,20190509.0,20190516,20190516,EXP,,CN-JNJFOC-20190515008,JANSSEN,,46.0,YR,A,M,Y,,,20190516.0,,CN,CN,CN,2019,Q2,Adult
163217901,16321790,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,,2019,Q2,Nocturia,,2019,Q2,1,I,2019.0,20190509.0,20190516,20190516,EXP,,CN-JNJFOC-20190515008,JANSSEN,,46.0,YR,A,M,Y,,,20190516.0,,CN,CN,CN,2019,Q2,Adult
163217911,16321791,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2019,Q2,Peripheral ischaemia,,2019,Q2,1,I,,20190513.0,20190516,20190516,EXP,GB-MHRA-EYC 00199130,GB-JNJFOC-20190516882,JANSSEN,,69.0,YR,E,M,Y,,,20190516.0,,PH,GB,GB,2019,Q2,Elderly
163218951,16321895,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY; RECEIVING FOR 14 MONTHS,,,U,,,,,100.0,MG,,QD,2019,Q2,Candiduria,,2019,Q2,1,I,,20190506.0,20190516,20190516,EXP,,US-TEVA-2019-US-1049675,TEVA,"RAJ R, HENDRIE J, JACOB A, ADAMS D. CANDIDEMIA FOLLOWING URETERIC STENT PLACEMENT IN A PATIENT WITH TYPE 2 DIABETES TREATED WITH CANAGLIFLOZIN. FRONT-ENDOCRINOL-(LAUSANNE) 2019;:.",38.0,YR,,F,Y,,,20190516.0,,OT,US,US,2019,Q2,Adult
163218951,16321895,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY; RECEIVING FOR 14 MONTHS,,,U,,,,,100.0,MG,,QD,2019,Q2,Klebsiella infection,,2019,Q2,1,I,,20190506.0,20190516,20190516,EXP,,US-TEVA-2019-US-1049675,TEVA,"RAJ R, HENDRIE J, JACOB A, ADAMS D. CANDIDEMIA FOLLOWING URETERIC STENT PLACEMENT IN A PATIENT WITH TYPE 2 DIABETES TREATED WITH CANAGLIFLOZIN. FRONT-ENDOCRINOL-(LAUSANNE) 2019;:.",38.0,YR,,F,Y,,,20190516.0,,OT,US,US,2019,Q2,Adult
163218951,16321895,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY; RECEIVING FOR 14 MONTHS,,,U,,,,,100.0,MG,,QD,2019,Q2,Systemic candida,,2019,Q2,1,I,,20190506.0,20190516,20190516,EXP,,US-TEVA-2019-US-1049675,TEVA,"RAJ R, HENDRIE J, JACOB A, ADAMS D. CANDIDEMIA FOLLOWING URETERIC STENT PLACEMENT IN A PATIENT WITH TYPE 2 DIABETES TREATED WITH CANAGLIFLOZIN. FRONT-ENDOCRINOL-(LAUSANNE) 2019;:.",38.0,YR,,F,Y,,,20190516.0,,OT,US,US,2019,Q2,Adult
163370394,16337039,5,SS,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,"100 MG, UNK",,,,,,,,100.0,MG,,,2019,Q2,Abdominal pain upper,,2019,Q2,4,F,,20190618.0,20190521,20190627,EXP,,JP-PFIZER INC-2019211597,PFIZER,"TAKEMOTO, Y.. A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS RELATED WITH A SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITION AFTER THE CHOLECYSTECTOMY FOR CHOLECYSTITIS IN A PATIENT WITH TYPE 2 DIABETES. JOURNAL OF THE JAPAN DIABETES SOCIETY. 2019;62(2):94-100",71.0,YR,,F,Y,57.0,KG,20190627.0,,OT,JP,JP,2019,Q2,Elderly
163370394,16337039,5,SS,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,"100 MG, UNK",,,,,,,,100.0,MG,,,2019,Q2,Cholecystitis acute,,2019,Q2,4,F,,20190618.0,20190521,20190627,EXP,,JP-PFIZER INC-2019211597,PFIZER,"TAKEMOTO, Y.. A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS RELATED WITH A SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITION AFTER THE CHOLECYSTECTOMY FOR CHOLECYSTITIS IN A PATIENT WITH TYPE 2 DIABETES. JOURNAL OF THE JAPAN DIABETES SOCIETY. 2019;62(2):94-100",71.0,YR,,F,Y,57.0,KG,20190627.0,,OT,JP,JP,2019,Q2,Elderly
163370394,16337039,5,SS,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,"100 MG, UNK",,,,,,,,100.0,MG,,,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,4,F,,20190618.0,20190521,20190627,EXP,,JP-PFIZER INC-2019211597,PFIZER,"TAKEMOTO, Y.. A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS RELATED WITH A SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITION AFTER THE CHOLECYSTECTOMY FOR CHOLECYSTITIS IN A PATIENT WITH TYPE 2 DIABETES. JOURNAL OF THE JAPAN DIABETES SOCIETY. 2019;62(2):94-100",71.0,YR,,F,Y,57.0,KG,20190627.0,,OT,JP,JP,2019,Q2,Elderly
163371822,16337182,1,PS,CANAGLIFLOZIN TABLET,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q2,Neoplasm malignant,,2019,Q2,2,F,20190117.0,20190612.0,20190521,20190628,EXP,,JP-JNJFOC-20190314349,JOHNSON AND JOHNSON,,68.0,YR,,M,Y,,,20190628.0,,MD,JP,JP,2019,Q2,Elderly
163371822,16337182,1,PS,CANAGLIFLOZIN TABLET,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q2,Respiratory failure,,2019,Q2,2,F,20190117.0,20190612.0,20190521,20190628,EXP,,JP-JNJFOC-20190314349,JOHNSON AND JOHNSON,,68.0,YR,,M,Y,,,20190628.0,,MD,JP,JP,2019,Q2,Elderly
163507071,16350707,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,,,,,100.0,MG,,QD,2019,Q2,Diabetes mellitus inadequate control,,2019,Q2,1,I,2018.0,20190509.0,20190524,20190524,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-047322,BRISTOL MYERS SQUIBB,,46.0,YR,,M,Y,,,20190524.0,,MD,CN,CN,2019,Q2,Adult
163507071,16350707,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,,,,,100.0,MG,,QD,2019,Q2,Ketosis,,2019,Q2,1,I,2018.0,20190509.0,20190524,20190524,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-047322,BRISTOL MYERS SQUIBB,,46.0,YR,,M,Y,,,20190524.0,,MD,CN,CN,2019,Q2,Adult
163619191,16361919,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2019,Q2,Necrotising fasciitis,,2019,Q2,1,I,20190415.0,20190523.0,20190528,20190528,EXP,GB-MHRA-EYC 00199750,GB-JNJFOC-20190532913,JANSSEN,,56.0,YR,A,F,Y,98.9,KG,20190528.0,,MD,GB,GB,2019,Q2,Adult
163653082,16365308,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM,,,U,,,,,100.0,MG,,,2019,Q2,Abdominal pain upper,,2019,Q2,2,F,,20190530.0,20190529,20190613,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050380,BRISTOL MYERS SQUIBB,TAKEMOTO. A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS RELATED WITH A SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR AFTER THE CHOLECYSTECTOMY FOR CHOLECYSTITIS IN A PATIENT WITH TYPE 2 DIABETES. JOURNAL OF THE JAPAN DIABETES SOCIETY. 2019;62(2):94-100,71.0,YR,,F,Y,55.0,KG,20190613.0,,OT,JP,JP,2019,Q2,Elderly
163653082,16365308,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM,,,U,,,,,100.0,MG,,,2019,Q2,Cholecystitis acute,,2019,Q2,2,F,,20190530.0,20190529,20190613,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050380,BRISTOL MYERS SQUIBB,TAKEMOTO. A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS RELATED WITH A SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR AFTER THE CHOLECYSTECTOMY FOR CHOLECYSTITIS IN A PATIENT WITH TYPE 2 DIABETES. JOURNAL OF THE JAPAN DIABETES SOCIETY. 2019;62(2):94-100,71.0,YR,,F,Y,55.0,KG,20190613.0,,OT,JP,JP,2019,Q2,Elderly
163653082,16365308,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM,,,U,,,,,100.0,MG,,,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,2,F,,20190530.0,20190529,20190613,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050380,BRISTOL MYERS SQUIBB,TAKEMOTO. A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS RELATED WITH A SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR AFTER THE CHOLECYSTECTOMY FOR CHOLECYSTITIS IN A PATIENT WITH TYPE 2 DIABETES. JOURNAL OF THE JAPAN DIABETES SOCIETY. 2019;62(2):94-100,71.0,YR,,F,Y,55.0,KG,20190613.0,,OT,JP,JP,2019,Q2,Elderly
163653082,16365308,6,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,Y,,,,,100.0,MG,TABLET,,2019,Q2,Abdominal pain upper,,2019,Q2,2,F,,20190530.0,20190529,20190613,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050380,BRISTOL MYERS SQUIBB,TAKEMOTO. A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS RELATED WITH A SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR AFTER THE CHOLECYSTECTOMY FOR CHOLECYSTITIS IN A PATIENT WITH TYPE 2 DIABETES. JOURNAL OF THE JAPAN DIABETES SOCIETY. 2019;62(2):94-100,71.0,YR,,F,Y,55.0,KG,20190613.0,,OT,JP,JP,2019,Q2,Elderly
163653082,16365308,6,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,Y,,,,,100.0,MG,TABLET,,2019,Q2,Cholecystitis acute,,2019,Q2,2,F,,20190530.0,20190529,20190613,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050380,BRISTOL MYERS SQUIBB,TAKEMOTO. A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS RELATED WITH A SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR AFTER THE CHOLECYSTECTOMY FOR CHOLECYSTITIS IN A PATIENT WITH TYPE 2 DIABETES. JOURNAL OF THE JAPAN DIABETES SOCIETY. 2019;62(2):94-100,71.0,YR,,F,Y,55.0,KG,20190613.0,,OT,JP,JP,2019,Q2,Elderly
163653082,16365308,6,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,Y,,,,,100.0,MG,TABLET,,2019,Q2,Euglycaemic diabetic ketoacidosis,,2019,Q2,2,F,,20190530.0,20190529,20190613,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050380,BRISTOL MYERS SQUIBB,TAKEMOTO. A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS RELATED WITH A SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR AFTER THE CHOLECYSTECTOMY FOR CHOLECYSTITIS IN A PATIENT WITH TYPE 2 DIABETES. JOURNAL OF THE JAPAN DIABETES SOCIETY. 2019;62(2):94-100,71.0,YR,,F,Y,55.0,KG,20190613.0,,OT,JP,JP,2019,Q2,Elderly
163838131,16383813,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",1700.0,MG,D,, UNK,,,100.0,MG,,QD,2019,Q2,Hepatitis,,2019,Q2,1,I,20180823.0,20190524.0,20190603,20190603,EXP,ES-AEMPS-412098,ES-MYLANLABS-2019M1050976,MYLAN,,75.0,YR,,F,Y,,,20190603.0,,MD,ES,ES,2019,Q2,Elderly
163902661,16390266,2,C,VOKANAMET [CANAGLIFLOZIN HEMIHYDRATE;METFORMIN HYDROCHLORIDE],,2,Unknown,FORM STRENGTH: 50/1000 MG,,,D,,,,,,,,,2019,Q2,Lactic acidosis,,2019,Q2,1,I,,20190521.0,20190604,20190604,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-053140,BRISTOL MYERS SQUIBB,,70.0,YR,,M,Y,,,20190604.0,,OT,ES,ES,2019,Q2,Elderly
163902661,16390266,2,C,VOKANAMET [CANAGLIFLOZIN HEMIHYDRATE;METFORMIN HYDROCHLORIDE],,2,Unknown,FORM STRENGTH: 50/1000 MG,,,D,,,,,,,,,2019,Q2,Renal failure,,2019,Q2,1,I,,20190521.0,20190604,20190604,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-053140,BRISTOL MYERS SQUIBB,,70.0,YR,,M,Y,,,20190604.0,,OT,ES,ES,2019,Q2,Elderly
163902661,16390266,2,C,VOKANAMET [CANAGLIFLOZIN HEMIHYDRATE;METFORMIN HYDROCHLORIDE],,2,Unknown,FORM STRENGTH: 50/1000 MG,,,D,,,,,,,,,2019,Q2,Toxicity to various agents,,2019,Q2,1,I,,20190521.0,20190604,20190604,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-053140,BRISTOL MYERS SQUIBB,,70.0,YR,,M,Y,,,20190604.0,,OT,ES,ES,2019,Q2,Elderly
164210181,16421018,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2019,Q2,Depression,,2019,Q2,1,I,20170725.0,20190610.0,20190612,20190612,EXP,GB-MHRA-INP36E4B76A-A21C-40D2-B105-3FBE631E4694,GB-JNJFOC-20190613817,JANSSEN,,69.0,YR,E,M,Y,111.0,KG,20190612.0,,MD,GB,GB,2019,Q2,Elderly
164210181,16421018,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2019,Q2,Hyperhidrosis,,2019,Q2,1,I,20170725.0,20190610.0,20190612,20190612,EXP,GB-MHRA-INP36E4B76A-A21C-40D2-B105-3FBE631E4694,GB-JNJFOC-20190613817,JANSSEN,,69.0,YR,E,M,Y,111.0,KG,20190612.0,,MD,GB,GB,2019,Q2,Elderly
164210181,16421018,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2019,Q2,Insomnia,,2019,Q2,1,I,20170725.0,20190610.0,20190612,20190612,EXP,GB-MHRA-INP36E4B76A-A21C-40D2-B105-3FBE631E4694,GB-JNJFOC-20190613817,JANSSEN,,69.0,YR,E,M,Y,111.0,KG,20190612.0,,MD,GB,GB,2019,Q2,Elderly
164210181,16421018,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2019,Q2,Urinary tract infection,,2019,Q2,1,I,20170725.0,20190610.0,20190612,20190612,EXP,GB-MHRA-INP36E4B76A-A21C-40D2-B105-3FBE631E4694,GB-JNJFOC-20190613817,JANSSEN,,69.0,YR,E,M,Y,111.0,KG,20190612.0,,MD,GB,GB,2019,Q2,Elderly
164241621,16424162,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,QD,2019,Q2,Hyperglycaemia,,2019,Q2,1,I,,20190606.0,20190613,20190613,EXP,,CA-TEVA-2019-CA-1062320,TEVA,,74.0,YR,,M,Y,,,20190613.0,,OT,CA,CA,2019,Q2,Elderly
164241621,16424162,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,QD,2019,Q2,Ketoacidosis,,2019,Q2,1,I,,20190606.0,20190613,20190613,EXP,,CA-TEVA-2019-CA-1062320,TEVA,,74.0,YR,,M,Y,,,20190613.0,,OT,CA,CA,2019,Q2,Elderly
164833101,16483310,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q2,Peripheral arterial occlusive disease,,2019,Q2,1,I,,20190611.0,20190627,20190627,EXP,,JP-JNJFOC-20190632144,JOHNSON AND JOHNSON,,69.0,YR,,M,Y,,,20190627.0,,MD,JP,JP,2019,Q2,Elderly
164833191,16483319,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q2,Atrial fibrillation,,2019,Q2,1,I,20180129.0,20190612.0,20190627,20190627,EXP,,JP-JNJFOC-20190629283,JOHNSON AND JOHNSON,,59.0,YR,,M,Y,,,20190627.0,,MD,JP,JP,2019,Q2,Adult
164834131,16483413,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q2,Haemoptysis,,2019,Q2,1,I,20190429.0,20190619.0,20190627,20190627,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-060638,BRISTOL MYERS SQUIBB,,71.0,YR,,F,Y,80.5,KG,20190627.0,,OT,US,US,2019,Q2,Elderly
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Adverse drug reaction,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Arthralgia,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Arthritis,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Blood creatinine decreased,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Blood uric acid decreased,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Drug ineffective,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Gastrointestinal haemorrhage,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Glycosylated haemoglobin increased,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Haemoglobin decreased,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Hepatic cirrhosis,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Hepatosplenomegaly,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Hypertrophy,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Inflammatory marker increased,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Joint effusion,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Joint swelling,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Liver disorder,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Low density lipoprotein increased,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Nausea,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Nonalcoholic fatty liver disease,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Pain in extremity,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Psoriasis,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Psoriatic arthropathy,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Red blood cell sedimentation rate increased,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Rheumatoid arthritis,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Therapeutic product effect decreased,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Therapeutic product effect incomplete,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Type 2 diabetes mellitus,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974091,16497409,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,TABLET,,2019,Q2,Varices oesophageal,,2019,Q2,1,I,,20190622.0,20190628,20190628,EXP,,CA-SA-2019SA170683,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190628.0,,OT,CA,CA,2019,Q2,Adult
164974611,16497461,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,CANAGLU,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q2,Myocardial ischaemia,,2019,Q2,1,I,20180206.0,20190613.0,20190628,20190628,EXP,,JP-JNJFOC-20190633017,JOHNSON AND JOHNSON,,75.0,YR,,M,Y,73.0,KG,20190628.0,,MD,JP,JP,2019,Q2,Elderly
125995372,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2019,Q3,Acute kidney injury,,2019,Q3,2,F,,20160713.0,20160727,20190719,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20190719.0,,CN,GB,JP,2019,Q3,Adult
125995372,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2019,Q3,Dehydration,,2019,Q3,2,F,,20160713.0,20160727,20190719,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20190719.0,,CN,GB,JP,2019,Q3,Adult
125995372,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2019,Q3,Diabetes mellitus inadequate control,,2019,Q3,2,F,,20160713.0,20160727,20190719,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20190719.0,,CN,GB,JP,2019,Q3,Adult
125995372,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,2,F,,20160713.0,20160727,20190719,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20190719.0,,CN,GB,JP,2019,Q3,Adult
125995372,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2019,Q3,Exploratory operation,,2019,Q3,2,F,,20160713.0,20160727,20190719,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20190719.0,,CN,GB,JP,2019,Q3,Adult
125995372,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2019,Q3,Haemodialysis,,2019,Q3,2,F,,20160713.0,20160727,20190719,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20190719.0,,CN,GB,JP,2019,Q3,Adult
125995372,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2019,Q3,Intestinal ischaemia,,2019,Q3,2,F,,20160713.0,20160727,20190719,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20190719.0,,CN,GB,JP,2019,Q3,Adult
125995372,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2019,Q3,Intestinal resection,,2019,Q3,2,F,,20160713.0,20160727,20190719,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20190719.0,,CN,GB,JP,2019,Q3,Adult
125995372,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2019,Q3,Lactic acidosis,,2019,Q3,2,F,,20160713.0,20160727,20190719,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20190719.0,,CN,GB,JP,2019,Q3,Adult
125995372,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2019,Q3,Product prescribing error,,2019,Q3,2,F,,20160713.0,20160727,20190719,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20190719.0,,CN,GB,JP,2019,Q3,Adult
125995372,12599537,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNK",,,,,,,,300.0,MG,,,2019,Q3,Weight decreased,,2019,Q3,2,F,,20160713.0,20160727,20190719,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-059723,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,73.0,KG,20190719.0,,CN,GB,JP,2019,Q3,Adult
127551487,12755148,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Asthma,,2019,Q3,7,F,201608.0,20190820.0,20160916,20190830,EXP,,JP-JNJFOC-20160915062,JOHNSON AND JOHNSON,,74.0,YR,,M,Y,64.0,KG,20190830.0,,MD,JP,JP,2019,Q3,Elderly
127551487,12755148,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Bladder diverticulum,,2019,Q3,7,F,201608.0,20190820.0,20160916,20190830,EXP,,JP-JNJFOC-20160915062,JOHNSON AND JOHNSON,,74.0,YR,,M,Y,64.0,KG,20190830.0,,MD,JP,JP,2019,Q3,Elderly
127551487,12755148,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Cholelithiasis,,2019,Q3,7,F,201608.0,20190820.0,20160916,20190830,EXP,,JP-JNJFOC-20160915062,JOHNSON AND JOHNSON,,74.0,YR,,M,Y,64.0,KG,20190830.0,,MD,JP,JP,2019,Q3,Elderly
127551487,12755148,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Chronic gastritis,,2019,Q3,7,F,201608.0,20190820.0,20160916,20190830,EXP,,JP-JNJFOC-20160915062,JOHNSON AND JOHNSON,,74.0,YR,,M,Y,64.0,KG,20190830.0,,MD,JP,JP,2019,Q3,Elderly
127551487,12755148,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Chronic obstructive pulmonary disease,,2019,Q3,7,F,201608.0,20190820.0,20160916,20190830,EXP,,JP-JNJFOC-20160915062,JOHNSON AND JOHNSON,,74.0,YR,,M,Y,64.0,KG,20190830.0,,MD,JP,JP,2019,Q3,Elderly
127551487,12755148,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Decreased appetite,,2019,Q3,7,F,201608.0,20190820.0,20160916,20190830,EXP,,JP-JNJFOC-20160915062,JOHNSON AND JOHNSON,,74.0,YR,,M,Y,64.0,KG,20190830.0,,MD,JP,JP,2019,Q3,Elderly
127551487,12755148,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Dehydration,,2019,Q3,7,F,201608.0,20190820.0,20160916,20190830,EXP,,JP-JNJFOC-20160915062,JOHNSON AND JOHNSON,,74.0,YR,,M,Y,64.0,KG,20190830.0,,MD,JP,JP,2019,Q3,Elderly
127551487,12755148,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Diverticulum intestinal,,2019,Q3,7,F,201608.0,20190820.0,20160916,20190830,EXP,,JP-JNJFOC-20160915062,JOHNSON AND JOHNSON,,74.0,YR,,M,Y,64.0,KG,20190830.0,,MD,JP,JP,2019,Q3,Elderly
127551487,12755148,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Hyponatraemia,,2019,Q3,7,F,201608.0,20190820.0,20160916,20190830,EXP,,JP-JNJFOC-20160915062,JOHNSON AND JOHNSON,,74.0,YR,,M,Y,64.0,KG,20190830.0,,MD,JP,JP,2019,Q3,Elderly
127551487,12755148,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Iron deficiency anaemia,,2019,Q3,7,F,201608.0,20190820.0,20160916,20190830,EXP,,JP-JNJFOC-20160915062,JOHNSON AND JOHNSON,,74.0,YR,,M,Y,64.0,KG,20190830.0,,MD,JP,JP,2019,Q3,Elderly
127551487,12755148,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Pneumonia,,2019,Q3,7,F,201608.0,20190820.0,20160916,20190830,EXP,,JP-JNJFOC-20160915062,JOHNSON AND JOHNSON,,74.0,YR,,M,Y,64.0,KG,20190830.0,,MD,JP,JP,2019,Q3,Elderly
127551487,12755148,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Pollakiuria,,2019,Q3,7,F,201608.0,20190820.0,20160916,20190830,EXP,,JP-JNJFOC-20160915062,JOHNSON AND JOHNSON,,74.0,YR,,M,Y,64.0,KG,20190830.0,,MD,JP,JP,2019,Q3,Elderly
127551487,12755148,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Renal cyst,,2019,Q3,7,F,201608.0,20190820.0,20160916,20190830,EXP,,JP-JNJFOC-20160915062,JOHNSON AND JOHNSON,,74.0,YR,,M,Y,64.0,KG,20190830.0,,MD,JP,JP,2019,Q3,Elderly
127626746,12762674,1,PS,CANAGLIFLOZIN TABLET,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Cataract,,2019,Q3,6,F,20160406.0,20190619.0,20160920,20190703,EXP,,JP-JNJFOC-20160915069,JOHNSON AND JOHNSON,,66.0,YR,,F,Y,54.0,KG,20190703.0,,MD,JP,JP,2019,Q3,Elderly
127626746,12762674,1,PS,CANAGLIFLOZIN TABLET,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Synovial cyst,,2019,Q3,6,F,20160406.0,20190619.0,20160920,20190703,EXP,,JP-JNJFOC-20160915069,JOHNSON AND JOHNSON,,66.0,YR,,F,Y,54.0,KG,20190703.0,,MD,JP,JP,2019,Q3,Elderly
128582693,12858269,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Borderline personality disorder,,2019,Q3,3,F,20160312.0,20190819.0,20161018,20190827,EXP,,JP-JNJFOC-20161013100,JOHNSON AND JOHNSON,,39.0,YR,,F,Y,86.0,KG,20190827.0,,MD,JP,JP,2019,Q3,Adult
128582693,12858269,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Facial paralysis,,2019,Q3,3,F,20160312.0,20190819.0,20161018,20190827,EXP,,JP-JNJFOC-20161013100,JOHNSON AND JOHNSON,,39.0,YR,,F,Y,86.0,KG,20190827.0,,MD,JP,JP,2019,Q3,Adult
128819145,12881914,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Blood cholesterol increased,,2019,Q3,5,F,20160721.0,20190611.0,20161025,20190719,EXP,,JP-JNJFOC-20160926105,JOHNSON AND JOHNSON,,49.0,YR,,F,Y,51.0,KG,20190719.0,,MD,JP,JP,2019,Q3,Adult
128819145,12881914,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Foot fracture,,2019,Q3,5,F,20160721.0,20190611.0,20161025,20190719,EXP,,JP-JNJFOC-20160926105,JOHNSON AND JOHNSON,,49.0,YR,,F,Y,51.0,KG,20190719.0,,MD,JP,JP,2019,Q3,Adult
128819145,12881914,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Protein urine present,,2019,Q3,5,F,20160721.0,20190611.0,20161025,20190719,EXP,,JP-JNJFOC-20160926105,JOHNSON AND JOHNSON,,49.0,YR,,F,Y,51.0,KG,20190719.0,,MD,JP,JP,2019,Q3,Adult
128819145,12881914,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Sudden hearing loss,,2019,Q3,5,F,20160721.0,20190611.0,20161025,20190719,EXP,,JP-JNJFOC-20160926105,JOHNSON AND JOHNSON,,49.0,YR,,F,Y,51.0,KG,20190719.0,,MD,JP,JP,2019,Q3,Adult
128819145,12881914,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Urine ketone body present,,2019,Q3,5,F,20160721.0,20190611.0,20161025,20190719,EXP,,JP-JNJFOC-20160926105,JOHNSON AND JOHNSON,,49.0,YR,,F,Y,51.0,KG,20190719.0,,MD,JP,JP,2019,Q3,Adult
129302505,12930250,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Azotaemia,,2019,Q3,5,F,20160711.0,20190708.0,20161110,20190722,EXP,,JP-JNJFOC-20161004528,JOHNSON AND JOHNSON,,67.0,YR,,M,Y,63.0,KG,20190722.0,,MD,JP,JP,2019,Q3,Elderly
129302505,12930250,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Dehydration,,2019,Q3,5,F,20160711.0,20190708.0,20161110,20190722,EXP,,JP-JNJFOC-20161004528,JOHNSON AND JOHNSON,,67.0,YR,,M,Y,63.0,KG,20190722.0,,MD,JP,JP,2019,Q3,Elderly
129302505,12930250,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Polycythaemia,,2019,Q3,5,F,20160711.0,20190708.0,20161110,20190722,EXP,,JP-JNJFOC-20161004528,JOHNSON AND JOHNSON,,67.0,YR,,M,Y,63.0,KG,20190722.0,,MD,JP,JP,2019,Q3,Elderly
130091427,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Blood pressure diastolic decreased,,2019,Q3,7,F,2016.0,20190902.0,20161208,20190916,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20190916.0,,MD,JP,JP,2019,Q3,Elderly
130091427,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Blood pressure increased,,2019,Q3,7,F,2016.0,20190902.0,20161208,20190916,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20190916.0,,MD,JP,JP,2019,Q3,Elderly
130091427,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Cardiac failure,,2019,Q3,7,F,2016.0,20190902.0,20161208,20190916,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20190916.0,,MD,JP,JP,2019,Q3,Elderly
130091427,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Cold sweat,,2019,Q3,7,F,2016.0,20190902.0,20161208,20190916,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20190916.0,,MD,JP,JP,2019,Q3,Elderly
130091427,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Feeling cold,,2019,Q3,7,F,2016.0,20190902.0,20161208,20190916,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20190916.0,,MD,JP,JP,2019,Q3,Elderly
130091427,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Heart rate increased,,2019,Q3,7,F,2016.0,20190902.0,20161208,20190916,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20190916.0,,MD,JP,JP,2019,Q3,Elderly
130091427,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Hyperhidrosis,,2019,Q3,7,F,2016.0,20190902.0,20161208,20190916,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20190916.0,,MD,JP,JP,2019,Q3,Elderly
130091427,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Ileus,,2019,Q3,7,F,2016.0,20190902.0,20161208,20190916,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20190916.0,,MD,JP,JP,2019,Q3,Elderly
130091427,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Melaena,,2019,Q3,7,F,2016.0,20190902.0,20161208,20190916,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20190916.0,,MD,JP,JP,2019,Q3,Elderly
130091427,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Oedema peripheral,,2019,Q3,7,F,2016.0,20190902.0,20161208,20190916,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20190916.0,,MD,JP,JP,2019,Q3,Elderly
130091427,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Pollakiuria,,2019,Q3,7,F,2016.0,20190902.0,20161208,20190916,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20190916.0,,MD,JP,JP,2019,Q3,Elderly
130091427,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Renal impairment,,2019,Q3,7,F,2016.0,20190902.0,20161208,20190916,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20190916.0,,MD,JP,JP,2019,Q3,Elderly
130091427,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Weight decreased,,2019,Q3,7,F,2016.0,20190902.0,20161208,20190916,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20190916.0,,MD,JP,JP,2019,Q3,Elderly
130398444,13039844,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,UNKNOWN,QD,2019,Q3,Atrial fibrillation,,2019,Q3,4,F,20160813.0,20190902.0,20161219,20190912,EXP,,JP-JNJFOC-20161201691,JOHNSON AND JOHNSON,,60.0,YR,,M,Y,85.0,KG,20190912.0,,MD,JP,JP,2019,Q3,Adult
130398444,13039844,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,UNKNOWN,QD,2019,Q3,Prostatitis,,2019,Q3,4,F,20160813.0,20190902.0,20161219,20190912,EXP,,JP-JNJFOC-20161201691,JOHNSON AND JOHNSON,,60.0,YR,,M,Y,85.0,KG,20190912.0,,MD,JP,JP,2019,Q3,Adult
130398444,13039844,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,UNKNOWN,QD,2019,Q3,Atrial fibrillation,,2019,Q3,4,F,20160813.0,20190902.0,20161219,20190912,EXP,,JP-JNJFOC-20161201691,JOHNSON AND JOHNSON,,60.0,YR,,M,Y,85.0,KG,20190912.0,,MD,JP,JP,2019,Q3,Adult
130398444,13039844,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,UNKNOWN,QD,2019,Q3,Prostatitis,,2019,Q3,4,F,20160813.0,20190902.0,20161219,20190912,EXP,,JP-JNJFOC-20161201691,JOHNSON AND JOHNSON,,60.0,YR,,M,Y,85.0,KG,20190912.0,,MD,JP,JP,2019,Q3,Adult
130931454,13093145,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Azotaemia,,2019,Q3,4,F,20160906.0,20190705.0,20170106,20190719,EXP,,JP-JNJFOC-20170104450,JOHNSON AND JOHNSON,,63.0,YR,,F,Y,47.0,KG,20190719.0,,MD,JP,JP,2019,Q3,Adult
130931454,13093145,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Polycythaemia,,2019,Q3,4,F,20160906.0,20190705.0,20170106,20190719,EXP,,JP-JNJFOC-20170104450,JOHNSON AND JOHNSON,,63.0,YR,,F,Y,47.0,KG,20190719.0,,MD,JP,JP,2019,Q3,Adult
130984255,13098425,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Azotaemia,,2019,Q3,5,F,20161121.0,20190802.0,20170109,20190809,EXP,,JP-JNJFOC-20170105059,JOHNSON AND JOHNSON,,67.0,YR,,F,Y,67.0,KG,20190809.0,,MD,JP,JP,2019,Q3,Elderly
130984255,13098425,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Polycythaemia,,2019,Q3,5,F,20161121.0,20190802.0,20170109,20190809,EXP,,JP-JNJFOC-20170105059,JOHNSON AND JOHNSON,,67.0,YR,,F,Y,67.0,KG,20190809.0,,MD,JP,JP,2019,Q3,Elderly
132043814,13204381,1,PS,CANAGLIFLOZIN TABLET,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Fracture,,2019,Q3,4,F,2016.0,20190619.0,20170209,20190703,EXP,,JP-JNJFOC-20170208533,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,66.0,KG,20190703.0,,MD,JP,JP,2019,Q3,Adult
132043814,13204381,1,PS,CANAGLIFLOZIN TABLET,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Hepatic function abnormal,,2019,Q3,4,F,2016.0,20190619.0,20170209,20190703,EXP,,JP-JNJFOC-20170208533,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,66.0,KG,20190703.0,,MD,JP,JP,2019,Q3,Adult
132043814,13204381,1,PS,CANAGLIFLOZIN TABLET,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Road traffic accident,,2019,Q3,4,F,2016.0,20190619.0,20170209,20190703,EXP,,JP-JNJFOC-20170208533,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,66.0,KG,20190703.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Bacterial test positive,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Constipation,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Haemorrhoids,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Inappropriate schedule of product administration,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Influenza,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Low density lipoprotein increased,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Musculoskeletal stiffness,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Off label use,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Polyuria,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Pruritus genital,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Rhinitis allergic,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Urine ketone body present,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QOD,2019,Q3,Bacterial test positive,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QOD,2019,Q3,Constipation,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QOD,2019,Q3,Haemorrhoids,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QOD,2019,Q3,Inappropriate schedule of product administration,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QOD,2019,Q3,Influenza,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QOD,2019,Q3,Low density lipoprotein increased,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QOD,2019,Q3,Musculoskeletal stiffness,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QOD,2019,Q3,Off label use,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QOD,2019,Q3,Polyuria,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QOD,2019,Q3,Pruritus genital,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QOD,2019,Q3,Rhinitis allergic,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QOD,2019,Q3,Urine ketone body present,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Bacterial test positive,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Constipation,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Haemorrhoids,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Inappropriate schedule of product administration,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Influenza,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Low density lipoprotein increased,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Musculoskeletal stiffness,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Off label use,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Polyuria,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Pruritus genital,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Rhinitis allergic,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
136297764,13629776,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Urine ketone body present,,2019,Q3,4,F,20160601.0,20190913.0,20170608,20190927,EXP,,JP-JNJFOC-20170116149,JOHNSON AND JOHNSON,,50.0,YR,,F,Y,59.0,KG,20190927.0,,MD,JP,JP,2019,Q3,Adult
137215904,13721590,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Atrial fibrillation,,2019,Q3,4,F,20170129.0,20190802.0,20170706,20190812,EXP,,JP-JNJFOC-20170702889,JOHNSON AND JOHNSON,,76.0,YR,,M,Y,77.0,KG,20190812.0,,MD,JP,JP,2019,Q3,Elderly
137526064,13752606,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Abdominal pain upper,,2019,Q3,4,F,20160616.0,20190704.0,20170713,20190717,EXP,,JP-JNJFOC-20161220046,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,93.0,KG,20190717.0,,MD,JP,JP,2019,Q3,Adult
137526064,13752606,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Angina pectoris,,2019,Q3,4,F,20160616.0,20190704.0,20170713,20190717,EXP,,JP-JNJFOC-20161220046,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,93.0,KG,20190717.0,,MD,JP,JP,2019,Q3,Adult
138813686,13881368,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Albumin urine present,,2019,Q3,6,F,20161020.0,20190911.0,20170818,20190926,EXP,,JP-JNJFOC-20170816517,JOHNSON AND JOHNSON,,69.0,YR,,F,Y,55.0,KG,20190926.0,,MD,JP,JP,2019,Q3,Elderly
138813686,13881368,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Bacterial test positive,,2019,Q3,6,F,20161020.0,20190911.0,20170818,20190926,EXP,,JP-JNJFOC-20170816517,JOHNSON AND JOHNSON,,69.0,YR,,F,Y,55.0,KG,20190926.0,,MD,JP,JP,2019,Q3,Elderly
138813686,13881368,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Blood ketone body increased,,2019,Q3,6,F,20161020.0,20190911.0,20170818,20190926,EXP,,JP-JNJFOC-20170816517,JOHNSON AND JOHNSON,,69.0,YR,,F,Y,55.0,KG,20190926.0,,MD,JP,JP,2019,Q3,Elderly
138813686,13881368,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Urine ketone body present,,2019,Q3,6,F,20161020.0,20190911.0,20170818,20190926,EXP,,JP-JNJFOC-20170816517,JOHNSON AND JOHNSON,,69.0,YR,,F,Y,55.0,KG,20190926.0,,MD,JP,JP,2019,Q3,Elderly
139405322,13940532,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Drug eruption,,2019,Q3,2,F,20161214.0,20190819.0,20170906,20190828,EXP,,JP-JNJFOC-20170318759,JOHNSON AND JOHNSON,,78.0,YR,,F,Y,67.0,KG,20190828.0,,MD,JP,JP,2019,Q3,Elderly
139405322,13940532,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Helicobacter infection,,2019,Q3,2,F,20161214.0,20190819.0,20170906,20190828,EXP,,JP-JNJFOC-20170318759,JOHNSON AND JOHNSON,,78.0,YR,,F,Y,67.0,KG,20190828.0,,MD,JP,JP,2019,Q3,Elderly
139405322,13940532,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Pruritus generalised,,2019,Q3,2,F,20161214.0,20190819.0,20170906,20190828,EXP,,JP-JNJFOC-20170318759,JOHNSON AND JOHNSON,,78.0,YR,,F,Y,67.0,KG,20190828.0,,MD,JP,JP,2019,Q3,Elderly
140924084,14092408,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Urinary tract infection,,2019,Q3,4,F,20170828.0,20190911.0,20171016,20190925,EXP,,JP-JNJFOC-20171013421,JOHNSON AND JOHNSON,,65.0,YR,,F,Y,102.0,KG,20190925.0,,MD,JP,JP,2019,Q3,Elderly
140924084,14092408,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Urine ketone body present,,2019,Q3,4,F,20170828.0,20190911.0,20171016,20190925,EXP,,JP-JNJFOC-20171013421,JOHNSON AND JOHNSON,,65.0,YR,,F,Y,102.0,KG,20190925.0,,MD,JP,JP,2019,Q3,Elderly
142182872,14218287,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Cerebral infarction,,2019,Q3,2,F,20170514.0,20190806.0,20171123,20190814,EXP,,JP-JNJFOC-20171125937,JOHNSON AND JOHNSON,,69.0,YR,,M,Y,82.0,KG,20190814.0,,MD,JP,JP,2019,Q3,Elderly
142182872,14218287,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Intracranial aneurysm,,2019,Q3,2,F,20170514.0,20190806.0,20171123,20190814,EXP,,JP-JNJFOC-20171125937,JOHNSON AND JOHNSON,,69.0,YR,,M,Y,82.0,KG,20190814.0,,MD,JP,JP,2019,Q3,Elderly
143375764,14337576,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Cystitis,,2019,Q3,4,F,20160909.0,20190911.0,20171229,20190919,EXP,,JP-JNJFOC-20171234912,JOHNSON AND JOHNSON,,49.0,YR,,F,Y,77.0,KG,20190919.0,,MD,JP,JP,2019,Q3,Adult
143375764,14337576,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Menopausal symptoms,,2019,Q3,4,F,20160909.0,20190911.0,20171229,20190919,EXP,,JP-JNJFOC-20171234912,JOHNSON AND JOHNSON,,49.0,YR,,F,Y,77.0,KG,20190919.0,,MD,JP,JP,2019,Q3,Adult
143375764,14337576,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Uterine leiomyoma,,2019,Q3,4,F,20160909.0,20190911.0,20171229,20190919,EXP,,JP-JNJFOC-20171234912,JOHNSON AND JOHNSON,,49.0,YR,,F,Y,77.0,KG,20190919.0,,MD,JP,JP,2019,Q3,Adult
143375764,14337576,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Vulvitis,,2019,Q3,4,F,20160909.0,20190911.0,20171229,20190919,EXP,,JP-JNJFOC-20171234912,JOHNSON AND JOHNSON,,49.0,YR,,F,Y,77.0,KG,20190919.0,,MD,JP,JP,2019,Q3,Adult
144527454,14452745,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Gastric ulcer,,2019,Q3,4,F,201611.0,20190626.0,20180129,20190711,EXP,,JP-JNJFOC-20180132105,JOHNSON AND JOHNSON,,54.0,YR,,M,Y,115.0,KG,20190711.0,,MD,JP,JP,2019,Q3,Adult
144527454,14452745,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Hypertension,,2019,Q3,4,F,201611.0,20190626.0,20180129,20190711,EXP,,JP-JNJFOC-20180132105,JOHNSON AND JOHNSON,,54.0,YR,,M,Y,115.0,KG,20190711.0,,MD,JP,JP,2019,Q3,Adult
146075302,14607530,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Alcoholic liver disease,,2019,Q3,2,F,20170307.0,20190819.0,20180307,20190829,EXP,,JP-JNJFOC-20180306834,JOHNSON AND JOHNSON,,67.0,YR,,M,Y,69.0,KG,20190829.0,,MD,JP,JP,2019,Q3,Elderly
146075302,14607530,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Bile duct stone,,2019,Q3,2,F,20170307.0,20190819.0,20180307,20190829,EXP,,JP-JNJFOC-20180306834,JOHNSON AND JOHNSON,,67.0,YR,,M,Y,69.0,KG,20190829.0,,MD,JP,JP,2019,Q3,Elderly
146075302,14607530,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Hepatic steatosis,,2019,Q3,2,F,20170307.0,20190819.0,20180307,20190829,EXP,,JP-JNJFOC-20180306834,JOHNSON AND JOHNSON,,67.0,YR,,M,Y,69.0,KG,20190829.0,,MD,JP,JP,2019,Q3,Elderly
147086954,14708695,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Acute kidney injury,,2019,Q3,4,F,201512.0,20190813.0,20180403,20190821,EXP,,US-ASTRAZENECA-2018SE40300,ASTRAZENECA,,601.0,MON,,M,Y,124.7,KG,20190821.0,,,US,US,2019,Q3,Elderly
147086954,14708695,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Chronic kidney disease,,2019,Q3,4,F,201512.0,20190813.0,20180403,20190821,EXP,,US-ASTRAZENECA-2018SE40300,ASTRAZENECA,,601.0,MON,,M,Y,124.7,KG,20190821.0,,,US,US,2019,Q3,Elderly
147086954,14708695,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Renal failure,,2019,Q3,4,F,201512.0,20190813.0,20180403,20190821,EXP,,US-ASTRAZENECA-2018SE40300,ASTRAZENECA,,601.0,MON,,M,Y,124.7,KG,20190821.0,,,US,US,2019,Q3,Elderly
147086954,14708695,31,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Renal injury,,2019,Q3,4,F,201512.0,20190813.0,20180403,20190821,EXP,,US-ASTRAZENECA-2018SE40300,ASTRAZENECA,,601.0,MON,,M,Y,124.7,KG,20190821.0,,,US,US,2019,Q3,Elderly
147278362,14727836,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Appendicitis,,2019,Q3,2,F,201701.0,20190722.0,20180406,20190731,EXP,,JP-JNJFOC-20180406682,JOHNSON AND JOHNSON,,31.0,YR,,M,Y,97.0,KG,20190731.0,,OT,JP,JP,2019,Q3,Young Adult
147299379,14729937,20,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Acute kidney injury,,2019,Q3,9,F,201512.0,20190821.0,20180406,20190822,EXP,,US-PFIZER INC-2018137097,PFIZER,,50.0,YR,,M,Y,,,20190822.0,,OT,US,US,2019,Q3,Adult
147299379,14729937,20,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Chronic kidney disease,,2019,Q3,9,F,201512.0,20190821.0,20180406,20190822,EXP,,US-PFIZER INC-2018137097,PFIZER,,50.0,YR,,M,Y,,,20190822.0,,OT,US,US,2019,Q3,Adult
147299379,14729937,20,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Gastrooesophageal reflux disease,,2019,Q3,9,F,201512.0,20190821.0,20180406,20190822,EXP,,US-PFIZER INC-2018137097,PFIZER,,50.0,YR,,M,Y,,,20190822.0,,OT,US,US,2019,Q3,Adult
147299379,14729937,20,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Renal failure,,2019,Q3,9,F,201512.0,20190821.0,20180406,20190822,EXP,,US-PFIZER INC-2018137097,PFIZER,,50.0,YR,,M,Y,,,20190822.0,,OT,US,US,2019,Q3,Adult
147299379,14729937,20,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Renal injury,,2019,Q3,9,F,201512.0,20190821.0,20180406,20190822,EXP,,US-PFIZER INC-2018137097,PFIZER,,50.0,YR,,M,Y,,,20190822.0,,OT,US,US,2019,Q3,Adult
148419556,14841955,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Arthralgia,,2019,Q3,6,F,20160621.0,20190722.0,20180503,20190802,EXP,,JP-JNJFOC-20180500326,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,85.0,KG,20190802.0,,MD,JP,JP,2019,Q3,Elderly
148419556,14841955,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Atrial fibrillation,,2019,Q3,6,F,20160621.0,20190722.0,20180503,20190802,EXP,,JP-JNJFOC-20180500326,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,85.0,KG,20190802.0,,MD,JP,JP,2019,Q3,Elderly
148419556,14841955,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Palpitations,,2019,Q3,6,F,20160621.0,20190722.0,20180503,20190802,EXP,,JP-JNJFOC-20180500326,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,85.0,KG,20190802.0,,MD,JP,JP,2019,Q3,Elderly
149736672,14973667,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Anaemia,,2019,Q3,2,F,20171006.0,20190911.0,20180605,20190920,EXP,,JP-JNJFOC-20180602313,JOHNSON AND JOHNSON,,53.0,YR,,F,Y,52.0,KG,20190920.0,,MD,JP,JP,2019,Q3,Adult
151215684,15121568,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Cholangitis,,2019,Q3,4,F,20180308.0,20190719.0,20180709,20190731,EXP,,JP-JNJFOC-20180708793,JOHNSON AND JOHNSON,,40.0,YR,,F,Y,80.0,KG,20190731.0,,MD,JP,JP,2019,Q3,Adult
151215684,15121568,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Depression,,2019,Q3,4,F,20180308.0,20190719.0,20180709,20190731,EXP,,JP-JNJFOC-20180708793,JOHNSON AND JOHNSON,,40.0,YR,,F,Y,80.0,KG,20190731.0,,MD,JP,JP,2019,Q3,Adult
153164903,15316490,1,PS,CANAGLIFLOZIN TABLET,CANAGLIFLOZIN,1,Oral,,71400.0,MG,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Atrial fibrillation,,2019,Q3,3,F,20180322.0,20190617.0,20180824,20190701,EXP,,JP-JNJFOC-20180829659,JOHNSON AND JOHNSON,,79.0,YR,,F,Y,91.0,KG,20190701.0,,MD,JP,JP,2019,Q3,Elderly
153164903,15316490,1,PS,CANAGLIFLOZIN TABLET,CANAGLIFLOZIN,1,Oral,,71400.0,MG,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Cardiac failure congestive,,2019,Q3,3,F,20180322.0,20190617.0,20180824,20190701,EXP,,JP-JNJFOC-20180829659,JOHNSON AND JOHNSON,,79.0,YR,,F,Y,91.0,KG,20190701.0,,MD,JP,JP,2019,Q3,Elderly
153481892,15348189,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Angina pectoris,,2019,Q3,2,F,20180122.0,20190723.0,20180904,20190807,EXP,,JP-JNJFOC-20180902670,JOHNSON AND JOHNSON,,61.0,YR,,M,Y,,,20190807.0,,MD,JP,JP,2019,Q3,Adult
153481892,15348189,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Atrial fibrillation,,2019,Q3,2,F,20180122.0,20190723.0,20180904,20190807,EXP,,JP-JNJFOC-20180902670,JOHNSON AND JOHNSON,,61.0,YR,,M,Y,,,20190807.0,,MD,JP,JP,2019,Q3,Adult
153481892,15348189,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Cardiac failure congestive,,2019,Q3,2,F,20180122.0,20190723.0,20180904,20190807,EXP,,JP-JNJFOC-20180902670,JOHNSON AND JOHNSON,,61.0,YR,,M,Y,,,20190807.0,,MD,JP,JP,2019,Q3,Adult
153481892,15348189,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Gangrene,,2019,Q3,2,F,20180122.0,20190723.0,20180904,20190807,EXP,,JP-JNJFOC-20180902670,JOHNSON AND JOHNSON,,61.0,YR,,M,Y,,,20190807.0,,MD,JP,JP,2019,Q3,Adult
153481892,15348189,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Limb injury,,2019,Q3,2,F,20180122.0,20190723.0,20180904,20190807,EXP,,JP-JNJFOC-20180902670,JOHNSON AND JOHNSON,,61.0,YR,,M,Y,,,20190807.0,,MD,JP,JP,2019,Q3,Adult
153481892,15348189,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Nail injury,,2019,Q3,2,F,20180122.0,20190723.0,20180904,20190807,EXP,,JP-JNJFOC-20180902670,JOHNSON AND JOHNSON,,61.0,YR,,M,Y,,,20190807.0,,MD,JP,JP,2019,Q3,Adult
153743274,15374327,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Diabetes mellitus inadequate control,,2019,Q3,4,F,20171109.0,20190912.0,20180912,20190923,EXP,,JP-JNJFOC-20180911229,JOHNSON AND JOHNSON,,60.0,YR,,M,Y,81.0,KG,20190923.0,,MD,JP,JP,2019,Q3,Adult
153743274,15374327,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Herpes zoster,,2019,Q3,4,F,20171109.0,20190912.0,20180912,20190923,EXP,,JP-JNJFOC-20180911229,JOHNSON AND JOHNSON,,60.0,YR,,M,Y,81.0,KG,20190923.0,,MD,JP,JP,2019,Q3,Adult
153743283,15374328,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Hepatocellular carcinoma,,2019,Q3,3,F,201707.0,20190801.0,20180912,20190808,EXP,,JP-JNJFOC-20180911463,JOHNSON AND JOHNSON,,68.0,YR,,M,Y,68.0,KG,20190808.0,,MD,JP,JP,2019,Q3,Elderly
154113133,15411313,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2019,Q3,Drug hypersensitivity,,2019,Q3,3,F,,20190723.0,20180921,20190729,PER,,US-PFIZER INC-2018380693,PFIZER,,62.0,YR,,M,Y,,,20190729.0,,MD,US,US,2019,Q3,Adult
154524152,15452415,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Liver disorder,,2019,Q3,2,F,20170410.0,20190704.0,20181001,20190717,EXP,,JP-JNJFOC-20170709912,JOHNSON AND JOHNSON,,73.0,YR,,M,Y,83.0,KG,20190717.0,,MD,JP,JP,2019,Q3,Elderly
154524152,15452415,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Renal disorder,,2019,Q3,2,F,20170410.0,20190704.0,20181001,20190717,EXP,,JP-JNJFOC-20170709912,JOHNSON AND JOHNSON,,73.0,YR,,M,Y,83.0,KG,20190717.0,,MD,JP,JP,2019,Q3,Elderly
154524152,15452415,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Squamous cell carcinoma of lung,,2019,Q3,2,F,20170410.0,20190704.0,20181001,20190717,EXP,,JP-JNJFOC-20170709912,JOHNSON AND JOHNSON,,73.0,YR,,M,Y,83.0,KG,20190717.0,,MD,JP,JP,2019,Q3,Elderly
154687465,15468746,1,PS,CANAGLIFLOZIN TABLET,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Abdominal pain upper,,2019,Q3,5,F,2017.0,20190620.0,20181005,20190703,EXP,,JP-JNJFOC-20181007536,JOHNSON AND JOHNSON,,78.0,YR,,M,Y,93.0,KG,20190703.0,,MD,JP,JP,2019,Q3,Elderly
154687465,15468746,1,PS,CANAGLIFLOZIN TABLET,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Fall,,2019,Q3,5,F,2017.0,20190620.0,20181005,20190703,EXP,,JP-JNJFOC-20181007536,JOHNSON AND JOHNSON,,78.0,YR,,M,Y,93.0,KG,20190703.0,,MD,JP,JP,2019,Q3,Elderly
154687465,15468746,1,PS,CANAGLIFLOZIN TABLET,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Subdural hygroma,,2019,Q3,5,F,2017.0,20190620.0,20181005,20190703,EXP,,JP-JNJFOC-20181007536,JOHNSON AND JOHNSON,,78.0,YR,,M,Y,93.0,KG,20190703.0,,MD,JP,JP,2019,Q3,Elderly
156995485,15699548,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Albumin urine present,,2019,Q3,5,F,2016.0,20190823.0,20181207,20190916,EXP,,JP-JNJFOC-20181202259,JOHNSON AND JOHNSON,,41.0,YR,,M,Y,108.0,KG,20190916.0,,MD,JP,JP,2019,Q3,Adult
156995485,15699548,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Blood creatinine increased,,2019,Q3,5,F,2016.0,20190823.0,20181207,20190916,EXP,,JP-JNJFOC-20181202259,JOHNSON AND JOHNSON,,41.0,YR,,M,Y,108.0,KG,20190916.0,,MD,JP,JP,2019,Q3,Adult
156995485,15699548,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Road traffic accident,,2019,Q3,5,F,2016.0,20190823.0,20181207,20190916,EXP,,JP-JNJFOC-20181202259,JOHNSON AND JOHNSON,,41.0,YR,,M,Y,108.0,KG,20190916.0,,MD,JP,JP,2019,Q3,Adult
156995485,15699548,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Upper limb fracture,,2019,Q3,5,F,2016.0,20190823.0,20181207,20190916,EXP,,JP-JNJFOC-20181202259,JOHNSON AND JOHNSON,,41.0,YR,,M,Y,108.0,KG,20190916.0,,MD,JP,JP,2019,Q3,Adult
156995485,15699548,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Upper respiratory tract infection,,2019,Q3,5,F,2016.0,20190823.0,20181207,20190916,EXP,,JP-JNJFOC-20181202259,JOHNSON AND JOHNSON,,41.0,YR,,M,Y,108.0,KG,20190916.0,,MD,JP,JP,2019,Q3,Adult
157056274,15705627,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Lateral medullary syndrome,,2019,Q3,4,F,20181112.0,20190819.0,20181210,20190829,EXP,,JP-JNJFOC-20181209506,JOHNSON AND JOHNSON,,70.0,YR,,M,Y,59.0,KG,20190829.0,,MD,JP,JP,2019,Q3,Elderly
157104293,15710429,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Conjunctivitis allergic,,2019,Q3,3,F,20171215.0,20190828.0,20181211,20190910,EXP,,JP-JNJFOC-20181210435,JOHNSON AND JOHNSON,,5.0,DEC,,M,Y,,,20190910.0,,MD,JP,JP,2019,Q3,Child
157104293,15710429,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Vitreous haemorrhage,,2019,Q3,3,F,20171215.0,20190828.0,20181211,20190910,EXP,,JP-JNJFOC-20181210435,JOHNSON AND JOHNSON,,5.0,DEC,,M,Y,,,20190910.0,,MD,JP,JP,2019,Q3,Child
157104293,15710429,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Conjunctivitis allergic,,2019,Q3,3,F,20171215.0,20190828.0,20181211,20190910,EXP,,JP-JNJFOC-20181210435,JOHNSON AND JOHNSON,,5.0,DEC,,M,Y,,,20190910.0,,MD,JP,JP,2019,Q3,Child
157104293,15710429,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Vitreous haemorrhage,,2019,Q3,3,F,20171215.0,20190828.0,20181211,20190910,EXP,,JP-JNJFOC-20181210435,JOHNSON AND JOHNSON,,5.0,DEC,,M,Y,,,20190910.0,,MD,JP,JP,2019,Q3,Child
157409263,15740926,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Acute kidney injury,,2019,Q3,3,F,20180623.0,20190805.0,20181219,20190809,EXP,,JP-JNJFOC-20181219629,JOHNSON AND JOHNSON,,62.0,YR,,M,Y,82.0,KG,20190809.0,,MD,JP,JP,2019,Q3,Adult
157409263,15740926,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Gastroenteritis,,2019,Q3,3,F,20180623.0,20190805.0,20181219,20190809,EXP,,JP-JNJFOC-20181219629,JOHNSON AND JOHNSON,,62.0,YR,,M,Y,82.0,KG,20190809.0,,MD,JP,JP,2019,Q3,Adult
157530662,15753066,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, DAILY",,,Y,,,,,100.0,MG,,QD,2019,Q3,Pituitary tumour benign,,2019,Q3,2,F,,20190828.0,20181221,20190829,EXP,,"JP-IMPAX LABORATORIES, LLC-2018-IPXL-04237",IMPAX,,47.0,YR,,F,Y,87.5,KG,20190829.0,,MD,JP,JP,2019,Q3,Adult
157530662,15753066,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, DAILY",,,Y,,,,,100.0,MG,,QD,2019,Q3,Pituitary-dependent Cushing's syndrome,,2019,Q3,2,F,,20190828.0,20181221,20190829,EXP,,"JP-IMPAX LABORATORIES, LLC-2018-IPXL-04237",IMPAX,,47.0,YR,,F,Y,87.5,KG,20190829.0,,MD,JP,JP,2019,Q3,Adult
157704822,15770482,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,50.0,MG,FILM-COATED TABLET,QD,2019,Q3,Angina pectoris,,2019,Q3,2,F,20151023.0,20190808.0,20181228,20190816,EXP,,JP-JNJFOC-20181233424,JOHNSON AND JOHNSON,,73.0,YR,,M,Y,74.0,KG,20190816.0,,MD,JP,JP,2019,Q3,Elderly
157704822,15770482,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,50.0,MG,FILM-COATED TABLET,QD,2019,Q3,Incorrect dose administered,,2019,Q3,2,F,20151023.0,20190808.0,20181228,20190816,EXP,,JP-JNJFOC-20181233424,JOHNSON AND JOHNSON,,73.0,YR,,M,Y,74.0,KG,20190816.0,,MD,JP,JP,2019,Q3,Elderly
157704822,15770482,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,50.0,MG,FILM-COATED TABLET,QD,2019,Q3,Off label use,,2019,Q3,2,F,20151023.0,20190808.0,20181228,20190816,EXP,,JP-JNJFOC-20181233424,JOHNSON AND JOHNSON,,73.0,YR,,M,Y,74.0,KG,20190816.0,,MD,JP,JP,2019,Q3,Elderly
157704822,15770482,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Angina pectoris,,2019,Q3,2,F,20151023.0,20190808.0,20181228,20190816,EXP,,JP-JNJFOC-20181233424,JOHNSON AND JOHNSON,,73.0,YR,,M,Y,74.0,KG,20190816.0,,MD,JP,JP,2019,Q3,Elderly
157704822,15770482,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Incorrect dose administered,,2019,Q3,2,F,20151023.0,20190808.0,20181228,20190816,EXP,,JP-JNJFOC-20181233424,JOHNSON AND JOHNSON,,73.0,YR,,M,Y,74.0,KG,20190816.0,,MD,JP,JP,2019,Q3,Elderly
157704822,15770482,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Off label use,,2019,Q3,2,F,20151023.0,20190808.0,20181228,20190816,EXP,,JP-JNJFOC-20181233424,JOHNSON AND JOHNSON,,73.0,YR,,M,Y,74.0,KG,20190816.0,,MD,JP,JP,2019,Q3,Elderly
157769243,15776924,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Atrial fibrillation,,2019,Q3,3,F,20180823.0,20190701.0,20181231,20190716,EXP,,JP-JNJFOC-20181235110,JOHNSON AND JOHNSON,,47.0,YR,,M,Y,129.0,KG,20190716.0,,MD,JP,JP,2019,Q3,Adult
158671353,15867135,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Cerebral infarction,,2019,Q3,3,F,20190115.0,20190717.0,20190125,20190730,EXP,,JP-JNJFOC-20190132099,JOHNSON AND JOHNSON,,50.0,YR,,M,Y,,,20190730.0,,MD,JP,JP,2019,Q3,Adult
159011982,15901198,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Glaucoma,,2019,Q3,2,F,20180529.0,20190726.0,20190201,20190806,EXP,,JP-JNJFOC-20190137993,JOHNSON AND JOHNSON,,64.0,YR,,M,Y,81.0,KG,20190806.0,,MD,JP,JP,2019,Q3,Adult
160430152,16043015,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Diarrhoea,,2019,Q3,2,F,201708.0,20190913.0,20190306,20190924,EXP,,JP-JNJFOC-20180316192,JOHNSON AND JOHNSON,,5.0,DEC,,F,Y,,,20190924.0,,MD,JP,JP,2019,Q3,Child
160430152,16043015,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Intervertebral disc protrusion,,2019,Q3,2,F,201708.0,20190913.0,20190306,20190924,EXP,,JP-JNJFOC-20180316192,JOHNSON AND JOHNSON,,5.0,DEC,,F,Y,,,20190924.0,,MD,JP,JP,2019,Q3,Child
160430152,16043015,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Neurogenic bladder,,2019,Q3,2,F,201708.0,20190913.0,20190306,20190924,EXP,,JP-JNJFOC-20180316192,JOHNSON AND JOHNSON,,5.0,DEC,,F,Y,,,20190924.0,,MD,JP,JP,2019,Q3,Child
160430152,16043015,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Pain in extremity,,2019,Q3,2,F,201708.0,20190913.0,20190306,20190924,EXP,,JP-JNJFOC-20180316192,JOHNSON AND JOHNSON,,5.0,DEC,,F,Y,,,20190924.0,,MD,JP,JP,2019,Q3,Child
160430152,16043015,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Urinary incontinence,,2019,Q3,2,F,201708.0,20190913.0,20190306,20190924,EXP,,JP-JNJFOC-20180316192,JOHNSON AND JOHNSON,,5.0,DEC,,F,Y,,,20190924.0,,MD,JP,JP,2019,Q3,Child
160430173,16043017,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Dementia Alzheimer's type,,2019,Q3,3,F,20170112.0,20190725.0,20190306,20190806,EXP,,JP-JNJFOC-20190305687,JOHNSON AND JOHNSON,,86.0,YR,,M,Y,,,20190806.0,,MD,JP,JP,2019,Q3,Elderly
160430173,16043017,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Road traffic accident,,2019,Q3,3,F,20170112.0,20190725.0,20190306,20190806,EXP,,JP-JNJFOC-20190305687,JOHNSON AND JOHNSON,,86.0,YR,,M,Y,,,20190806.0,,MD,JP,JP,2019,Q3,Elderly
160430173,16043017,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Spinal compression fracture,,2019,Q3,3,F,20170112.0,20190725.0,20190306,20190806,EXP,,JP-JNJFOC-20190305687,JOHNSON AND JOHNSON,,86.0,YR,,M,Y,,,20190806.0,,MD,JP,JP,2019,Q3,Elderly
160430173,16043017,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Spinal osteoarthritis,,2019,Q3,3,F,20170112.0,20190725.0,20190306,20190806,EXP,,JP-JNJFOC-20190305687,JOHNSON AND JOHNSON,,86.0,YR,,M,Y,,,20190806.0,,MD,JP,JP,2019,Q3,Elderly
160775233,16077523,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Hepatic function abnormal,,2019,Q3,3,F,20180207.0,20190722.0,20190315,20190801,EXP,,JP-JNJFOC-20190316053,JOHNSON AND JOHNSON,,56.0,YR,,F,Y,,,20190801.0,,MD,JP,JP,2019,Q3,Adult
160775233,16077523,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Metastases to lung,,2019,Q3,3,F,20180207.0,20190722.0,20190315,20190801,EXP,,JP-JNJFOC-20190316053,JOHNSON AND JOHNSON,,56.0,YR,,F,Y,,,20190801.0,,MD,JP,JP,2019,Q3,Adult
161285212,16128521,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Urine ketone body present,,2019,Q3,2,F,20160121.0,20190605.0,20190328,20190711,EXP,,JP-JNJFOC-20181018620,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,,,20190711.0,,MD,JP,JP,2019,Q3,Adult
162277365,16227736,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, DAILY",,,,,,,,300.0,MG,TABLET,,2019,Q3,Intentional product misuse,,2019,Q3,5,F,201902.0,20190909.0,20190423,20190918,EXP,,US-PFIZER INC-2016573618,PFIZER,,50.0,YR,,M,Y,95.0,KG,20190918.0,,OT,US,US,2019,Q3,Adult
162277365,16227736,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, DAILY",,,,,,,,300.0,MG,TABLET,,2019,Q3,Osteonecrosis,,2019,Q3,5,F,201902.0,20190909.0,20190423,20190918,EXP,,US-PFIZER INC-2016573618,PFIZER,,50.0,YR,,M,Y,95.0,KG,20190918.0,,OT,US,US,2019,Q3,Adult
163352934,16335293,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,U,,,,,100.0,MG,,,2019,Q3,Cholecystitis acute,,2019,Q3,4,F,,20190612.0,20190521,20190702,EXP,,JP-009507513-1905JPN008264,MERCK,,71.0,YR,,F,Y,54.6,KG,20190702.0,,OT,JP,JP,2019,Q3,Elderly
163352934,16335293,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,U,,,,,100.0,MG,,,2019,Q3,Euglycaemic diabetic ketoacidosis,,2019,Q3,4,F,,20190612.0,20190521,20190702,EXP,,JP-009507513-1905JPN008264,MERCK,,71.0,YR,,F,Y,54.6,KG,20190702.0,,OT,JP,JP,2019,Q3,Elderly
163611661,16361166,4,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Gastrointestinal haemorrhage,,2019,Q3,1,I,20180615.0,,20190524,20190524,DIR,,,FDA-CTU,,78.0,YR,,M,N,59.0,KG,20190524.0,N,PH,US,US,2019,Q3,Elderly
163611661,16361166,4,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q3,Hypovolaemic shock,,2019,Q3,1,I,20180615.0,,20190524,20190524,DIR,,,FDA-CTU,,78.0,YR,,M,N,59.0,KG,20190524.0,N,PH,US,US,2019,Q3,Elderly
163710754,16371075,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Pemphigoid,,2019,Q3,4,F,201901.0,20190712.0,20190530,20190724,EXP,,JP-JNJFOC-20190535154,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,,,20190724.0,,PH,JP,JP,2019,Q3,Elderly
163710754,16371075,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Pemphigoid,,2019,Q3,4,F,201901.0,20190712.0,20190530,20190724,EXP,,JP-JNJFOC-20190535154,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,,,20190724.0,,PH,JP,JP,2019,Q3,Elderly
163841552,16384155,1,PS,CANAGLIFLOZIN TABLET,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Bile duct cancer,,2019,Q3,2,F,20180514.0,20190617.0,20190603,20190701,EXP,,JP-JNJFOC-20190600175,JOHNSON AND JOHNSON,,62.0,YR,,M,Y,,,20190701.0,,MD,JP,JP,2019,Q3,Adult
164145992,16414599,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Diabetic ketoacidosis,,2019,Q3,2,F,20170925.0,20190624.0,20190611,20190708,EXP,,JP-JNJFOC-20190601602,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,,,20190708.0,,MD,JP,JP,2019,Q3,Elderly
164145992,16414599,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Myelodysplastic syndrome,,2019,Q3,2,F,20170925.0,20190624.0,20190611,20190708,EXP,,JP-JNJFOC-20190601602,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,,,20190708.0,,MD,JP,JP,2019,Q3,Elderly
164167603,16416760,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Carotid artery stenosis,,2019,Q3,3,F,20171104.0,20190911.0,20190611,20190919,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20190919.0,,MD,JP,JP,2019,Q3,Adult
164167603,16416760,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Cellulitis,,2019,Q3,3,F,20171104.0,20190911.0,20190611,20190919,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20190919.0,,MD,JP,JP,2019,Q3,Adult
164167603,16416760,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Transient ischaemic attack,,2019,Q3,3,F,20171104.0,20190911.0,20190611,20190919,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20190919.0,,MD,JP,JP,2019,Q3,Adult
164167603,16416760,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Carotid artery stenosis,,2019,Q3,3,F,20171104.0,20190911.0,20190611,20190919,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20190919.0,,MD,JP,JP,2019,Q3,Adult
164167603,16416760,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Cellulitis,,2019,Q3,3,F,20171104.0,20190911.0,20190611,20190919,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20190919.0,,MD,JP,JP,2019,Q3,Adult
164167603,16416760,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Transient ischaemic attack,,2019,Q3,3,F,20171104.0,20190911.0,20190611,20190919,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20190919.0,,MD,JP,JP,2019,Q3,Adult
164167603,16416760,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Carotid artery stenosis,,2019,Q3,3,F,20171104.0,20190911.0,20190611,20190919,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20190919.0,,MD,JP,JP,2019,Q3,Adult
164167603,16416760,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Cellulitis,,2019,Q3,3,F,20171104.0,20190911.0,20190611,20190919,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20190919.0,,MD,JP,JP,2019,Q3,Adult
164167603,16416760,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Transient ischaemic attack,,2019,Q3,3,F,20171104.0,20190911.0,20190611,20190919,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20190919.0,,MD,JP,JP,2019,Q3,Adult
164167603,16416760,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Carotid artery stenosis,,2019,Q3,3,F,20171104.0,20190911.0,20190611,20190919,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20190919.0,,MD,JP,JP,2019,Q3,Adult
164167603,16416760,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Cellulitis,,2019,Q3,3,F,20171104.0,20190911.0,20190611,20190919,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20190919.0,,MD,JP,JP,2019,Q3,Adult
164167603,16416760,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Transient ischaemic attack,,2019,Q3,3,F,20171104.0,20190911.0,20190611,20190919,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20190919.0,,MD,JP,JP,2019,Q3,Adult
164167603,16416760,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Carotid artery stenosis,,2019,Q3,3,F,20171104.0,20190911.0,20190611,20190919,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20190919.0,,MD,JP,JP,2019,Q3,Adult
164167603,16416760,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Cellulitis,,2019,Q3,3,F,20171104.0,20190911.0,20190611,20190919,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20190919.0,,MD,JP,JP,2019,Q3,Adult
164167603,16416760,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Transient ischaemic attack,,2019,Q3,3,F,20171104.0,20190911.0,20190611,20190919,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20190919.0,,MD,JP,JP,2019,Q3,Adult
164341222,16434122,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,," UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Lethargy,,2019,Q3,2,F,20190308.0,20190719.0,20190614,20190726,PER,,US-JNJFOC-20190607547,JOHNSON AND JOHNSON,,60.0,YR,,M,Y,93.07,KG,20190726.0,,CN,US,US,2019,Q3,Adult
164341222,16434122,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,," UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Listless,,2019,Q3,2,F,20190308.0,20190719.0,20190614,20190726,PER,,US-JNJFOC-20190607547,JOHNSON AND JOHNSON,,60.0,YR,,M,Y,93.07,KG,20190726.0,,CN,US,US,2019,Q3,Adult
164341222,16434122,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,," UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Nausea,,2019,Q3,2,F,20190308.0,20190719.0,20190614,20190726,PER,,US-JNJFOC-20190607547,JOHNSON AND JOHNSON,,60.0,YR,,M,Y,93.07,KG,20190726.0,,CN,US,US,2019,Q3,Adult
164341222,16434122,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,," UNKNOWN,UNKNOWN",,204042.0,100.0,MG,TABLET,QD,2019,Q3,Rash,,2019,Q3,2,F,20190308.0,20190719.0,20190614,20190726,PER,,US-JNJFOC-20190607547,JOHNSON AND JOHNSON,,60.0,YR,,M,Y,93.07,KG,20190726.0,,CN,US,US,2019,Q3,Adult
164974613,16497461,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,CANAGLU,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Myocardial ischaemia,,2019,Q3,3,F,20180206.0,20190806.0,20190628,20190814,EXP,,JP-JNJFOC-20190633017,JOHNSON AND JOHNSON,,75.0,YR,,M,Y,73.0,KG,20190814.0,,MD,JP,JP,2019,Q3,Elderly
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Adverse drug reaction,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Arthralgia,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Arthritis,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Blood creatinine decreased,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Blood uric acid decreased,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Drug ineffective,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Gastrointestinal haemorrhage,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Glycosylated haemoglobin increased,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Haemoglobin decreased,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Hepatic cirrhosis,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Hepatosplenomegaly,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Hypertrophy,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Inflammatory marker increased,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Joint effusion,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Joint swelling,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Liver disorder,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Low density lipoprotein increased,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Nausea,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Nonalcoholic fatty liver disease,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Pain in extremity,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Psoriasis,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Red blood cell sedimentation rate increased,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Therapeutic product effect decreased,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Therapeutic product effect incomplete,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
164997191,16499719,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,U,,,,,300.0,MG,,,2019,Q3,Varices oesophageal,,2019,Q3,1,I,,20190622.0,20190701,20190701,EXP,,CA-SA-2019SA170730,SANOFI AVENTIS,,47.0,YR,A,F,Y,,,20190701.0,,MD,CA,CA,2019,Q3,Adult
165339763,16533976,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Cataract,,2019,Q3,3,F,,20190812.0,20190705,20190815,EXP,,US-PFIZER INC-2019283677,PFIZER,"CHOU, T.. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS ONLINE CASE REPORTS. 2019;7 (3):48-51",48.0,YR,,F,Y,112.0,KG,20190815.0,,MD,US,US,2019,Q3,Adult
165339763,16533976,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Diabetes mellitus inadequate control,,2019,Q3,3,F,,20190812.0,20190705,20190815,EXP,,US-PFIZER INC-2019283677,PFIZER,"CHOU, T.. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS ONLINE CASE REPORTS. 2019;7 (3):48-51",48.0,YR,,F,Y,112.0,KG,20190815.0,,MD,US,US,2019,Q3,Adult
165420351,16542035,1,PS,CANAGLIFLOZIN TABLET,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,300.0,MG,TABLET,QD,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,20190325.0,20190625.0,20190708,20190708,EXP,,US-JNJFOC-20190638102,JOHNSON AND JOHNSON,,49.0,YR,,M,Y,,,20190708.0,,MD,US,US,2019,Q3,Adult
165586601,16558660,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,300.0,MG,TABLET,QD,2019,Q3,Fournier's gangrene,,2019,Q3,1,I,20190614.0,20190627.0,20190711,20190711,EXP,,US-JNJFOC-20190638572,JOHNSON AND JOHNSON,,50.0,YR,,M,Y,86.3,KG,20190711.0,,MD,US,US,2019,Q3,Adult
165586601,16558660,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,300.0,MG,TABLET,QD,2019,Q3,Furuncle,,2019,Q3,1,I,20190614.0,20190627.0,20190711,20190711,EXP,,US-JNJFOC-20190638572,JOHNSON AND JOHNSON,,50.0,YR,,M,Y,86.3,KG,20190711.0,,MD,US,US,2019,Q3,Adult
165586601,16558660,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,300.0,MG,TABLET,QD,2019,Q3,Sepsis,,2019,Q3,1,I,20190614.0,20190627.0,20190711,20190711,EXP,,US-JNJFOC-20190638572,JOHNSON AND JOHNSON,,50.0,YR,,M,Y,86.3,KG,20190711.0,,MD,US,US,2019,Q3,Adult
165590721,16559072,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Dizziness,,2019,Q3,1,I,20170910.0,20190625.0,20190711,20190711,EXP,,JP-JNJFOC-20190708063,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,,,20190711.0,,MD,JP,JP,2019,Q3,Elderly
165590721,16559072,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Epiglottitis,,2019,Q3,1,I,20170910.0,20190625.0,20190711,20190711,EXP,,JP-JNJFOC-20190708063,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,,,20190711.0,,MD,JP,JP,2019,Q3,Elderly
165590721,16559072,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Internal haemorrhage,,2019,Q3,1,I,20170910.0,20190625.0,20190711,20190711,EXP,,JP-JNJFOC-20190708063,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,,,20190711.0,,MD,JP,JP,2019,Q3,Elderly
165599811,16559981,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Cataract,,2019,Q3,1,I,,20190627.0,20190711,20190711,EXP,,US-APOTEX-2019AP017836,APOTEX,"CHOU TY, BRICEL S, YAZDANIE M.. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. DOI: 10.1016/J.JCRO.2019.04.002. JCRS ONLINE CASE REPORTS. 2019",48.0,YR,,F,Y,112.0,KG,20190711.0,,MD,US,US,2019,Q3,Adult
165599811,16559981,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2019,Q3,Cataract subcapsular,,2019,Q3,1,I,,20190627.0,20190711,20190711,EXP,,US-APOTEX-2019AP017836,APOTEX,"CHOU TY, BRICEL S, YAZDANIE M.. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. DOI: 10.1016/J.JCRO.2019.04.002. JCRS ONLINE CASE REPORTS. 2019",48.0,YR,,F,Y,112.0,KG,20190711.0,,MD,US,US,2019,Q3,Adult
165624082,16562408,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Blood cholesterol increased,,2019,Q3,2,F,2016.0,20190725.0,20190711,20190805,EXP,,JP-JNJFOC-20160926571,JOHNSON AND JOHNSON,,55.0,YR,,F,Y,66.0,KG,20190805.0,,MD,JP,JP,2019,Q3,Adult
165624082,16562408,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Blood triglycerides increased,,2019,Q3,2,F,2016.0,20190725.0,20190711,20190805,EXP,,JP-JNJFOC-20160926571,JOHNSON AND JOHNSON,,55.0,YR,,F,Y,66.0,KG,20190805.0,,MD,JP,JP,2019,Q3,Adult
165624082,16562408,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Periodontitis,,2019,Q3,2,F,2016.0,20190725.0,20190711,20190805,EXP,,JP-JNJFOC-20160926571,JOHNSON AND JOHNSON,,55.0,YR,,F,Y,66.0,KG,20190805.0,,MD,JP,JP,2019,Q3,Adult
165624082,16562408,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Sinus tachycardia,,2019,Q3,2,F,2016.0,20190725.0,20190711,20190805,EXP,,JP-JNJFOC-20160926571,JOHNSON AND JOHNSON,,55.0,YR,,F,Y,66.0,KG,20190805.0,,MD,JP,JP,2019,Q3,Adult
165624082,16562408,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Weight increased,,2019,Q3,2,F,2016.0,20190725.0,20190711,20190805,EXP,,JP-JNJFOC-20160926571,JOHNSON AND JOHNSON,,55.0,YR,,F,Y,66.0,KG,20190805.0,,MD,JP,JP,2019,Q3,Adult
165644061,16564406,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Cataract,,2019,Q3,1,I,,20190701.0,20190712,20190712,EXP,US-MLMSERVICE-20190626-1823401-1,US-LUPIN PHARMACEUTICALS INC.-2019-04370,LUPIN,,48.0,YR,,F,Y,112.0,KG,20190712.0,,CN,GB,US,2019,Q3,Adult
165644061,16564406,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Hyperglycaemia,,2019,Q3,1,I,,20190701.0,20190712,20190712,EXP,US-MLMSERVICE-20190626-1823401-1,US-LUPIN PHARMACEUTICALS INC.-2019-04370,LUPIN,,48.0,YR,,F,Y,112.0,KG,20190712.0,,CN,GB,US,2019,Q3,Adult
165644061,16564406,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Toxicity to various agents,,2019,Q3,1,I,,20190701.0,20190712,20190712,EXP,US-MLMSERVICE-20190626-1823401-1,US-LUPIN PHARMACEUTICALS INC.-2019-04370,LUPIN,,48.0,YR,,F,Y,112.0,KG,20190712.0,,CN,GB,US,2019,Q3,Adult
165715842,16571584,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Diplegia,,2019,Q3,2,F,20180612.0,20190731.0,20190715,20190808,EXP,,JP-JNJFOC-20190712323,JOHNSON AND JOHNSON,,49.0,YR,,M,Y,,,20190808.0,,MD,JP,JP,2019,Q3,Adult
165742031,16574203,3,C,INVOKANA [CANAGLIFLOZIN HEMIHYDRATE],,2,,,,,,,,,,,,,,2019,Q3,Blood glucose abnormal,,2019,Q3,1,I,2019.0,20190419.0,20190715,20190715,PER,,US-NOVOPROD-659751,NOVO NORDISK,,52.0,YR,,F,Y,,,20190715.0,,CN,US,US,2019,Q3,Adult
165742031,16574203,3,C,INVOKANA [CANAGLIFLOZIN HEMIHYDRATE],,2,,,,,,,,,,,,,,2019,Q3,Diarrhoea,,2019,Q3,1,I,2019.0,20190419.0,20190715,20190715,PER,,US-NOVOPROD-659751,NOVO NORDISK,,52.0,YR,,F,Y,,,20190715.0,,CN,US,US,2019,Q3,Adult
165742031,16574203,3,C,INVOKANA [CANAGLIFLOZIN HEMIHYDRATE],,2,,,,,,,,,,,,,,2019,Q3,Eructation,,2019,Q3,1,I,2019.0,20190419.0,20190715,20190715,PER,,US-NOVOPROD-659751,NOVO NORDISK,,52.0,YR,,F,Y,,,20190715.0,,CN,US,US,2019,Q3,Adult
165742031,16574203,3,C,INVOKANA [CANAGLIFLOZIN HEMIHYDRATE],,2,,,,,,,,,,,,,,2019,Q3,Inappropriate schedule of product administration,,2019,Q3,1,I,2019.0,20190419.0,20190715,20190715,PER,,US-NOVOPROD-659751,NOVO NORDISK,,52.0,YR,,F,Y,,,20190715.0,,CN,US,US,2019,Q3,Adult
165742031,16574203,3,C,INVOKANA [CANAGLIFLOZIN HEMIHYDRATE],,2,,,,,,,,,,,,,,2019,Q3,Vision blurred,,2019,Q3,1,I,2019.0,20190419.0,20190715,20190715,PER,,US-NOVOPROD-659751,NOVO NORDISK,,52.0,YR,,F,Y,,,20190715.0,,CN,US,US,2019,Q3,Adult
165742031,16574203,3,C,INVOKANA [CANAGLIFLOZIN HEMIHYDRATE],,2,,,,,,,,,,,,,,2019,Q3,Weight decreased,,2019,Q3,1,I,2019.0,20190419.0,20190715,20190715,PER,,US-NOVOPROD-659751,NOVO NORDISK,,52.0,YR,,F,Y,,,20190715.0,,CN,US,US,2019,Q3,Adult
165795841,16579584,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,D,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Death,,2019,Q3,1,I,,20190702.0,20190716,20190716,EXP,,JP-JNJFOC-20190718813,JOHNSON AND JOHNSON,,83.0,YR,,M,Y,,,20190716.0,,MD,JP,JP,2019,Q3,Elderly
165795862,16579586,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Atrial fibrillation,,2019,Q3,2,F,,20190730.0,20190716,20190808,EXP,,JP-JNJFOC-20190720257,JOHNSON AND JOHNSON,,62.0,YR,,M,Y,,,20190808.0,,MD,JP,JP,2019,Q3,Adult
165808951,16580895,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",81500.0,MG,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Papillary thyroid cancer,,2019,Q3,1,I,20180730.0,20190703.0,20190716,20190716,EXP,,JP-JNJFOC-20190719678,JOHNSON AND JOHNSON,,44.0,YR,,M,Y,,,20190716.0,,MD,JP,JP,2019,Q3,Adult
165809791,16580979,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,FILM-COATED TABLET,,2019,Q3,Blood glucose increased,,2019,Q3,1,I,20190528.0,20190703.0,20190716,20190716,EXP,GB-MHRA-EYC 00202492,GB-JNJFOC-20190706369,JOHNSON AND JOHNSON,,45.0,YR,,M,Y,132.0,KG,20190716.0,,PH,GB,GB,2019,Q3,Adult
165809791,16580979,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,FILM-COATED TABLET,,2019,Q3,Groin abscess,,2019,Q3,1,I,20190528.0,20190703.0,20190716,20190716,EXP,GB-MHRA-EYC 00202492,GB-JNJFOC-20190706369,JOHNSON AND JOHNSON,,45.0,YR,,M,Y,132.0,KG,20190716.0,,PH,GB,GB,2019,Q3,Adult
165813922,16581392,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Abdominal discomfort,,2019,Q3,2,F,20160626.0,20190809.0,20190716,20190820,EXP,,JP-JNJFOC-20160805443,JOHNSON AND JOHNSON,,68.0,YR,,M,Y,71.0,KG,20190820.0,,MD,JP,JP,2019,Q3,Elderly
165813922,16581392,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Cerebral infarction,,2019,Q3,2,F,20160626.0,20190809.0,20190716,20190820,EXP,,JP-JNJFOC-20160805443,JOHNSON AND JOHNSON,,68.0,YR,,M,Y,71.0,KG,20190820.0,,MD,JP,JP,2019,Q3,Elderly
165847271,16584727,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,800.0,MG,Y,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Metabolic acidosis,,2019,Q3,1,I,20180207.0,20190610.0,20190717,20190717,EXP,,JP-JNJFOC-20190712447,JOHNSON AND JOHNSON,,57.0,YR,,F,Y,,,20190717.0,,MD,JP,JP,2019,Q3,Adult
165847271,16584727,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,800.0,MG,Y,,,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Nasopharyngitis,,2019,Q3,1,I,20180207.0,20190610.0,20190717,20190717,EXP,,JP-JNJFOC-20190712447,JOHNSON AND JOHNSON,,57.0,YR,,F,Y,,,20190717.0,,MD,JP,JP,2019,Q3,Adult
166015602,16601560,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Diarrhoea,,2019,Q3,2,F,20190428.0,20190807.0,20190719,20190821,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20190821.0,,MD,JP,JP,2019,Q3,Adult
166015602,16601560,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Hyperglycaemia,,2019,Q3,2,F,20190428.0,20190807.0,20190719,20190821,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20190821.0,,MD,JP,JP,2019,Q3,Adult
166015602,16601560,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Pyrexia,,2019,Q3,2,F,20190428.0,20190807.0,20190719,20190821,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20190821.0,,MD,JP,JP,2019,Q3,Adult
166015602,16601560,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Shock,,2019,Q3,2,F,20190428.0,20190807.0,20190719,20190821,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20190821.0,,MD,JP,JP,2019,Q3,Adult
166015602,16601560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Diarrhoea,,2019,Q3,2,F,20190428.0,20190807.0,20190719,20190821,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20190821.0,,MD,JP,JP,2019,Q3,Adult
166015602,16601560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Hyperglycaemia,,2019,Q3,2,F,20190428.0,20190807.0,20190719,20190821,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20190821.0,,MD,JP,JP,2019,Q3,Adult
166015602,16601560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Pyrexia,,2019,Q3,2,F,20190428.0,20190807.0,20190719,20190821,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20190821.0,,MD,JP,JP,2019,Q3,Adult
166015602,16601560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Shock,,2019,Q3,2,F,20190428.0,20190807.0,20190719,20190821,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20190821.0,,MD,JP,JP,2019,Q3,Adult
166015602,16601560,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Diarrhoea,,2019,Q3,2,F,20190428.0,20190807.0,20190719,20190821,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20190821.0,,MD,JP,JP,2019,Q3,Adult
166015602,16601560,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Hyperglycaemia,,2019,Q3,2,F,20190428.0,20190807.0,20190719,20190821,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20190821.0,,MD,JP,JP,2019,Q3,Adult
166015602,16601560,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Pyrexia,,2019,Q3,2,F,20190428.0,20190807.0,20190719,20190821,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20190821.0,,MD,JP,JP,2019,Q3,Adult
166015602,16601560,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Shock,,2019,Q3,2,F,20190428.0,20190807.0,20190719,20190821,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20190821.0,,MD,JP,JP,2019,Q3,Adult
166103071,16610307,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Depressed level of consciousness,,2019,Q3,1,I,,20190527.0,20190722,20190722,EXP,,JP-JNJFOC-20190616720,JOHNSON AND JOHNSON,,90.0,YR,,,Y,,,20190722.0,,MD,JP,JP,2019,Q3,Elderly
166114662,16611466,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,UNKNOWN,QD,2019,Q3,Diabetes mellitus inadequate control,,2019,Q3,2,F,20171114.0,20190829.0,20190722,20190910,EXP,,JP-JNJFOC-20180717799,JOHNSON AND JOHNSON,,61.0,YR,,M,Y,68.0,KG,20190910.0,,MD,JP,JP,2019,Q3,Adult
166114662,16611466,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,UNKNOWN,QD,2019,Q3,Hyperglycaemia,,2019,Q3,2,F,20171114.0,20190829.0,20190722,20190910,EXP,,JP-JNJFOC-20180717799,JOHNSON AND JOHNSON,,61.0,YR,,M,Y,68.0,KG,20190910.0,,MD,JP,JP,2019,Q3,Adult
166114662,16611466,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,UNKNOWN,QD,2019,Q3,Sinus bradycardia,,2019,Q3,2,F,20171114.0,20190829.0,20190722,20190910,EXP,,JP-JNJFOC-20180717799,JOHNSON AND JOHNSON,,61.0,YR,,M,Y,68.0,KG,20190910.0,,MD,JP,JP,2019,Q3,Adult
166272811,16627281,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,FILM-COATED TABLET,,2019,Q3,Diarrhoea,,2019,Q3,1,I,,20190709.0,20190724,20190724,EXP,,JP-JNJFOC-20190727511,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20190724.0,,CN,JP,JP,2019,Q3,Adult
166272811,16627281,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,FILM-COATED TABLET,,2019,Q3,Eructation,,2019,Q3,1,I,,20190709.0,20190724,20190724,EXP,,JP-JNJFOC-20190727511,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20190724.0,,CN,JP,JP,2019,Q3,Adult
166272811,16627281,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,FILM-COATED TABLET,,2019,Q3,Intestinal obstruction,,2019,Q3,1,I,,20190709.0,20190724,20190724,EXP,,JP-JNJFOC-20190727511,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20190724.0,,CN,JP,JP,2019,Q3,Adult
166272811,16627281,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,FILM-COATED TABLET,,2019,Q3,Physical deconditioning,,2019,Q3,1,I,,20190709.0,20190724,20190724,EXP,,JP-JNJFOC-20190727511,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20190724.0,,CN,JP,JP,2019,Q3,Adult
166274131,16627413,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2019,Q3,Head injury,,2019,Q3,1,I,20190513.0,20190712.0,20190724,20190724,EXP,,US-JNJFOC-20190722101,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20190724.0,,CN,US,US,2019,Q3,Adult
166274131,16627413,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2019,Q3,Myocardial infarction,,2019,Q3,1,I,20190513.0,20190712.0,20190724,20190724,EXP,,US-JNJFOC-20190722101,JOHNSON AND JOHNSON,,57.0,YR,,M,Y,,,20190724.0,,CN,US,US,2019,Q3,Adult
166275131,16627513,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Herpes zoster,,2019,Q3,1,I,20180531.0,20190711.0,20190724,20190724,EXP,,JP-JNJFOC-20190728436,JOHNSON AND JOHNSON,,50.0,YR,,M,Y,,,20190724.0,,MD,JP,JP,2019,Q3,Adult
166275511,16627551,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,300.0,MG,FILM-COATED TABLET,QD,2019,Q3,Knee operation,,2019,Q3,1,I,20190515.0,20190711.0,20190724,20190724,EXP,,US-JNJFOC-20190719457,JOHNSON AND JOHNSON,,39.0,YR,,M,Y,98.06,KG,20190724.0,,CN,US,US,2019,Q3,Adult
166313552,16631355,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Blood creatine phosphokinase increased,,2019,Q3,2,F,20190422.0,20190918.0,20190725,20190927,EXP,,JP-JNJFOC-20190723814,JOHNSON AND JOHNSON,,48.0,YR,,M,Y,,,20190927.0,,MD,JP,JP,2019,Q3,Adult
166313552,16631355,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"40 MILLIGRAM, QD",,,,,,,204042.0,40.0,MG,FILM-COATED TABLET,QD,2019,Q3,Blood creatine phosphokinase increased,,2019,Q3,2,F,20190422.0,20190918.0,20190725,20190927,EXP,,JP-JNJFOC-20190723814,JOHNSON AND JOHNSON,,48.0,YR,,M,Y,,,20190927.0,,MD,JP,JP,2019,Q3,Adult
166385951,16638595,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,, UNKNOWN,,204353.0,,,TABLET,,2019,Q3,Extremity necrosis,,2019,Q3,1,I,201905.0,20190716.0,20190726,20190726,EXP,,ES-JNJFOC-20190724061,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,,,20190726.0,,MD,ES,ES,2019,Q3,Elderly
166385951,16638595,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,, UNKNOWN,,204353.0,,,TABLET,,2019,Q3,Toe amputation,,2019,Q3,1,I,201905.0,20190716.0,20190726,20190726,EXP,,ES-JNJFOC-20190724061,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,,,20190726.0,,MD,ES,ES,2019,Q3,Elderly
166387921,16638792,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Large intestine polyp,,2019,Q3,1,I,20190328.0,20190717.0,20190726,20190726,EXP,,JP-JNJFOC-20190736757,JOHNSON AND JOHNSON,,62.0,YR,,M,Y,,,20190726.0,,MD,JP,JP,2019,Q3,Adult
166389151,16638915,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2019,Q3,Primary biliary cholangitis,,2019,Q3,1,I,20180925.0,20190717.0,20190726,20190726,EXP,,JP-JNJFOC-20190736703,JOHNSON AND JOHNSON,,61.0,YR,,F,Y,,,20190726.0,,MD,JP,JP,2019,Q3,Adult
166432291,16643229,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,,20171108.0,20190729,20190729,EXP,,JP-JNJFOC-20171121181,JOHNSON AND JOHNSON,TOYOOKA I. 2H-25 A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS DURING ORAL TREATMENT WITH SGLT2 INHIBITORS. 2017 OCT;207.,67.0,YR,,M,Y,,,20190729.0,,MD,JP,JP,2019,Q3,Elderly
166432291,16643229,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Gastroenteritis,,2019,Q3,1,I,,20171108.0,20190729,20190729,EXP,,JP-JNJFOC-20171121181,JOHNSON AND JOHNSON,TOYOOKA I. 2H-25 A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS DURING ORAL TREATMENT WITH SGLT2 INHIBITORS. 2017 OCT;207.,67.0,YR,,M,Y,,,20190729.0,,MD,JP,JP,2019,Q3,Elderly
166432291,16643229,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Laboratory test abnormal,,2019,Q3,1,I,,20171108.0,20190729,20190729,EXP,,JP-JNJFOC-20171121181,JOHNSON AND JOHNSON,TOYOOKA I. 2H-25 A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS DURING ORAL TREATMENT WITH SGLT2 INHIBITORS. 2017 OCT;207.,67.0,YR,,M,Y,,,20190729.0,,MD,JP,JP,2019,Q3,Elderly
166432291,16643229,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Weight decreased,,2019,Q3,1,I,,20171108.0,20190729,20190729,EXP,,JP-JNJFOC-20171121181,JOHNSON AND JOHNSON,TOYOOKA I. 2H-25 A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS DURING ORAL TREATMENT WITH SGLT2 INHIBITORS. 2017 OCT;207.,67.0,YR,,M,Y,,,20190729.0,,MD,JP,JP,2019,Q3,Elderly
166484661,16648466,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q3,Pyelonephritis acute,,2019,Q3,1,I,,20190718.0,20190730,20190730,EXP,GB-MHRA-EYC 00203211,GB-JNJFOC-20190726654,JOHNSON AND JOHNSON,,45.0,YR,,F,Y,,,20190730.0,,MD,GB,GB,2019,Q3,Adult
166484661,16648466,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q3,Sepsis,,2019,Q3,1,I,,20190718.0,20190730,20190730,EXP,GB-MHRA-EYC 00203211,GB-JNJFOC-20190726654,JOHNSON AND JOHNSON,,45.0,YR,,F,Y,,,20190730.0,,MD,GB,GB,2019,Q3,Adult
166605261,16660526,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",90400.0,MG,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Gastric cancer,,2019,Q3,1,I,20180806.0,20190722.0,20190802,20190802,EXP,,JP-JNJFOC-20190800134,JOHNSON AND JOHNSON,,66.0,YR,,M,Y,,,20190802.0,,MD,JP,JP,2019,Q3,Elderly
166655363,16665536,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD, MORNING",3900.0,MG,D,,,,,100.0,MG,TABLET,QD,2019,Q3,Acute kidney injury,,2019,Q3,3,F,20190702.0,20190912.0,20190803,20190918,EXP,,JP-009507513-1907JPN003780J,MERCK,,44.0,YR,,M,Y,114.0,KG,20190918.0,,CN,JP,JP,2019,Q3,Adult
166655363,16665536,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD, MORNING",3900.0,MG,D,,,,,100.0,MG,TABLET,QD,2019,Q3,Dermatitis exfoliative generalised,,2019,Q3,3,F,20190702.0,20190912.0,20190803,20190918,EXP,,JP-009507513-1907JPN003780J,MERCK,,44.0,YR,,M,Y,114.0,KG,20190918.0,,CN,JP,JP,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Adverse drug reaction,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Arthralgia,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Arthritis,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Blood creatinine decreased,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Blood uric acid decreased,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Drug ineffective,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Gastrointestinal haemorrhage,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Glycosylated haemoglobin increased,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Haemoglobin decreased,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Hepatic cirrhosis,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Hepatosplenomegaly,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Hypertrophy,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Inflammatory marker increased,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Joint effusion,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Joint swelling,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Liver disorder,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Low density lipoprotein increased,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Nausea,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Nonalcoholic fatty liver disease,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Pain in extremity,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Psoriasis,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Psoriatic arthropathy,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Red blood cell sedimentation rate increased,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Rheumatoid arthritis,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Therapeutic product effect decreased,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Therapeutic product effect incomplete,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Type 2 diabetes mellitus,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166659582,16665958,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,300.0,MG,,,2019,Q3,Varices oesophageal,,2019,Q3,2,F,,20190801.0,20190805,20190806,EXP,,CA-ABBVIE-19K-028-2872285-00,ABBVIE,,47.0,YR,,F,Y,,,20190806.0,,MD,CA,CA,2019,Q3,Adult
166678431,16667843,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Gastric cancer,,2019,Q3,1,I,20181127.0,20190725.0,20190805,20190805,EXP,,JP-JNJFOC-20190803921,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,,,20190805.0,,MD,JP,JP,2019,Q3,Elderly
166680781,16668078,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q3,Fournier's gangrene,,2019,Q3,1,I,20190603.0,20190729.0,20190805,20190805,EXP,ES-AEMPS-524736,ES-JNJFOC-20190741033,JOHNSON AND JOHNSON,,68.0,YR,,M,Y,,,20190805.0,,MD,ES,ES,2019,Q3,Elderly
166691832,16669183,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,2,F,20190711.0,20190814.0,20190805,20190816,EXP,GB-MHRA-EYC 00204563,GB-JNJFOC-20190801678,JOHNSON AND JOHNSON,,60.0,YR,,F,Y,65.0,KG,20190816.0,,MD,GB,GB,2019,Q3,Adult
166742411,16674241,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Rectal cancer,,2019,Q3,1,I,20190419.0,20190729.0,20190806,20190806,EXP,,JP-JNJFOC-20190803825,JOHNSON AND JOHNSON,,58.0,YR,,F,Y,89.4,KG,20190806.0,,MD,JP,JP,2019,Q3,Adult
166750471,16675047,2,SS,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,TABLET,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,201907.0,20190725.0,20190806,20190806,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-076412,BRISTOL MYERS SQUIBB,,86.0,YR,,F,Y,,,20190806.0,,PH,JP,JP,2019,Q3,Elderly
166770711,16677071,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",75300.0,MG,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Subdural haematoma,,2019,Q3,1,I,20180224.0,20190729.0,20190807,20190807,EXP,,JP-JNJFOC-20190806795,JOHNSON AND JOHNSON,,95.0,YR,,M,Y,,,20190807.0,,MD,JP,JP,2019,Q3,Elderly
166771391,16677139,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,, UNKNOWN,,204042.0,100.0,MG,TABLET,,2019,Q3,Diabetic ketosis,,2019,Q3,1,I,20190701.0,20190801.0,20190807,20190807,EXP,GB-MHRA-EYC 00204177,GB-JNJFOC-20190801754,JOHNSON AND JOHNSON,,32.0,YR,,M,Y,,,20190807.0,,PH,GB,GB,2019,Q3,Young Adult
166771391,16677139,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,, UNKNOWN,,204042.0,100.0,MG,TABLET,,2019,Q3,Ketosis,,2019,Q3,1,I,20190701.0,20190801.0,20190807,20190807,EXP,GB-MHRA-EYC 00204177,GB-JNJFOC-20190801754,JOHNSON AND JOHNSON,,32.0,YR,,M,Y,,,20190807.0,,PH,GB,GB,2019,Q3,Young Adult
166771391,16677139,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,, UNKNOWN,,204042.0,100.0,MG,TABLET,,2019,Q3,Polyuria,,2019,Q3,1,I,20190701.0,20190801.0,20190807,20190807,EXP,GB-MHRA-EYC 00204177,GB-JNJFOC-20190801754,JOHNSON AND JOHNSON,,32.0,YR,,M,Y,,,20190807.0,,PH,GB,GB,2019,Q3,Young Adult
166794001,16679400,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Angina unstable,,2019,Q3,1,I,20170405.0,20190729.0,20190807,20190807,EXP,,JP-JNJFOC-20190807457,JOHNSON AND JOHNSON,,66.0,YR,,F,Y,,,20190807.0,,MD,JP,JP,2019,Q3,Elderly
166874201,16687420,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Conjunctivitis allergic,,2019,Q3,1,I,20170309.0,20170605.0,20190809,20190809,EXP,,JP-JNJFOC-20170612818,JOHNSON AND JOHNSON,,74.0,YR,,F,Y,50.0,KG,20190809.0,,MD,JP,JP,2019,Q3,Elderly
166874201,16687420,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Peripheral artery occlusion,,2019,Q3,1,I,20170309.0,20170605.0,20190809,20190809,EXP,,JP-JNJFOC-20170612818,JOHNSON AND JOHNSON,,74.0,YR,,F,Y,50.0,KG,20190809.0,,MD,JP,JP,2019,Q3,Elderly
166874201,16687420,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Rhinitis allergic,,2019,Q3,1,I,20170309.0,20170605.0,20190809,20190809,EXP,,JP-JNJFOC-20170612818,JOHNSON AND JOHNSON,,74.0,YR,,F,Y,50.0,KG,20190809.0,,MD,JP,JP,2019,Q3,Elderly
166877211,16687721,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Acute myocardial infarction,,2019,Q3,1,I,20181016.0,20190801.0,20190809,20190809,EXP,,JP-JNJFOC-20190808493,JOHNSON AND JOHNSON,,56.0,YR,,M,Y,,,20190809.0,,MD,JP,JP,2019,Q3,Adult
166996241,16699624,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Hepatic function abnormal,,2019,Q3,1,I,,20190806.0,20190813,20190813,EXP,,JP-JNJFOC-20190812932,JOHNSON AND JOHNSON,,73.0,YR,,F,Y,,,20190813.0,,MD,JP,JP,2019,Q3,Elderly
167037142,16703714,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,TABLET,,2019,Q3,Hepatitis,,2019,Q3,2,F,,20190516.0,20190814,20190814,EXP,ES-AEMPS-412098,ES-JNJFOC-20190713666,JOHNSON AND JOHNSON,,75.0,YR,,F,Y,,,20190814.0,,MD,ES,ES,2019,Q3,Elderly
167112491,16711249,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",99400.0,MG,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Chronic obstructive pulmonary disease,,2019,Q3,1,I,20190418.0,20190807.0,20190816,20190816,EXP,,JP-JNJFOC-20190816645,JOHNSON AND JOHNSON,,59.0,YR,,F,Y,,,20190816.0,,MD,JP,JP,2019,Q3,Adult
167112491,16711249,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",99400.0,MG,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Intussusception,,2019,Q3,1,I,20190418.0,20190807.0,20190816,20190816,EXP,,JP-JNJFOC-20190816645,JOHNSON AND JOHNSON,,59.0,YR,,F,Y,,,20190816.0,,MD,JP,JP,2019,Q3,Adult
167112542,16711254,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",83300.0,MG,U,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Lung neoplasm malignant,,2019,Q3,2,F,20180831.0,20190903.0,20190816,20190912,EXP,,JP-JNJFOC-20190816653,JOHNSON AND JOHNSON,,58.0,YR,,F,Y,,,20190912.0,,MD,JP,JP,2019,Q3,Adult
167147602,16714760,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Cataract,,2019,Q3,2,F,,20190819.0,20190819,20190826,EXP,,PHHY2019US190044,SANDOZ,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS ONLINE CASE REPORTS. 2019;7(3):48-51",48.0,YR,,F,Y,112.0,KG,20190826.0,,OT,US,US,2019,Q3,Adult
167147602,16714760,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Diabetes mellitus inadequate control,,2019,Q3,2,F,,20190819.0,20190819,20190826,EXP,,PHHY2019US190044,SANDOZ,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS ONLINE CASE REPORTS. 2019;7(3):48-51",48.0,YR,,F,Y,112.0,KG,20190826.0,,OT,US,US,2019,Q3,Adult
167147602,16714760,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q3,Vision blurred,,2019,Q3,2,F,,20190819.0,20190819,20190826,EXP,,PHHY2019US190044,SANDOZ,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS ONLINE CASE REPORTS. 2019;7(3):48-51",48.0,YR,,F,Y,112.0,KG,20190826.0,,OT,US,US,2019,Q3,Adult
167207151,16720715,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2019,Q3,Cataract,,2019,Q3,1,I,,20190806.0,20190820,20190820,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-19-04620,HIKMA,"CHOU T, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS ONLINE CASE REPORTS. 2019 JUN 01;7:3:48-51.",48.0,YR,,F,Y,112.0,KG,20190820.0,,MD,US,US,2019,Q3,Adult
167207151,16720715,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2019,Q3,Labelled drug-drug interaction medication error,,2019,Q3,1,I,,20190806.0,20190820,20190820,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-19-04620,HIKMA,"CHOU T, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS ONLINE CASE REPORTS. 2019 JUN 01;7:3:48-51.",48.0,YR,,F,Y,112.0,KG,20190820.0,,MD,US,US,2019,Q3,Adult
167208711,16720871,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2019,Q3,Cataract subcapsular,,2019,Q3,1,I,,20190813.0,20190820,20190820,EXP,,US-MYLANLABS-2019M1077392,MYLAN,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS-ONLINE-CASE-REP 2019;7(3):48-51.",48.0,YR,,F,Y,112.0,KG,20190820.0,,MD,US,US,2019,Q3,Adult
167208711,16720871,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2019,Q3,Lens disorder,,2019,Q3,1,I,,20190813.0,20190820,20190820,EXP,,US-MYLANLABS-2019M1077392,MYLAN,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS-ONLINE-CASE-REP 2019;7(3):48-51.",48.0,YR,,F,Y,112.0,KG,20190820.0,,MD,US,US,2019,Q3,Adult
167208711,16720871,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2019,Q3,Toxicity to various agents,,2019,Q3,1,I,,20190813.0,20190820,20190820,EXP,,US-MYLANLABS-2019M1077392,MYLAN,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS-ONLINE-CASE-REP 2019;7(3):48-51.",48.0,YR,,F,Y,112.0,KG,20190820.0,,MD,US,US,2019,Q3,Adult
167208711,16720871,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,U,,,,,,,,2019,Q3,Cataract subcapsular,,2019,Q3,1,I,,20190813.0,20190820,20190820,EXP,,US-MYLANLABS-2019M1077392,MYLAN,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS-ONLINE-CASE-REP 2019;7(3):48-51.",48.0,YR,,F,Y,112.0,KG,20190820.0,,MD,US,US,2019,Q3,Adult
167208711,16720871,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,U,,,,,,,,2019,Q3,Lens disorder,,2019,Q3,1,I,,20190813.0,20190820,20190820,EXP,,US-MYLANLABS-2019M1077392,MYLAN,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS-ONLINE-CASE-REP 2019;7(3):48-51.",48.0,YR,,F,Y,112.0,KG,20190820.0,,MD,US,US,2019,Q3,Adult
167208711,16720871,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,U,,,,,,,,2019,Q3,Toxicity to various agents,,2019,Q3,1,I,,20190813.0,20190820,20190820,EXP,,US-MYLANLABS-2019M1077392,MYLAN,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS-ONLINE-CASE-REP 2019;7(3):48-51.",48.0,YR,,F,Y,112.0,KG,20190820.0,,MD,US,US,2019,Q3,Adult
167213431,16721343,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q3,Dry gangrene,,2019,Q3,1,I,,20190814.0,20190820,20190820,EXP,GB-MHRA-EYC 00200775,GB-JNJFOC-20190816993,JOHNSON AND JOHNSON,,65.0,YR,,M,Y,,,20190820.0,,PH,GB,GB,2019,Q3,Elderly
167213431,16721343,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q3,Pain in extremity,,2019,Q3,1,I,,20190814.0,20190820,20190820,EXP,GB-MHRA-EYC 00200775,GB-JNJFOC-20190816993,JOHNSON AND JOHNSON,,65.0,YR,,M,Y,,,20190820.0,,PH,GB,GB,2019,Q3,Elderly
167213431,16721343,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q3,Peripheral artery occlusion,,2019,Q3,1,I,,20190814.0,20190820,20190820,EXP,GB-MHRA-EYC 00200775,GB-JNJFOC-20190816993,JOHNSON AND JOHNSON,,65.0,YR,,M,Y,,,20190820.0,,PH,GB,GB,2019,Q3,Elderly
167213431,16721343,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q3,Stenosis,,2019,Q3,1,I,,20190814.0,20190820,20190820,EXP,GB-MHRA-EYC 00200775,GB-JNJFOC-20190816993,JOHNSON AND JOHNSON,,65.0,YR,,M,Y,,,20190820.0,,PH,GB,GB,2019,Q3,Elderly
167213801,16721380,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Herpes zoster,,2019,Q3,1,I,20180809.0,20190809.0,20190820,20190820,EXP,,JP-JNJFOC-20190820939,JOHNSON AND JOHNSON,,73.0,YR,,F,Y,55.0,KG,20190820.0,,MD,JP,JP,2019,Q3,Elderly
167243501,16724350,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,,20190812.0,20190821,20190821,EXP,,US-ASTRAZENECA-2019SF15283,ASTRAZENECA,,61.0,YR,,M,Y,,,20190821.0,,MD,US,US,2019,Q3,Adult
167244101,16724410,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",75300.0,MG,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Cerebral infarction,,2019,Q3,1,I,20171230.0,20190708.0,20190821,20190821,EXP,,JP-JNJFOC-20190814238,JOHNSON AND JOHNSON,,74.0,YR,,M,Y,,,20190821.0,,MD,JP,JP,2019,Q3,Elderly
167244101,16724410,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",75300.0,MG,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Cerebral infarction,,2019,Q3,1,I,20171230.0,20190708.0,20190821,20190821,EXP,,JP-JNJFOC-20190814238,JOHNSON AND JOHNSON,,74.0,YR,,M,Y,,,20190821.0,,MD,JP,JP,2019,Q3,Elderly
167244261,16724426,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Bronchitis,,2019,Q3,1,I,20190111.0,20190722.0,20190821,20190821,EXP,,JP-JNJFOC-20190811690,JOHNSON AND JOHNSON,,70.0,YR,,,Y,,,20190821.0,,MD,JP,JP,2019,Q3,Elderly
167244261,16724426,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Cataract,,2019,Q3,1,I,20190111.0,20190722.0,20190821,20190821,EXP,,JP-JNJFOC-20190811690,JOHNSON AND JOHNSON,,70.0,YR,,,Y,,,20190821.0,,MD,JP,JP,2019,Q3,Elderly
167364701,16736470,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,UNKNOWN,,2019,Q3,Acute kidney injury,,2019,Q3,1,I,20190802.0,20190821.0,20190823,20190823,EXP,GB-MHRA-EYC 00205683,GB-JNJFOC-20190827416,JOHNSON AND JOHNSON,,61.0,YR,,F,Y,,,20190823.0,,PH,GB,GB,2019,Q3,Adult
167364701,16736470,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,UNKNOWN,,2019,Q3,Condition aggravated,,2019,Q3,1,I,20190802.0,20190821.0,20190823,20190823,EXP,GB-MHRA-EYC 00205683,GB-JNJFOC-20190827416,JOHNSON AND JOHNSON,,61.0,YR,,F,Y,,,20190823.0,,PH,GB,GB,2019,Q3,Adult
167364701,16736470,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,UNKNOWN,,2019,Q3,Somnolence,,2019,Q3,1,I,20190802.0,20190821.0,20190823,20190823,EXP,GB-MHRA-EYC 00205683,GB-JNJFOC-20190827416,JOHNSON AND JOHNSON,,61.0,YR,,F,Y,,,20190823.0,,PH,GB,GB,2019,Q3,Adult
167401941,16740194,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Cataract nuclear,,2019,Q3,1,I,,20190819.0,20190826,20190826,EXP,,US-PFIZER INC-2019360243,PFIZER,"CHOU, Y.. HYPERGLYCAEMIA, BILATERAL NUCLEAR SCLEROSIS AND POSTERIOR SUBCAPSULAR CATARACT DUE TO DRUG TOXICITY: CASE REPORT. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS. 2019;7(3):48-51",48.0,YR,,F,Y,,,20190826.0,,OT,US,US,2019,Q3,Adult
167401941,16740194,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Cataract subcapsular,,2019,Q3,1,I,,20190819.0,20190826,20190826,EXP,,US-PFIZER INC-2019360243,PFIZER,"CHOU, Y.. HYPERGLYCAEMIA, BILATERAL NUCLEAR SCLEROSIS AND POSTERIOR SUBCAPSULAR CATARACT DUE TO DRUG TOXICITY: CASE REPORT. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS. 2019;7(3):48-51",48.0,YR,,F,Y,,,20190826.0,,OT,US,US,2019,Q3,Adult
167401941,16740194,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Hyperglycaemia,,2019,Q3,1,I,,20190819.0,20190826,20190826,EXP,,US-PFIZER INC-2019360243,PFIZER,"CHOU, Y.. HYPERGLYCAEMIA, BILATERAL NUCLEAR SCLEROSIS AND POSTERIOR SUBCAPSULAR CATARACT DUE TO DRUG TOXICITY: CASE REPORT. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS. 2019;7(3):48-51",48.0,YR,,F,Y,,,20190826.0,,OT,US,US,2019,Q3,Adult
167401941,16740194,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Toxicity to various agents,,2019,Q3,1,I,,20190819.0,20190826,20190826,EXP,,US-PFIZER INC-2019360243,PFIZER,"CHOU, Y.. HYPERGLYCAEMIA, BILATERAL NUCLEAR SCLEROSIS AND POSTERIOR SUBCAPSULAR CATARACT DUE TO DRUG TOXICITY: CASE REPORT. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS. 2019;7(3):48-51",48.0,YR,,F,Y,,,20190826.0,,OT,US,US,2019,Q3,Adult
167401941,16740194,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q3,Vision blurred,,2019,Q3,1,I,,20190819.0,20190826,20190826,EXP,,US-PFIZER INC-2019360243,PFIZER,"CHOU, Y.. HYPERGLYCAEMIA, BILATERAL NUCLEAR SCLEROSIS AND POSTERIOR SUBCAPSULAR CATARACT DUE TO DRUG TOXICITY: CASE REPORT. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS. 2019;7(3):48-51",48.0,YR,,F,Y,,,20190826.0,,OT,US,US,2019,Q3,Adult
167450361,16745036,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Cataract subcapsular,,2019,Q3,1,I,,20190819.0,20190827,20190827,EXP,,US-TEVA-2019-US-1098665,TEVA,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS-ONLINE-CASE-REP 2019;7(3):48-51.",48.0,YR,,F,Y,112.0,KG,20190827.0,,MD,US,US,2019,Q3,Adult
167450361,16745036,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Hyperglycaemia,,2019,Q3,1,I,,20190819.0,20190827,20190827,EXP,,US-TEVA-2019-US-1098665,TEVA,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS-ONLINE-CASE-REP 2019;7(3):48-51.",48.0,YR,,F,Y,112.0,KG,20190827.0,,MD,US,US,2019,Q3,Adult
167450361,16745036,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Lens disorder,,2019,Q3,1,I,,20190819.0,20190827,20190827,EXP,,US-TEVA-2019-US-1098665,TEVA,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS-ONLINE-CASE-REP 2019;7(3):48-51.",48.0,YR,,F,Y,112.0,KG,20190827.0,,MD,US,US,2019,Q3,Adult
167450361,16745036,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2019,Q3,Toxicity to various agents,,2019,Q3,1,I,,20190819.0,20190827,20190827,EXP,,US-TEVA-2019-US-1098665,TEVA,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS-ONLINE-CASE-REP 2019;7(3):48-51.",48.0,YR,,F,Y,112.0,KG,20190827.0,,MD,US,US,2019,Q3,Adult
167450361,16745036,8,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q3,Cataract subcapsular,,2019,Q3,1,I,,20190819.0,20190827,20190827,EXP,,US-TEVA-2019-US-1098665,TEVA,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS-ONLINE-CASE-REP 2019;7(3):48-51.",48.0,YR,,F,Y,112.0,KG,20190827.0,,MD,US,US,2019,Q3,Adult
167450361,16745036,8,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q3,Hyperglycaemia,,2019,Q3,1,I,,20190819.0,20190827,20190827,EXP,,US-TEVA-2019-US-1098665,TEVA,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS-ONLINE-CASE-REP 2019;7(3):48-51.",48.0,YR,,F,Y,112.0,KG,20190827.0,,MD,US,US,2019,Q3,Adult
167450361,16745036,8,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q3,Lens disorder,,2019,Q3,1,I,,20190819.0,20190827,20190827,EXP,,US-TEVA-2019-US-1098665,TEVA,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS-ONLINE-CASE-REP 2019;7(3):48-51.",48.0,YR,,F,Y,112.0,KG,20190827.0,,MD,US,US,2019,Q3,Adult
167450361,16745036,8,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q3,Toxicity to various agents,,2019,Q3,1,I,,20190819.0,20190827,20190827,EXP,,US-TEVA-2019-US-1098665,TEVA,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS-ONLINE-CASE-REP 2019;7(3):48-51.",48.0,YR,,F,Y,112.0,KG,20190827.0,,MD,US,US,2019,Q3,Adult
167590561,16759056,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",99700.0,MG,N,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Chronic kidney disease,,2019,Q3,1,I,20190301.0,20190819.0,20190830,20190830,EXP,,JP-JNJFOC-20190835681,JOHNSON AND JOHNSON,,67.0,YR,,M,Y,,,20190830.0,,MD,JP,JP,2019,Q3,Elderly
167625011,16762501,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,97.958336,DF,,, UNKNOWN,,,1.0,DF,,,2019,Q3,Hypersensitivity,,2019,Q3,1,I,20190515.0,20190825.0,20190831,20190831,EXP,GB-MHRA-TPP16316054C1348294YC1558622224043,GB-TEVA-2019-GB-1099890,TEVA,,68.0,YR,,F,Y,95.0,KG,20190831.0,,MD,GB,GB,2019,Q3,Elderly
167625011,16762501,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,97.958336,DF,,, UNKNOWN,,,1.0,DF,,,2019,Q3,Lip pain,,2019,Q3,1,I,20190515.0,20190825.0,20190831,20190831,EXP,GB-MHRA-TPP16316054C1348294YC1558622224043,GB-TEVA-2019-GB-1099890,TEVA,,68.0,YR,,F,Y,95.0,KG,20190831.0,,MD,GB,GB,2019,Q3,Elderly
167625011,16762501,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,97.958336,DF,,, UNKNOWN,,,1.0,DF,,,2019,Q3,Lip swelling,,2019,Q3,1,I,20190515.0,20190825.0,20190831,20190831,EXP,GB-MHRA-TPP16316054C1348294YC1558622224043,GB-TEVA-2019-GB-1099890,TEVA,,68.0,YR,,F,Y,95.0,KG,20190831.0,,MD,GB,GB,2019,Q3,Elderly
167634801,16763480,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 MG,,,,, UNKNOWN,,,100.0,MG,,,2019,Q3,Abdominal pain lower,,2019,Q3,1,I,20190628.0,20190825.0,20190902,20190902,EXP,GB-MHRA-EYC 00205474,GB-TEVA-2019-GB-1100256,TEVA,,62.0,YR,,M,Y,106.13,KG,20190902.0,,CN,GB,GB,2019,Q3,Adult
167634801,16763480,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 MG,,,,, UNKNOWN,,,100.0,MG,,,2019,Q3,Diarrhoea,,2019,Q3,1,I,20190628.0,20190825.0,20190902,20190902,EXP,GB-MHRA-EYC 00205474,GB-TEVA-2019-GB-1100256,TEVA,,62.0,YR,,M,Y,106.13,KG,20190902.0,,CN,GB,GB,2019,Q3,Adult
167634801,16763480,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 MG,,,,, UNKNOWN,,,100.0,MG,,,2019,Q3,Malaise,,2019,Q3,1,I,20190628.0,20190825.0,20190902,20190902,EXP,GB-MHRA-EYC 00205474,GB-TEVA-2019-GB-1100256,TEVA,,62.0,YR,,M,Y,106.13,KG,20190902.0,,CN,GB,GB,2019,Q3,Adult
167652561,16765256,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2019,Q3,Cataract nuclear,Cataract nuclear,2019,Q3,1,I,,20190819.0,20190903,20190903,EXP,,US-ZYDUS-040223,ZYDUS PHARM,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS-ONLINE-CASE-REP 2019;7(3):48-51.",48.0,YR,,F,Y,112.0,KG,20190903.0,,MD,US,US,2019,Q3,Adult
167652561,16765256,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2019,Q3,Cataract subcapsular,,2019,Q3,1,I,,20190819.0,20190903,20190903,EXP,,US-ZYDUS-040223,ZYDUS PHARM,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS-ONLINE-CASE-REP 2019;7(3):48-51.",48.0,YR,,F,Y,112.0,KG,20190903.0,,MD,US,US,2019,Q3,Adult
167652561,16765256,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,,,2019,Q3,Toxicity to various agents,,2019,Q3,1,I,,20190819.0,20190903,20190903,EXP,,US-ZYDUS-040223,ZYDUS PHARM,"CHOU TY, BRICEL S, YAZDANIE M. RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED. JCRS-ONLINE-CASE-REP 2019;7(3):48-51.",48.0,YR,,F,Y,112.0,KG,20190903.0,,MD,US,US,2019,Q3,Adult
167751421,16775142,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q3,Dizziness,,2019,Q3,1,I,,20190822.0,20190905,20190905,EXP,,CA-ROCHE-2391289,ROCHE,,66.0,YR,,M,Y,,,20190905.0,,MD,CA,CA,2019,Q3,Elderly
167751421,16775142,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q3,Drug ineffective,,2019,Q3,1,I,,20190822.0,20190905,20190905,EXP,,CA-ROCHE-2391289,ROCHE,,66.0,YR,,M,Y,,,20190905.0,,MD,CA,CA,2019,Q3,Elderly
167751421,16775142,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q3,Dyspnoea,,2019,Q3,1,I,,20190822.0,20190905,20190905,EXP,,CA-ROCHE-2391289,ROCHE,,66.0,YR,,M,Y,,,20190905.0,,MD,CA,CA,2019,Q3,Elderly
167751421,16775142,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q3,Fatigue,,2019,Q3,1,I,,20190822.0,20190905,20190905,EXP,,CA-ROCHE-2391289,ROCHE,,66.0,YR,,M,Y,,,20190905.0,,MD,CA,CA,2019,Q3,Elderly
167751421,16775142,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q3,Flushing,,2019,Q3,1,I,,20190822.0,20190905,20190905,EXP,,CA-ROCHE-2391289,ROCHE,,66.0,YR,,M,Y,,,20190905.0,,MD,CA,CA,2019,Q3,Elderly
167751421,16775142,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q3,Headache,,2019,Q3,1,I,,20190822.0,20190905,20190905,EXP,,CA-ROCHE-2391289,ROCHE,,66.0,YR,,M,Y,,,20190905.0,,MD,CA,CA,2019,Q3,Elderly
167751421,16775142,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q3,Hypoxia,,2019,Q3,1,I,,20190822.0,20190905,20190905,EXP,,CA-ROCHE-2391289,ROCHE,,66.0,YR,,M,Y,,,20190905.0,,MD,CA,CA,2019,Q3,Elderly
167751421,16775142,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q3,Muscular weakness,,2019,Q3,1,I,,20190822.0,20190905,20190905,EXP,,CA-ROCHE-2391289,ROCHE,,66.0,YR,,M,Y,,,20190905.0,,MD,CA,CA,2019,Q3,Elderly
167751421,16775142,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q3,Nausea,,2019,Q3,1,I,,20190822.0,20190905,20190905,EXP,,CA-ROCHE-2391289,ROCHE,,66.0,YR,,M,Y,,,20190905.0,,MD,CA,CA,2019,Q3,Elderly
167986971,16798697,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Myocardial infarction,,2019,Q3,1,I,,20190902.0,20190912,20190912,EXP,,JP-JNJFOC-20190912100,JOHNSON AND JOHNSON,,46.0,YR,,M,Y,89.0,KG,20190912.0,,MD,JP,JP,2019,Q3,Adult
167987351,16798735,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q3,Euglycaemic diabetic ketoacidosis,,2019,Q3,1,I,,20190903.0,20190912,20190912,EXP,,US-JNJFOC-20190902660,JOHNSON AND JOHNSON,NOUR C. CANAGLIFLOZIN-INDUCED EUGLYCEMIC DIABETIC KETOACIDOSIS IN A TYPE 2 DIABETIC. JOURNAL OF GENERAL INTERNAL MEDICINE. 2019;34 (2 SUPPLEMENT):S500-S501.,47.0,YR,,M,Y,,,20190912.0,,OT,US,US,2019,Q3,Adult
167988661,16798866,10,C,canagliflozin 100 mg tablet,,2,,,,,,,,,,,,,,2019,Q3,Cardiac tamponade,,2019,Q3,1,I,20190627.0,,20190722,20190722,DIR,,,FDA-CTU,,69.0,YR,,F,N,76.5,KG,20190719.0,N,PH,US,US,2019,Q3,Elderly
167988661,16798866,10,C,canagliflozin 100 mg tablet,,2,,,,,,,,,,,,,,2019,Q3,Diabetic ketoacidosis,,2019,Q3,1,I,20190627.0,,20190722,20190722,DIR,,,FDA-CTU,,69.0,YR,,F,N,76.5,KG,20190719.0,N,PH,US,US,2019,Q3,Elderly
167988661,16798866,10,C,canagliflozin 100 mg tablet,,2,,,,,,,,,,,,,,2019,Q3,Dizziness,,2019,Q3,1,I,20190627.0,,20190722,20190722,DIR,,,FDA-CTU,,69.0,YR,,F,N,76.5,KG,20190719.0,N,PH,US,US,2019,Q3,Elderly
167988661,16798866,10,C,canagliflozin 100 mg tablet,,2,,,,,,,,,,,,,,2019,Q3,Epistaxis,,2019,Q3,1,I,20190627.0,,20190722,20190722,DIR,,,FDA-CTU,,69.0,YR,,F,N,76.5,KG,20190719.0,N,PH,US,US,2019,Q3,Elderly
167988661,16798866,10,C,canagliflozin 100 mg tablet,,2,,,,,,,,,,,,,,2019,Q3,Gastrointestinal haemorrhage,,2019,Q3,1,I,20190627.0,,20190722,20190722,DIR,,,FDA-CTU,,69.0,YR,,F,N,76.5,KG,20190719.0,N,PH,US,US,2019,Q3,Elderly
167988661,16798866,10,C,canagliflozin 100 mg tablet,,2,,,,,,,,,,,,,,2019,Q3,Haemoglobin decreased,,2019,Q3,1,I,20190627.0,,20190722,20190722,DIR,,,FDA-CTU,,69.0,YR,,F,N,76.5,KG,20190719.0,N,PH,US,US,2019,Q3,Elderly
167988661,16798866,10,C,canagliflozin 100 mg tablet,,2,,,,,,,,,,,,,,2019,Q3,Hepatic failure,,2019,Q3,1,I,20190627.0,,20190722,20190722,DIR,,,FDA-CTU,,69.0,YR,,F,N,76.5,KG,20190719.0,N,PH,US,US,2019,Q3,Elderly
167988661,16798866,10,C,canagliflozin 100 mg tablet,,2,,,,,,,,,,,,,,2019,Q3,Hypophagia,,2019,Q3,1,I,20190627.0,,20190722,20190722,DIR,,,FDA-CTU,,69.0,YR,,F,N,76.5,KG,20190719.0,N,PH,US,US,2019,Q3,Elderly
167988661,16798866,10,C,canagliflozin 100 mg tablet,,2,,,,,,,,,,,,,,2019,Q3,Malaise,,2019,Q3,1,I,20190627.0,,20190722,20190722,DIR,,,FDA-CTU,,69.0,YR,,F,N,76.5,KG,20190719.0,N,PH,US,US,2019,Q3,Elderly
167988661,16798866,10,C,canagliflozin 100 mg tablet,,2,,,,,,,,,,,,,,2019,Q3,Nausea,,2019,Q3,1,I,20190627.0,,20190722,20190722,DIR,,,FDA-CTU,,69.0,YR,,F,N,76.5,KG,20190719.0,N,PH,US,US,2019,Q3,Elderly
167988661,16798866,10,C,canagliflozin 100 mg tablet,,2,,,,,,,,,,,,,,2019,Q3,Renal failure,,2019,Q3,1,I,20190627.0,,20190722,20190722,DIR,,,FDA-CTU,,69.0,YR,,F,N,76.5,KG,20190719.0,N,PH,US,US,2019,Q3,Elderly
167988661,16798866,10,C,canagliflozin 100 mg tablet,,2,,,,,,,,,,,,,,2019,Q3,Weight decreased,,2019,Q3,1,I,20190627.0,,20190722,20190722,DIR,,,FDA-CTU,,69.0,YR,,F,N,76.5,KG,20190719.0,N,PH,US,US,2019,Q3,Elderly
168046711,16804671,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Crohn's disease,,2019,Q3,1,I,20180825.0,20190322.0,20190913,20190913,EXP,,JP-JNJFOC-20190422957,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20190913.0,,MD,JP,JP,2019,Q3,Adult
168067961,16806796,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Dehydration,,2019,Q3,1,I,,20190905.0,20190913,20190913,EXP,,ES-NOVOPROD-684111,NOVO NORDISK,,50.0,YR,,F,Y,,,20190913.0,,MD,ES,ES,2019,Q3,Adult
168067961,16806796,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q3,Renal failure,,2019,Q3,1,I,,20190905.0,20190913,20190913,EXP,,ES-NOVOPROD-684111,NOVO NORDISK,,50.0,YR,,F,Y,,,20190913.0,,MD,ES,ES,2019,Q3,Adult
168214561,16821456,10,C,INVOKANA [CANAGLIFLOZIN HEMIHYDRATE],,2,,UNK,,,,,,,,,,,,2019,Q3,Blood pressure diastolic abnormal,,2019,Q3,1,I,,20190906.0,20190918,20190918,EXP,,CA-PFIZER INC-2019394996,PFIZER,,56.0,YR,,M,Y,95.0,KG,20190918.0,,OT,CA,CA,2019,Q3,Adult
168214561,16821456,10,C,INVOKANA [CANAGLIFLOZIN HEMIHYDRATE],,2,,UNK,,,,,,,,,,,,2019,Q3,Blood pressure fluctuation,,2019,Q3,1,I,,20190906.0,20190918,20190918,EXP,,CA-PFIZER INC-2019394996,PFIZER,,56.0,YR,,M,Y,95.0,KG,20190918.0,,OT,CA,CA,2019,Q3,Adult
168214561,16821456,10,C,INVOKANA [CANAGLIFLOZIN HEMIHYDRATE],,2,,UNK,,,,,,,,,,,,2019,Q3,Blood pressure increased,,2019,Q3,1,I,,20190906.0,20190918,20190918,EXP,,CA-PFIZER INC-2019394996,PFIZER,,56.0,YR,,M,Y,95.0,KG,20190918.0,,OT,CA,CA,2019,Q3,Adult
168214561,16821456,10,C,INVOKANA [CANAGLIFLOZIN HEMIHYDRATE],,2,,UNK,,,,,,,,,,,,2019,Q3,Blood pressure systolic abnormal,,2019,Q3,1,I,,20190906.0,20190918,20190918,EXP,,CA-PFIZER INC-2019394996,PFIZER,,56.0,YR,,M,Y,95.0,KG,20190918.0,,OT,CA,CA,2019,Q3,Adult
168214561,16821456,10,C,INVOKANA [CANAGLIFLOZIN HEMIHYDRATE],,2,,UNK,,,,,,,,,,,,2019,Q3,Blood pressure systolic increased,,2019,Q3,1,I,,20190906.0,20190918,20190918,EXP,,CA-PFIZER INC-2019394996,PFIZER,,56.0,YR,,M,Y,95.0,KG,20190918.0,,OT,CA,CA,2019,Q3,Adult
168214561,16821456,10,C,INVOKANA [CANAGLIFLOZIN HEMIHYDRATE],,2,,UNK,,,,,,,,,,,,2019,Q3,Carpal tunnel syndrome,,2019,Q3,1,I,,20190906.0,20190918,20190918,EXP,,CA-PFIZER INC-2019394996,PFIZER,,56.0,YR,,M,Y,95.0,KG,20190918.0,,OT,CA,CA,2019,Q3,Adult
168214561,16821456,10,C,INVOKANA [CANAGLIFLOZIN HEMIHYDRATE],,2,,UNK,,,,,,,,,,,,2019,Q3,Heart rate increased,,2019,Q3,1,I,,20190906.0,20190918,20190918,EXP,,CA-PFIZER INC-2019394996,PFIZER,,56.0,YR,,M,Y,95.0,KG,20190918.0,,OT,CA,CA,2019,Q3,Adult
168214561,16821456,10,C,INVOKANA [CANAGLIFLOZIN HEMIHYDRATE],,2,,UNK,,,,,,,,,,,,2019,Q3,Hypersensitivity,,2019,Q3,1,I,,20190906.0,20190918,20190918,EXP,,CA-PFIZER INC-2019394996,PFIZER,,56.0,YR,,M,Y,95.0,KG,20190918.0,,OT,CA,CA,2019,Q3,Adult
168214561,16821456,10,C,INVOKANA [CANAGLIFLOZIN HEMIHYDRATE],,2,,UNK,,,,,,,,,,,,2019,Q3,Infusion related reaction,,2019,Q3,1,I,,20190906.0,20190918,20190918,EXP,,CA-PFIZER INC-2019394996,PFIZER,,56.0,YR,,M,Y,95.0,KG,20190918.0,,OT,CA,CA,2019,Q3,Adult
168214561,16821456,10,C,INVOKANA [CANAGLIFLOZIN HEMIHYDRATE],,2,,UNK,,,,,,,,,,,,2019,Q3,Injection site extravasation,,2019,Q3,1,I,,20190906.0,20190918,20190918,EXP,,CA-PFIZER INC-2019394996,PFIZER,,56.0,YR,,M,Y,95.0,KG,20190918.0,,OT,CA,CA,2019,Q3,Adult
168214561,16821456,10,C,INVOKANA [CANAGLIFLOZIN HEMIHYDRATE],,2,,UNK,,,,,,,,,,,,2019,Q3,Oxygen saturation decreased,,2019,Q3,1,I,,20190906.0,20190918,20190918,EXP,,CA-PFIZER INC-2019394996,PFIZER,,56.0,YR,,M,Y,95.0,KG,20190918.0,,OT,CA,CA,2019,Q3,Adult
168214561,16821456,10,C,INVOKANA [CANAGLIFLOZIN HEMIHYDRATE],,2,,UNK,,,,,,,,,,,,2019,Q3,Rheumatoid arthritis,,2019,Q3,1,I,,20190906.0,20190918,20190918,EXP,,CA-PFIZER INC-2019394996,PFIZER,,56.0,YR,,M,Y,95.0,KG,20190918.0,,OT,CA,CA,2019,Q3,Adult
168214561,16821456,10,C,INVOKANA [CANAGLIFLOZIN HEMIHYDRATE],,2,,UNK,,,,,,,,,,,,2019,Q3,Type 2 diabetes mellitus,,2019,Q3,1,I,,20190906.0,20190918,20190918,EXP,,CA-PFIZER INC-2019394996,PFIZER,,56.0,YR,,M,Y,95.0,KG,20190918.0,,OT,CA,CA,2019,Q3,Adult
168227092,16822709,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Urinary retention,,2019,Q3,2,F,20190824.0,20190913.0,20190918,20190923,EXP,,JP-JNJFOC-20190916571,JOHNSON AND JOHNSON,,65.0,YR,,M,Y,,,20190923.0,,MD,JP,JP,2019,Q3,Elderly
168345721,16834572,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Osteoarthritis,,2019,Q3,1,I,2018.0,20190911.0,20190920,20190920,EXP,,JP-JNJFOC-20190925204,JOHNSON AND JOHNSON,,73.0,YR,,M,Y,,,20190920.0,,MD,JP,JP,2019,Q3,Elderly
168345761,16834576,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Breast cancer,,2019,Q3,1,I,20171115.0,20190911.0,20190920,20190920,EXP,,JP-JNJFOC-20190925997,JOHNSON AND JOHNSON,,58.0,YR,,F,Y,,,20190920.0,,MD,JP,JP,2019,Q3,Adult
168345761,16834576,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Nasopharyngeal cancer,,2019,Q3,1,I,20171115.0,20190911.0,20190920,20190920,EXP,,JP-JNJFOC-20190925997,JOHNSON AND JOHNSON,,58.0,YR,,F,Y,,,20190920.0,,MD,JP,JP,2019,Q3,Adult
168345781,16834578,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",103500.0,MG,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Diverticulitis,,2019,Q3,1,I,20190713.0,20190911.0,20190920,20190920,EXP,,JP-JNJFOC-20190925620,JOHNSON AND JOHNSON,,38.0,YR,,F,Y,,,20190920.0,,MD,JP,JP,2019,Q3,Adult
168345781,16834578,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",103500.0,MG,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Diverticulitis,,2019,Q3,1,I,20190713.0,20190911.0,20190920,20190920,EXP,,JP-JNJFOC-20190925620,JOHNSON AND JOHNSON,,38.0,YR,,F,Y,,,20190920.0,,MD,JP,JP,2019,Q3,Adult
168347761,16834776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Hypertension,,2019,Q3,1,I,20170531.0,20180507.0,20190920,20190920,EXP,,JP-JNJFOC-20180514939,JOHNSON AND JOHNSON,,79.0,YR,,F,Y,52.0,KG,20190920.0,,MD,JP,JP,2019,Q3,Elderly
168347761,16834776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Myocardial infarction,,2019,Q3,1,I,20170531.0,20180507.0,20190920,20190920,EXP,,JP-JNJFOC-20180514939,JOHNSON AND JOHNSON,,79.0,YR,,F,Y,52.0,KG,20190920.0,,MD,JP,JP,2019,Q3,Elderly
168391271,16839127,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",107700.0,MG,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Colon adenoma,,2019,Q3,1,I,20190616.0,20190911.0,20190923,20190923,EXP,,JP-JNJFOC-20190927607,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,,,20190923.0,,MD,JP,JP,2019,Q3,Elderly
168391271,16839127,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",107700.0,MG,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Colon adenoma,,2019,Q3,1,I,20190616.0,20190911.0,20190923,20190923,EXP,,JP-JNJFOC-20190927607,JOHNSON AND JOHNSON,,68.0,YR,,F,Y,,,20190923.0,,MD,JP,JP,2019,Q3,Elderly
168392211,16839221,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Rotator cuff syndrome,,2019,Q3,1,I,20190329.0,20190913.0,20190923,20190923,EXP,JP-MTPC-MTPC2019-0071709,JP-JNJFOC-20190928252,JOHNSON AND JOHNSON,,48.0,YR,,M,Y,,,20190923.0,,MD,JP,JP,2019,Q3,Adult
168425081,16842508,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,,100.0,MG,TABLET,QD,2019,Q3,Abdominal pain upper,,2019,Q3,1,I,,20150604.0,20190924,20190924,EXP,,GB-EMD SERONO-8028827,EMD SERONO INC,,69.0,YR,,M,Y,,,20190924.0,,OT,GB,GB,2019,Q3,Elderly
168425081,16842508,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,,100.0,MG,TABLET,QD,2019,Q3,Pyrexia,,2019,Q3,1,I,,20150604.0,20190924,20190924,EXP,,GB-EMD SERONO-8028827,EMD SERONO INC,,69.0,YR,,M,Y,,,20190924.0,,OT,GB,GB,2019,Q3,Elderly
168502191,16850219,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Urinary calculus removal,,2019,Q3,1,I,20190705.0,20190912.0,20190925,20190925,EXP,,JP-JNJFOC-20190929620,JOHNSON AND JOHNSON,,64.0,YR,,M,Y,,,20190925.0,,MD,JP,JP,2019,Q3,Adult
168577641,16857764,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q3,Pemphigoid,,2019,Q3,1,I,201907.0,20190918.0,20190926,20190926,EXP,,JP-JNJFOC-20190933572,JOHNSON AND JOHNSON,,85.0,YR,,M,Y,,,20190926.0,,PH,JP,JP,2019,Q3,Elderly
168582241,16858224,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",86000.0,MG,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q3,Cardiac failure,,2019,Q3,1,I,20190122.0,20190919.0,20190926,20190926,EXP,,JP-JNJFOC-20190933768,JOHNSON AND JOHNSON,,59.0,YR,,M,Y,,,20190926.0,,MD,JP,JP,2019,Q3,Adult
168609271,16860927,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q3,Gastritis,,2019,Q3,1,I,20190917.0,20190920.0,20190927,20190927,EXP,,"GR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-103384",BOEHRINGER INGELHEIM,,83.0,YR,,M,Y,,,20190927.0,,MD,GR,GR,2019,Q3,Elderly
168609271,16860927,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q3,Haemodynamic instability,,2019,Q3,1,I,20190917.0,20190920.0,20190927,20190927,EXP,,"GR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-103384",BOEHRINGER INGELHEIM,,83.0,YR,,M,Y,,,20190927.0,,MD,GR,GR,2019,Q3,Elderly
168609271,16860927,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q3,Melaena,,2019,Q3,1,I,20190917.0,20190920.0,20190927,20190927,EXP,,"GR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-103384",BOEHRINGER INGELHEIM,,83.0,YR,,M,Y,,,20190927.0,,MD,GR,GR,2019,Q3,Elderly
168686301,16868630,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q3,Toxic skin eruption,,2019,Q3,1,I,,20190919.0,20190930,20190930,EXP,,JP-JNJFOC-20190936839,JOHNSON AND JOHNSON,,69.0,YR,,M,Y,,,20190930.0,,PH,JP,JP,2019,Q3,Elderly
123638682,12363868,7,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2019,Q4,Drug ineffective,,2019,Q4,2,F,20150421.0,20160101.0,20160512,20191216,PER,,US-UCBSA-2015016239,UCB,,49.0,YR,,F,Y,,,20191216.0,,PH,US,US,2019,Q4,Adult
123638682,12363868,7,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2019,Q4,Off label use,,2019,Q4,2,F,20150421.0,20160101.0,20160512,20191216,PER,,US-UCBSA-2015016239,UCB,,49.0,YR,,F,Y,,,20191216.0,,PH,US,US,2019,Q4,Adult
123638682,12363868,7,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2019,Q4,Pruritus,,2019,Q4,2,F,20150421.0,20160101.0,20160512,20191216,PER,,US-UCBSA-2015016239,UCB,,49.0,YR,,F,Y,,,20191216.0,,PH,US,US,2019,Q4,Adult
128582694,12858269,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Asthma,,2019,Q4,4,F,20160312.0,20191205.0,20161018,20191218,EXP,,JP-JNJFOC-20161013100,JOHNSON AND JOHNSON,,39.0,YR,,F,Y,86.0,KG,20191218.0,,MD,JP,JP,2019,Q4,Adult
128582694,12858269,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Borderline personality disorder,,2019,Q4,4,F,20160312.0,20191205.0,20161018,20191218,EXP,,JP-JNJFOC-20161013100,JOHNSON AND JOHNSON,,39.0,YR,,F,Y,86.0,KG,20191218.0,,MD,JP,JP,2019,Q4,Adult
128582694,12858269,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Facial paralysis,,2019,Q4,4,F,20160312.0,20191205.0,20161018,20191218,EXP,,JP-JNJFOC-20161013100,JOHNSON AND JOHNSON,,39.0,YR,,F,Y,86.0,KG,20191218.0,,MD,JP,JP,2019,Q4,Adult
128710716,12871071,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Blood ketone body increased,,2019,Q4,6,F,20160530.0,20191212.0,20161021,20191223,EXP,,JP-JNJFOC-20161018377,JOHNSON AND JOHNSON,,84.0,YR,,F,Y,68.0,KG,20191223.0,,MD,JP,JP,2019,Q4,Elderly
128710716,12871071,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Chronic gastritis,,2019,Q4,6,F,20160530.0,20191212.0,20161021,20191223,EXP,,JP-JNJFOC-20161018377,JOHNSON AND JOHNSON,,84.0,YR,,F,Y,68.0,KG,20191223.0,,MD,JP,JP,2019,Q4,Elderly
128710716,12871071,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Cystatin C increased,,2019,Q4,6,F,20160530.0,20191212.0,20161021,20191223,EXP,,JP-JNJFOC-20161018377,JOHNSON AND JOHNSON,,84.0,YR,,F,Y,68.0,KG,20191223.0,,MD,JP,JP,2019,Q4,Elderly
128710716,12871071,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Pancreatic carcinoma,,2019,Q4,6,F,20160530.0,20191212.0,20161021,20191223,EXP,,JP-JNJFOC-20161018377,JOHNSON AND JOHNSON,,84.0,YR,,F,Y,68.0,KG,20191223.0,,MD,JP,JP,2019,Q4,Elderly
130091428,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Blood pressure diastolic decreased,,2019,Q4,8,F,2016.0,20191002.0,20161208,20191014,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20191014.0,,MD,JP,JP,2019,Q4,Elderly
130091428,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Blood pressure increased,,2019,Q4,8,F,2016.0,20191002.0,20161208,20191014,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20191014.0,,MD,JP,JP,2019,Q4,Elderly
130091428,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Cardiac failure,,2019,Q4,8,F,2016.0,20191002.0,20161208,20191014,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20191014.0,,MD,JP,JP,2019,Q4,Elderly
130091428,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Cold sweat,,2019,Q4,8,F,2016.0,20191002.0,20161208,20191014,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20191014.0,,MD,JP,JP,2019,Q4,Elderly
130091428,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Feeling cold,,2019,Q4,8,F,2016.0,20191002.0,20161208,20191014,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20191014.0,,MD,JP,JP,2019,Q4,Elderly
130091428,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Heart rate increased,,2019,Q4,8,F,2016.0,20191002.0,20161208,20191014,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20191014.0,,MD,JP,JP,2019,Q4,Elderly
130091428,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Hyperhidrosis,,2019,Q4,8,F,2016.0,20191002.0,20161208,20191014,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20191014.0,,MD,JP,JP,2019,Q4,Elderly
130091428,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Ileus,,2019,Q4,8,F,2016.0,20191002.0,20161208,20191014,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20191014.0,,MD,JP,JP,2019,Q4,Elderly
130091428,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Melaena,,2019,Q4,8,F,2016.0,20191002.0,20161208,20191014,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20191014.0,,MD,JP,JP,2019,Q4,Elderly
130091428,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Oedema peripheral,,2019,Q4,8,F,2016.0,20191002.0,20161208,20191014,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20191014.0,,MD,JP,JP,2019,Q4,Elderly
130091428,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Pollakiuria,,2019,Q4,8,F,2016.0,20191002.0,20161208,20191014,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20191014.0,,MD,JP,JP,2019,Q4,Elderly
130091428,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Renal impairment,,2019,Q4,8,F,2016.0,20191002.0,20161208,20191014,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20191014.0,,MD,JP,JP,2019,Q4,Elderly
130091428,13009142,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Weight decreased,,2019,Q4,8,F,2016.0,20191002.0,20161208,20191014,EXP,,JP-JNJFOC-20161206833,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,61.0,KG,20191014.0,,MD,JP,JP,2019,Q4,Elderly
131626794,13162679,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Hepatic cancer,,2019,Q4,4,F,20160208.0,20191003.0,20170130,20191015,EXP,,JP-JNJFOC-20170124791,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,81.0,KG,20191015.0,,MD,JP,JP,2019,Q4,Elderly
131626794,13162679,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Hyperuricaemia,,2019,Q4,4,F,20160208.0,20191003.0,20170130,20191015,EXP,,JP-JNJFOC-20170124791,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,81.0,KG,20191015.0,,MD,JP,JP,2019,Q4,Elderly
131626794,13162679,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Renal impairment,,2019,Q4,4,F,20160208.0,20191003.0,20170130,20191015,EXP,,JP-JNJFOC-20170124791,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,81.0,KG,20191015.0,,MD,JP,JP,2019,Q4,Elderly
139867135,13986713,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Inguinal hernia,,2019,Q4,5,F,20161004.0,20191204.0,20170919,20191216,EXP,,JP-JNJFOC-20161209520,JOHNSON AND JOHNSON,,46.0,YR,,F,Y,61.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Adult
139867135,13986713,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Iron deficiency anaemia,,2019,Q4,5,F,20161004.0,20191204.0,20170919,20191216,EXP,,JP-JNJFOC-20161209520,JOHNSON AND JOHNSON,,46.0,YR,,F,Y,61.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Adult
139867135,13986713,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Lung opacity,,2019,Q4,5,F,20161004.0,20191204.0,20170919,20191216,EXP,,JP-JNJFOC-20161209520,JOHNSON AND JOHNSON,,46.0,YR,,F,Y,61.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Adult
139867135,13986713,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Nausea,,2019,Q4,5,F,20161004.0,20191204.0,20170919,20191216,EXP,,JP-JNJFOC-20161209520,JOHNSON AND JOHNSON,,46.0,YR,,F,Y,61.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Adult
139867135,13986713,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Treatment noncompliance,,2019,Q4,5,F,20161004.0,20191204.0,20170919,20191216,EXP,,JP-JNJFOC-20161209520,JOHNSON AND JOHNSON,,46.0,YR,,F,Y,61.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Adult
139867135,13986713,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Urine ketone body present,,2019,Q4,5,F,20161004.0,20191204.0,20170919,20191216,EXP,,JP-JNJFOC-20161209520,JOHNSON AND JOHNSON,,46.0,YR,,F,Y,61.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Adult
139867135,13986713,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Inguinal hernia,,2019,Q4,5,F,20161004.0,20191204.0,20170919,20191216,EXP,,JP-JNJFOC-20161209520,JOHNSON AND JOHNSON,,46.0,YR,,F,Y,61.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Adult
139867135,13986713,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Iron deficiency anaemia,,2019,Q4,5,F,20161004.0,20191204.0,20170919,20191216,EXP,,JP-JNJFOC-20161209520,JOHNSON AND JOHNSON,,46.0,YR,,F,Y,61.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Adult
139867135,13986713,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Lung opacity,,2019,Q4,5,F,20161004.0,20191204.0,20170919,20191216,EXP,,JP-JNJFOC-20161209520,JOHNSON AND JOHNSON,,46.0,YR,,F,Y,61.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Adult
139867135,13986713,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Nausea,,2019,Q4,5,F,20161004.0,20191204.0,20170919,20191216,EXP,,JP-JNJFOC-20161209520,JOHNSON AND JOHNSON,,46.0,YR,,F,Y,61.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Adult
139867135,13986713,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Treatment noncompliance,,2019,Q4,5,F,20161004.0,20191204.0,20170919,20191216,EXP,,JP-JNJFOC-20161209520,JOHNSON AND JOHNSON,,46.0,YR,,F,Y,61.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Adult
139867135,13986713,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Urine ketone body present,,2019,Q4,5,F,20161004.0,20191204.0,20170919,20191216,EXP,,JP-JNJFOC-20161209520,JOHNSON AND JOHNSON,,46.0,YR,,F,Y,61.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Adult
140037454,14003745,2,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,DOSE: 50/1000MG; EVERY MORNING,,,,," 17GG599,17GG599",,,2.0,DF,PROLONGED-RELEASE TABLET,,2019,Q4,Fungal infection,,2019,Q4,4,F,201401.0,20191106.0,20170922,20191115,PER,,US-JNJFOC-20170823921,JOHNSON AND JOHNSON,,65.0,YR,,F,Y,64.01,KG,20191115.0,,CN,US,US,2019,Q4,Elderly
140037454,14003745,2,SS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,DOSE: 50/1000MG; EVERY MORNING,,,,," 17GG599,17GG599",,,2.0,DF,PROLONGED-RELEASE TABLET,,2019,Q4,Urinary tract infection,,2019,Q4,4,F,201401.0,20191106.0,20170922,20191115,PER,,US-JNJFOC-20170823921,JOHNSON AND JOHNSON,,65.0,YR,,F,Y,64.01,KG,20191115.0,,CN,US,US,2019,Q4,Elderly
140369184,14036918,11,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,TABLET,,2019,Q4,Arthralgia,,2019,Q4,4,F,201605.0,20180514.0,20171004,20191211,EXP,,US-UCBSA-2016020304,UCB,,65.0,YR,,F,Y,,,20191211.0,,PH,US,US,2019,Q4,Elderly
140369184,14036918,11,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,TABLET,,2019,Q4,Arthritis,,2019,Q4,4,F,201605.0,20180514.0,20171004,20191211,EXP,,US-UCBSA-2016020304,UCB,,65.0,YR,,F,Y,,,20191211.0,,PH,US,US,2019,Q4,Elderly
140369184,14036918,11,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,TABLET,,2019,Q4,Bronchitis,,2019,Q4,4,F,201605.0,20180514.0,20171004,20191211,EXP,,US-UCBSA-2016020304,UCB,,65.0,YR,,F,Y,,,20191211.0,,PH,US,US,2019,Q4,Elderly
140369184,14036918,11,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,TABLET,,2019,Q4,Pneumonia,,2019,Q4,4,F,201605.0,20180514.0,20171004,20191211,EXP,,US-UCBSA-2016020304,UCB,,65.0,YR,,F,Y,,,20191211.0,,PH,US,US,2019,Q4,Elderly
140369184,14036918,11,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,TABLET,,2019,Q4,Rheumatoid arthritis,,2019,Q4,4,F,201605.0,20180514.0,20171004,20191211,EXP,,US-UCBSA-2016020304,UCB,,65.0,YR,,F,Y,,,20191211.0,,PH,US,US,2019,Q4,Elderly
140369184,14036918,11,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,TABLET,,2019,Q4,Sinusitis,,2019,Q4,4,F,201605.0,20180514.0,20171004,20191211,EXP,,US-UCBSA-2016020304,UCB,,65.0,YR,,F,Y,,,20191211.0,,PH,US,US,2019,Q4,Elderly
142182873,14218287,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Cerebral infarction,,2019,Q4,3,F,20170514.0,20191024.0,20171123,20191104,EXP,,JP-JNJFOC-20171125937,JOHNSON AND JOHNSON,,69.0,YR,,M,Y,82.0,KG,20191104.0,,MD,JP,JP,2019,Q4,Elderly
142182873,14218287,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Intracranial aneurysm,,2019,Q4,3,F,20170514.0,20191024.0,20171123,20191104,EXP,,JP-JNJFOC-20171125937,JOHNSON AND JOHNSON,,69.0,YR,,M,Y,82.0,KG,20191104.0,,MD,JP,JP,2019,Q4,Elderly
1472993710,14729937,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Acute kidney injury,,2019,Q4,10,F,201512.0,20191127.0,20180406,20191205,EXP,,US-PFIZER INC-2018137097,PFIZER,,50.0,YR,,M,Y,,,20191205.0,,CN,US,US,2019,Q4,Adult
1472993710,14729937,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Chronic kidney disease,,2019,Q4,10,F,201512.0,20191127.0,20180406,20191205,EXP,,US-PFIZER INC-2018137097,PFIZER,,50.0,YR,,M,Y,,,20191205.0,,CN,US,US,2019,Q4,Adult
1472993710,14729937,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Gastrooesophageal reflux disease,,2019,Q4,10,F,201512.0,20191127.0,20180406,20191205,EXP,,US-PFIZER INC-2018137097,PFIZER,,50.0,YR,,M,Y,,,20191205.0,,CN,US,US,2019,Q4,Adult
1472993710,14729937,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Renal failure,,2019,Q4,10,F,201512.0,20191127.0,20180406,20191205,EXP,,US-PFIZER INC-2018137097,PFIZER,,50.0,YR,,M,Y,,,20191205.0,,CN,US,US,2019,Q4,Adult
1472993710,14729937,21,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Renal injury,,2019,Q4,10,F,201512.0,20191127.0,20180406,20191205,EXP,,US-PFIZER INC-2018137097,PFIZER,,50.0,YR,,M,Y,,,20191205.0,,CN,US,US,2019,Q4,Adult
147413523,14741352,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,,100.0,MG,TABLET,,2019,Q4,Caesarean section,,2019,Q4,3,F,20180404.0,20191127.0,20180410,20191211,EXP,,KZ-JNJFOC-20171001412,JOHNSON AND JOHNSON,,27.0,YR,,F,Y,40.0,KG,20191211.0,,OT,KZ,KZ,2019,Q4,Young Adult
147413523,14741352,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,,100.0,MG,TABLET,,2019,Q4,Exposure during pregnancy,,2019,Q4,3,F,20180404.0,20191127.0,20180410,20191211,EXP,,KZ-JNJFOC-20171001412,JOHNSON AND JOHNSON,,27.0,YR,,F,Y,40.0,KG,20191211.0,,OT,KZ,KZ,2019,Q4,Young Adult
147902577,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Acne,,2019,Q4,7,F,2011.0,20181126.0,20180423,20191209,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20191209.0,,CN,US,US,2019,Q4,Adult
147902577,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Diarrhoea,,2019,Q4,7,F,2011.0,20181126.0,20180423,20191209,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20191209.0,,CN,US,US,2019,Q4,Adult
147902577,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Fall,,2019,Q4,7,F,2011.0,20181126.0,20180423,20191209,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20191209.0,,CN,US,US,2019,Q4,Adult
147902577,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Fatigue,,2019,Q4,7,F,2011.0,20181126.0,20180423,20191209,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20191209.0,,CN,US,US,2019,Q4,Adult
147902577,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Gingivitis,,2019,Q4,7,F,2011.0,20181126.0,20180423,20191209,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20191209.0,,CN,US,US,2019,Q4,Adult
147902577,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Limb injury,,2019,Q4,7,F,2011.0,20181126.0,20180423,20191209,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20191209.0,,CN,US,US,2019,Q4,Adult
147902577,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Nephrolithiasis,,2019,Q4,7,F,2011.0,20181126.0,20180423,20191209,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20191209.0,,CN,US,US,2019,Q4,Adult
147902577,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Off label use,,2019,Q4,7,F,2011.0,20181126.0,20180423,20191209,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20191209.0,,CN,US,US,2019,Q4,Adult
147902577,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Root canal infection,,2019,Q4,7,F,2011.0,20181126.0,20180423,20191209,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20191209.0,,CN,US,US,2019,Q4,Adult
147902577,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Sepsis,,2019,Q4,7,F,2011.0,20181126.0,20180423,20191209,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20191209.0,,CN,US,US,2019,Q4,Adult
147902577,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Tooth abscess,,2019,Q4,7,F,2011.0,20181126.0,20180423,20191209,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20191209.0,,CN,US,US,2019,Q4,Adult
147902577,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2019,Q4,Tooth infection,,2019,Q4,7,F,2011.0,20181126.0,20180423,20191209,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20191209.0,,CN,US,US,2019,Q4,Adult
149013413,14901341,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Generalised oedema,,2019,Q4,3,F,201701.0,20191218.0,20180516,20191230,EXP,,JP-JNJFOC-20180519333,JOHNSON AND JOHNSON,,43.0,YR,,F,Y,87.0,KG,20191230.0,,MD,JP,JP,2019,Q4,Adult
149013413,14901341,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Ventricular extrasystoles,,2019,Q4,3,F,201701.0,20191218.0,20180516,20191230,EXP,,JP-JNJFOC-20180519333,JOHNSON AND JOHNSON,,43.0,YR,,F,Y,87.0,KG,20191230.0,,MD,JP,JP,2019,Q4,Adult
149233602,14923360,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Dizziness,,2019,Q4,2,F,20170419.0,20191226.0,20180522,20191231,EXP,,JP-JNJFOC-20180526186,JOHNSON AND JOHNSON,,83.0,YR,,F,Y,52.0,KG,20191231.0,,MD,JP,JP,2019,Q4,Elderly
149233602,14923360,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Gait disturbance,,2019,Q4,2,F,20170419.0,20191226.0,20180522,20191231,EXP,,JP-JNJFOC-20180526186,JOHNSON AND JOHNSON,,83.0,YR,,F,Y,52.0,KG,20191231.0,,MD,JP,JP,2019,Q4,Elderly
149233602,14923360,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Herpes zoster,,2019,Q4,2,F,20170419.0,20191226.0,20180522,20191231,EXP,,JP-JNJFOC-20180526186,JOHNSON AND JOHNSON,,83.0,YR,,F,Y,52.0,KG,20191231.0,,MD,JP,JP,2019,Q4,Elderly
149958513,14995851,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Hepatic function abnormal,,2019,Q4,3,F,20170116.0,20190927.0,20180611,20191010,EXP,,JP-JNJFOC-20170924905,JOHNSON AND JOHNSON,,75.0,YR,,M,Y,62.0,KG,20191010.0,,OT,JP,JP,2019,Q4,Elderly
149958513,14995851,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Myocardial infarction,,2019,Q4,3,F,20170116.0,20190927.0,20180611,20191010,EXP,,JP-JNJFOC-20170924905,JOHNSON AND JOHNSON,,75.0,YR,,M,Y,62.0,KG,20191010.0,,OT,JP,JP,2019,Q4,Elderly
149958513,14995851,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Silent myocardial infarction,,2019,Q4,3,F,20170116.0,20190927.0,20180611,20191010,EXP,,JP-JNJFOC-20170924905,JOHNSON AND JOHNSON,,75.0,YR,,M,Y,62.0,KG,20191010.0,,OT,JP,JP,2019,Q4,Elderly
149958513,14995851,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Hepatic function abnormal,,2019,Q4,3,F,20170116.0,20190927.0,20180611,20191010,EXP,,JP-JNJFOC-20170924905,JOHNSON AND JOHNSON,,75.0,YR,,M,Y,62.0,KG,20191010.0,,OT,JP,JP,2019,Q4,Elderly
149958513,14995851,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Myocardial infarction,,2019,Q4,3,F,20170116.0,20190927.0,20180611,20191010,EXP,,JP-JNJFOC-20170924905,JOHNSON AND JOHNSON,,75.0,YR,,M,Y,62.0,KG,20191010.0,,OT,JP,JP,2019,Q4,Elderly
149958513,14995851,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Silent myocardial infarction,,2019,Q4,3,F,20170116.0,20190927.0,20180611,20191010,EXP,,JP-JNJFOC-20170924905,JOHNSON AND JOHNSON,,75.0,YR,,M,Y,62.0,KG,20191010.0,,OT,JP,JP,2019,Q4,Elderly
150295344,15029534,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Dehydration,,2019,Q4,4,F,20170908.0,20191126.0,20180619,20191210,EXP,,JP-JNJFOC-20180621915,JOHNSON AND JOHNSON,,63.0,YR,,M,Y,85.0,KG,20191210.0,,MD,JP,JP,2019,Q4,Adult
150295344,15029534,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Myocardial infarction,,2019,Q4,4,F,20170908.0,20191126.0,20180619,20191210,EXP,,JP-JNJFOC-20180621915,JOHNSON AND JOHNSON,,63.0,YR,,M,Y,85.0,KG,20191210.0,,MD,JP,JP,2019,Q4,Adult
151482867,15148286,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Liver disorder,,2019,Q4,7,F,20180618.0,20190917.0,20180716,20191018,EXP,,JP-JNJFOC-20180717171,JOHNSON AND JOHNSON,,50.0,YR,,M,Y,52.0,KG,20191018.0,,MD,JP,JP,2019,Q4,Adult
151482867,15148286,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Tubulointerstitial nephritis,,2019,Q4,7,F,20180618.0,20190917.0,20180716,20191018,EXP,,JP-JNJFOC-20180717171,JOHNSON AND JOHNSON,,50.0,YR,,M,Y,52.0,KG,20191018.0,,MD,JP,JP,2019,Q4,Adult
153955273,15395527,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Atrial fibrillation,,2019,Q4,3,F,20170908.0,20190918.0,20180918,20191001,EXP,,JP-JNJFOC-20180909834,JOHNSON AND JOHNSON,,5.0,DEC,,M,Y,,,20191001.0,,MD,JP,JP,2019,Q4,Child
154248253,15424825,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Cardiac failure,,2019,Q4,3,F,20160824.0,20190924.0,20180925,20191007,EXP,,JP-JNJFOC-20180834309,JOHNSON AND JOHNSON,,6.0,DEC,,M,Y,72.0,KG,20191007.0,,MD,JP,JP,2019,Q4,Child
154248253,15424825,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Haematuria,,2019,Q4,3,F,20160824.0,20190924.0,20180925,20191007,EXP,,JP-JNJFOC-20180834309,JOHNSON AND JOHNSON,,6.0,DEC,,M,Y,72.0,KG,20191007.0,,MD,JP,JP,2019,Q4,Child
154248253,15424825,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Myocardial ischaemia,,2019,Q4,3,F,20160824.0,20190924.0,20180925,20191007,EXP,,JP-JNJFOC-20180834309,JOHNSON AND JOHNSON,,6.0,DEC,,M,Y,72.0,KG,20191007.0,,MD,JP,JP,2019,Q4,Child
154248253,15424825,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Nephrolithiasis,,2019,Q4,3,F,20160824.0,20190924.0,20180925,20191007,EXP,,JP-JNJFOC-20180834309,JOHNSON AND JOHNSON,,6.0,DEC,,M,Y,72.0,KG,20191007.0,,MD,JP,JP,2019,Q4,Child
154248253,15424825,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Urinary tract infection,,2019,Q4,3,F,20160824.0,20190924.0,20180925,20191007,EXP,,JP-JNJFOC-20180834309,JOHNSON AND JOHNSON,,6.0,DEC,,M,Y,72.0,KG,20191007.0,,MD,JP,JP,2019,Q4,Child
154524153,15452415,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Liver disorder,,2019,Q4,3,F,20170410.0,20190927.0,20181001,20191010,EXP,,JP-JNJFOC-20170709912,JOHNSON AND JOHNSON,,73.0,YR,,M,Y,83.0,KG,20191010.0,,MD,JP,JP,2019,Q4,Elderly
154524153,15452415,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Renal disorder,,2019,Q4,3,F,20170410.0,20190927.0,20181001,20191010,EXP,,JP-JNJFOC-20170709912,JOHNSON AND JOHNSON,,73.0,YR,,M,Y,83.0,KG,20191010.0,,MD,JP,JP,2019,Q4,Elderly
154524153,15452415,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Squamous cell carcinoma of lung,,2019,Q4,3,F,20170410.0,20190927.0,20181001,20191010,EXP,,JP-JNJFOC-20170709912,JOHNSON AND JOHNSON,,73.0,YR,,M,Y,83.0,KG,20191010.0,,MD,JP,JP,2019,Q4,Elderly
154524204,15452420,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Arrhythmia,,2019,Q4,4,F,20180802.0,20191204.0,20181001,20191216,EXP,,JP-JNJFOC-20181000402,JOHNSON AND JOHNSON,,55.0,YR,,M,Y,76.1,KG,20191216.0,,MD,JP,JP,2019,Q4,Adult
154556742,15455674,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Dementia Alzheimer's type,,2019,Q4,2,F,20180226.0,20191001.0,20181002,20191010,EXP,,JP-JNJFOC-20181000645,JOHNSON AND JOHNSON,,83.0,YR,,F,Y,42.0,KG,20191010.0,,MD,JP,JP,2019,Q4,Elderly
154556753,15455675,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Helicobacter infection,,2019,Q4,3,F,20171101.0,20191021.0,20181002,20191101,EXP,,JP-JNJFOC-20181000557,JOHNSON AND JOHNSON,,66.0,YR,,M,Y,77.0,KG,20191101.0,,MD,JP,JP,2019,Q4,Elderly
154556753,15455675,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Neuropathy peripheral,,2019,Q4,3,F,20171101.0,20191021.0,20181002,20191101,EXP,,JP-JNJFOC-20181000557,JOHNSON AND JOHNSON,,66.0,YR,,M,Y,77.0,KG,20191101.0,,MD,JP,JP,2019,Q4,Elderly
154556753,15455675,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Oesophageal carcinoma,,2019,Q4,3,F,20171101.0,20191021.0,20181002,20191101,EXP,,JP-JNJFOC-20181000557,JOHNSON AND JOHNSON,,66.0,YR,,M,Y,77.0,KG,20191101.0,,MD,JP,JP,2019,Q4,Elderly
154556753,15455675,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Helicobacter infection,,2019,Q4,3,F,20171101.0,20191021.0,20181002,20191101,EXP,,JP-JNJFOC-20181000557,JOHNSON AND JOHNSON,,66.0,YR,,M,Y,77.0,KG,20191101.0,,MD,JP,JP,2019,Q4,Elderly
154556753,15455675,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Neuropathy peripheral,,2019,Q4,3,F,20171101.0,20191021.0,20181002,20191101,EXP,,JP-JNJFOC-20181000557,JOHNSON AND JOHNSON,,66.0,YR,,M,Y,77.0,KG,20191101.0,,MD,JP,JP,2019,Q4,Elderly
154556753,15455675,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Oesophageal carcinoma,,2019,Q4,3,F,20171101.0,20191021.0,20181002,20191101,EXP,,JP-JNJFOC-20181000557,JOHNSON AND JOHNSON,,66.0,YR,,M,Y,77.0,KG,20191101.0,,MD,JP,JP,2019,Q4,Elderly
154594962,15459496,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Angiocardiogram,,2019,Q4,2,F,20180820.0,20191009.0,20181003,20191018,EXP,,JP-JNJFOC-20181000202,JOHNSON AND JOHNSON,,7.0,DEC,,M,Y,,,20191018.0,,OT,JP,JP,2019,Q4,Child
154687443,15468744,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Duodenal ulcer perforation,,2019,Q4,3,F,20170813.0,20191202.0,20181005,20191211,EXP,,JP-JNJFOC-20181007517,JOHNSON AND JOHNSON,,66.0,YR,,M,Y,69.0,KG,20191211.0,,MD,JP,JP,2019,Q4,Elderly
154687443,15468744,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Gastroenteritis,,2019,Q4,3,F,20170813.0,20191202.0,20181005,20191211,EXP,,JP-JNJFOC-20181007517,JOHNSON AND JOHNSON,,66.0,YR,,M,Y,69.0,KG,20191211.0,,MD,JP,JP,2019,Q4,Elderly
154687443,15468744,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Duodenal ulcer perforation,,2019,Q4,3,F,20170813.0,20191202.0,20181005,20191211,EXP,,JP-JNJFOC-20181007517,JOHNSON AND JOHNSON,,66.0,YR,,M,Y,69.0,KG,20191211.0,,MD,JP,JP,2019,Q4,Elderly
154687443,15468744,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Gastroenteritis,,2019,Q4,3,F,20170813.0,20191202.0,20181005,20191211,EXP,,JP-JNJFOC-20181007517,JOHNSON AND JOHNSON,,66.0,YR,,M,Y,69.0,KG,20191211.0,,MD,JP,JP,2019,Q4,Elderly
154745883,15474588,14,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2019,Q4,Depression,,2019,Q4,3,F,2017.0,20190528.0,20181008,20191203,EXP,,US-UCBSA-2018001276,UCB,,46.0,YR,,M,Y,106.0,KG,20191203.0,,CN,US,US,2019,Q4,Adult
154745883,15474588,14,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2019,Q4,Dry skin,,2019,Q4,3,F,2017.0,20190528.0,20181008,20191203,EXP,,US-UCBSA-2018001276,UCB,,46.0,YR,,M,Y,106.0,KG,20191203.0,,CN,US,US,2019,Q4,Adult
154745883,15474588,14,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2019,Q4,Knee arthroplasty,,2019,Q4,3,F,2017.0,20190528.0,20181008,20191203,EXP,,US-UCBSA-2018001276,UCB,,46.0,YR,,M,Y,106.0,KG,20191203.0,,CN,US,US,2019,Q4,Adult
154745883,15474588,14,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2019,Q4,Musculoskeletal stiffness,,2019,Q4,3,F,2017.0,20190528.0,20181008,20191203,EXP,,US-UCBSA-2018001276,UCB,,46.0,YR,,M,Y,106.0,KG,20191203.0,,CN,US,US,2019,Q4,Adult
154745883,15474588,14,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2019,Q4,Product dose omission,,2019,Q4,3,F,2017.0,20190528.0,20181008,20191203,EXP,,US-UCBSA-2018001276,UCB,,46.0,YR,,M,Y,106.0,KG,20191203.0,,CN,US,US,2019,Q4,Adult
154745883,15474588,14,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2019,Q4,Pruritus,,2019,Q4,3,F,2017.0,20190528.0,20181008,20191203,EXP,,US-UCBSA-2018001276,UCB,,46.0,YR,,M,Y,106.0,KG,20191203.0,,CN,US,US,2019,Q4,Adult
154745883,15474588,14,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2019,Q4,Psoriatic arthropathy,,2019,Q4,3,F,2017.0,20190528.0,20181008,20191203,EXP,,US-UCBSA-2018001276,UCB,,46.0,YR,,M,Y,106.0,KG,20191203.0,,CN,US,US,2019,Q4,Adult
154745883,15474588,14,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2019,Q4,Stress,,2019,Q4,3,F,2017.0,20190528.0,20181008,20191203,EXP,,US-UCBSA-2018001276,UCB,,46.0,YR,,M,Y,106.0,KG,20191203.0,,CN,US,US,2019,Q4,Adult
156383965,15638396,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Herpes zoster,,2019,Q4,5,F,20170106.0,20191112.0,20181120,20191122,EXP,,JP-JNJFOC-20180723861,JOHNSON AND JOHNSON,,65.0,YR,,F,Y,54.0,KG,20191122.0,,MD,JP,JP,2019,Q4,Elderly
156383965,15638396,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Hyperbilirubinaemia,,2019,Q4,5,F,20170106.0,20191112.0,20181120,20191122,EXP,,JP-JNJFOC-20180723861,JOHNSON AND JOHNSON,,65.0,YR,,F,Y,54.0,KG,20191122.0,,MD,JP,JP,2019,Q4,Elderly
156383965,15638396,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Hypertension,,2019,Q4,5,F,20170106.0,20191112.0,20181120,20191122,EXP,,JP-JNJFOC-20180723861,JOHNSON AND JOHNSON,,65.0,YR,,F,Y,54.0,KG,20191122.0,,MD,JP,JP,2019,Q4,Elderly
156429052,15642905,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Tachycardia,,2019,Q4,2,F,20170926.0,20191129.0,20181121,20191212,EXP,,JP-JNJFOC-20181126492,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,62.0,KG,20191212.0,,MD,JP,JP,2019,Q4,Adult
156429052,15642905,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Urine ketone body,,2019,Q4,2,F,20170926.0,20191129.0,20181121,20191212,EXP,,JP-JNJFOC-20181126492,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,62.0,KG,20191212.0,,MD,JP,JP,2019,Q4,Adult
156429052,15642905,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Urine ketone body present,,2019,Q4,2,F,20170926.0,20191129.0,20181121,20191212,EXP,,JP-JNJFOC-20181126492,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,62.0,KG,20191212.0,,MD,JP,JP,2019,Q4,Adult
156995486,15699548,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Albumin urine present,,2019,Q4,6,F,2016.0,20191204.0,20181207,20191216,EXP,,JP-JNJFOC-20181202259,JOHNSON AND JOHNSON,,41.0,YR,,M,Y,108.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Adult
156995486,15699548,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Blood creatinine increased,,2019,Q4,6,F,2016.0,20191204.0,20181207,20191216,EXP,,JP-JNJFOC-20181202259,JOHNSON AND JOHNSON,,41.0,YR,,M,Y,108.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Adult
156995486,15699548,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Road traffic accident,,2019,Q4,6,F,2016.0,20191204.0,20181207,20191216,EXP,,JP-JNJFOC-20181202259,JOHNSON AND JOHNSON,,41.0,YR,,M,Y,108.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Adult
156995486,15699548,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Upper limb fracture,,2019,Q4,6,F,2016.0,20191204.0,20181207,20191216,EXP,,JP-JNJFOC-20181202259,JOHNSON AND JOHNSON,,41.0,YR,,M,Y,108.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Adult
156995486,15699548,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Upper respiratory tract infection,,2019,Q4,6,F,2016.0,20191204.0,20181207,20191216,EXP,,JP-JNJFOC-20181202259,JOHNSON AND JOHNSON,,41.0,YR,,M,Y,108.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Adult
157704833,15770483,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Dyslipidaemia,,2019,Q4,3,F,20180724.0,20191120.0,20181228,20191203,EXP,,JP-JNJFOC-20181233452,JOHNSON AND JOHNSON,,70.0,YR,,M,Y,61.0,KG,20191203.0,,MD,JP,JP,2019,Q4,Elderly
157704833,15770483,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Hypertension,,2019,Q4,3,F,20180724.0,20191120.0,20181228,20191203,EXP,,JP-JNJFOC-20181233452,JOHNSON AND JOHNSON,,70.0,YR,,M,Y,61.0,KG,20191203.0,,MD,JP,JP,2019,Q4,Elderly
157704833,15770483,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Myocardial ischaemia,,2019,Q4,3,F,20180724.0,20191120.0,20181228,20191203,EXP,,JP-JNJFOC-20181233452,JOHNSON AND JOHNSON,,70.0,YR,,M,Y,61.0,KG,20191203.0,,MD,JP,JP,2019,Q4,Elderly
157942914,15794291,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Hepatic function abnormal,,2019,Q4,4,F,20171013.0,20190927.0,20190107,20191008,EXP,,JP-JNJFOC-20190106425,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,79.0,KG,20191008.0,,MD,JP,JP,2019,Q4,Elderly
157942914,15794291,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Lung neoplasm malignant,,2019,Q4,4,F,20171013.0,20190927.0,20190107,20191008,EXP,,JP-JNJFOC-20190106425,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,79.0,KG,20191008.0,,MD,JP,JP,2019,Q4,Elderly
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Adverse drug reaction,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Arthralgia,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Arthritis,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Blood creatinine decreased,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Blood uric acid decreased,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Drug ineffective,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Gastrointestinal haemorrhage,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Glycosylated haemoglobin increased,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Haemoglobin decreased,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Hepatic cirrhosis,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Hepatosplenomegaly,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Hypertrophy,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Inflammatory marker increased,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Joint effusion,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Joint swelling,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Liver disorder,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Low density lipoprotein increased,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Nausea,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Nonalcoholic fatty liver disease,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Pain in extremity,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Psoriasis,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Red blood cell sedimentation rate increased,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Therapeutic product effect decreased,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Therapeutic product effect incomplete,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158468132,15846813,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,,,2019,Q4,Varices oesophageal,,2019,Q4,2,F,,20191120.0,20190121,20191128,EXP,,CA-TEVA-2019-CA-1001266,TEVA,,47.0,YR,,F,Y,,,20191128.0,,MD,CA,CA,2019,Q4,Adult
158671354,15867135,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Cerebral infarction,,2019,Q4,4,F,20190115.0,20191212.0,20190125,20191223,EXP,,JP-JNJFOC-20190132099,JOHNSON AND JOHNSON,,50.0,YR,,M,Y,,,20191223.0,,MD,JP,JP,2019,Q4,Adult
159919432,15991943,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204042.0,300.0,MG,TABLET,,2019,Q4,Blood glucose increased,,2019,Q4,2,F,201902.0,20191021.0,20190221,20191101,EXP,DK-DKMA-WBS-0021481,DK-JNJFOC-20190229427,JOHNSON AND JOHNSON,,64.0,YR,,M,Y,77.0,KG,20191101.0,,MD,DK,DK,2019,Q4,Adult
159919432,15991943,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204042.0,300.0,MG,TABLET,,2019,Q4,Decreased appetite,,2019,Q4,2,F,201902.0,20191021.0,20190221,20191101,EXP,DK-DKMA-WBS-0021481,DK-JNJFOC-20190229427,JOHNSON AND JOHNSON,,64.0,YR,,M,Y,77.0,KG,20191101.0,,MD,DK,DK,2019,Q4,Adult
159919432,15991943,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204042.0,300.0,MG,TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,2,F,201902.0,20191021.0,20190221,20191101,EXP,DK-DKMA-WBS-0021481,DK-JNJFOC-20190229427,JOHNSON AND JOHNSON,,64.0,YR,,M,Y,77.0,KG,20191101.0,,MD,DK,DK,2019,Q4,Adult
159919432,15991943,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204042.0,300.0,MG,TABLET,,2019,Q4,Discomfort,,2019,Q4,2,F,201902.0,20191021.0,20190221,20191101,EXP,DK-DKMA-WBS-0021481,DK-JNJFOC-20190229427,JOHNSON AND JOHNSON,,64.0,YR,,M,Y,77.0,KG,20191101.0,,MD,DK,DK,2019,Q4,Adult
159919432,15991943,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204042.0,300.0,MG,TABLET,,2019,Q4,Dyspnoea,,2019,Q4,2,F,201902.0,20191021.0,20190221,20191101,EXP,DK-DKMA-WBS-0021481,DK-JNJFOC-20190229427,JOHNSON AND JOHNSON,,64.0,YR,,M,Y,77.0,KG,20191101.0,,MD,DK,DK,2019,Q4,Adult
159919432,15991943,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204042.0,300.0,MG,TABLET,,2019,Q4,Fatigue,,2019,Q4,2,F,201902.0,20191021.0,20190221,20191101,EXP,DK-DKMA-WBS-0021481,DK-JNJFOC-20190229427,JOHNSON AND JOHNSON,,64.0,YR,,M,Y,77.0,KG,20191101.0,,MD,DK,DK,2019,Q4,Adult
159919432,15991943,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204042.0,300.0,MG,TABLET,,2019,Q4,Fluid intake reduced,,2019,Q4,2,F,201902.0,20191021.0,20190221,20191101,EXP,DK-DKMA-WBS-0021481,DK-JNJFOC-20190229427,JOHNSON AND JOHNSON,,64.0,YR,,M,Y,77.0,KG,20191101.0,,MD,DK,DK,2019,Q4,Adult
159919432,15991943,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204042.0,300.0,MG,TABLET,,2019,Q4,Gait disturbance,,2019,Q4,2,F,201902.0,20191021.0,20190221,20191101,EXP,DK-DKMA-WBS-0021481,DK-JNJFOC-20190229427,JOHNSON AND JOHNSON,,64.0,YR,,M,Y,77.0,KG,20191101.0,,MD,DK,DK,2019,Q4,Adult
159919432,15991943,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204042.0,300.0,MG,TABLET,,2019,Q4,Visual impairment,,2019,Q4,2,F,201902.0,20191021.0,20190221,20191101,EXP,DK-DKMA-WBS-0021481,DK-JNJFOC-20190229427,JOHNSON AND JOHNSON,,64.0,YR,,M,Y,77.0,KG,20191101.0,,MD,DK,DK,2019,Q4,Adult
160430153,16043015,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Diarrhoea,,2019,Q4,3,F,201708.0,20191203.0,20190306,20191213,EXP,,JP-JNJFOC-20180316192,JOHNSON AND JOHNSON,,5.0,DEC,,F,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Child
160430153,16043015,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Intervertebral disc protrusion,,2019,Q4,3,F,201708.0,20191203.0,20190306,20191213,EXP,,JP-JNJFOC-20180316192,JOHNSON AND JOHNSON,,5.0,DEC,,F,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Child
160430153,16043015,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Low density lipoprotein increased,,2019,Q4,3,F,201708.0,20191203.0,20190306,20191213,EXP,,JP-JNJFOC-20180316192,JOHNSON AND JOHNSON,,5.0,DEC,,F,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Child
160430153,16043015,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Neurogenic bladder,,2019,Q4,3,F,201708.0,20191203.0,20190306,20191213,EXP,,JP-JNJFOC-20180316192,JOHNSON AND JOHNSON,,5.0,DEC,,F,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Child
160430153,16043015,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Pain in extremity,,2019,Q4,3,F,201708.0,20191203.0,20190306,20191213,EXP,,JP-JNJFOC-20180316192,JOHNSON AND JOHNSON,,5.0,DEC,,F,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Child
160430153,16043015,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Urinary incontinence,,2019,Q4,3,F,201708.0,20191203.0,20190306,20191213,EXP,,JP-JNJFOC-20180316192,JOHNSON AND JOHNSON,,5.0,DEC,,F,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Child
160775234,16077523,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Hepatic function abnormal,,2019,Q4,4,F,20180207.0,20191217.0,20190315,20191226,EXP,,JP-JNJFOC-20190316053,JOHNSON AND JOHNSON,,56.0,YR,,F,Y,,,20191226.0,,MD,JP,JP,2019,Q4,Adult
160775234,16077523,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Metastases to lung,,2019,Q4,4,F,20180207.0,20191217.0,20190315,20191226,EXP,,JP-JNJFOC-20190316053,JOHNSON AND JOHNSON,,56.0,YR,,F,Y,,,20191226.0,,MD,JP,JP,2019,Q4,Adult
160892283,16089228,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Anaemia,,2019,Q4,3,F,201606.0,20190924.0,20190319,20191004,EXP,,JP-JNJFOC-20170526593,JOHNSON AND JOHNSON,,65.0,YR,,M,Y,64.0,KG,20191004.0,,MD,JP,JP,2019,Q4,Elderly
160892283,16089228,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Constipation,,2019,Q4,3,F,201606.0,20190924.0,20190319,20191004,EXP,,JP-JNJFOC-20170526593,JOHNSON AND JOHNSON,,65.0,YR,,M,Y,64.0,KG,20191004.0,,MD,JP,JP,2019,Q4,Elderly
160892283,16089228,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Electrolyte imbalance,,2019,Q4,3,F,201606.0,20190924.0,20190319,20191004,EXP,,JP-JNJFOC-20170526593,JOHNSON AND JOHNSON,,65.0,YR,,M,Y,64.0,KG,20191004.0,,MD,JP,JP,2019,Q4,Elderly
160892283,16089228,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Gastric cancer,,2019,Q4,3,F,201606.0,20190924.0,20190319,20191004,EXP,,JP-JNJFOC-20170526593,JOHNSON AND JOHNSON,,65.0,YR,,M,Y,64.0,KG,20191004.0,,MD,JP,JP,2019,Q4,Elderly
160892283,16089228,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Herpes zoster,,2019,Q4,3,F,201606.0,20190924.0,20190319,20191004,EXP,,JP-JNJFOC-20170526593,JOHNSON AND JOHNSON,,65.0,YR,,M,Y,64.0,KG,20191004.0,,MD,JP,JP,2019,Q4,Elderly
160892283,16089228,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Iron deficiency anaemia,,2019,Q4,3,F,201606.0,20190924.0,20190319,20191004,EXP,,JP-JNJFOC-20170526593,JOHNSON AND JOHNSON,,65.0,YR,,M,Y,64.0,KG,20191004.0,,MD,JP,JP,2019,Q4,Elderly
160892283,16089228,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Rhinitis allergic,,2019,Q4,3,F,201606.0,20190924.0,20190319,20191004,EXP,,JP-JNJFOC-20170526593,JOHNSON AND JOHNSON,,65.0,YR,,M,Y,64.0,KG,20191004.0,,MD,JP,JP,2019,Q4,Elderly
161913333,16191333,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Cystitis,,2019,Q4,3,F,20160122.0,20191003.0,20190412,20191015,EXP,,JP-JNJFOC-20170703763,JOHNSON AND JOHNSON,,74.0,YR,,F,Y,76.0,KG,20191015.0,,MD,JP,JP,2019,Q4,Elderly
161913333,16191333,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Dementia Alzheimer's type,,2019,Q4,3,F,20160122.0,20191003.0,20190412,20191015,EXP,,JP-JNJFOC-20170703763,JOHNSON AND JOHNSON,,74.0,YR,,F,Y,76.0,KG,20191015.0,,MD,JP,JP,2019,Q4,Elderly
162125683,16212568,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Cerebral infarction,,2019,Q4,3,F,201811.0,20191204.0,20190418,20191213,EXP,,JP-JNJFOC-20190427489,JOHNSON AND JOHNSON,,71.0,YR,,M,Y,,,20191213.0,,PH,JP,JP,2019,Q4,Elderly
162277367,16227736,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, DAILY",,,,,,,,300.0,MG,TABLET,,2019,Q4,Intentional product misuse,,2019,Q4,7,F,201902.0,20191210.0,20190423,20191213,EXP,,US-PFIZER INC-2016573618,PFIZER,,50.0,YR,,M,Y,95.0,KG,20191213.0,,OT,US,US,2019,Q4,Adult
162277367,16227736,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, DAILY",,,,,,,,300.0,MG,TABLET,,2019,Q4,Ligament sprain,,2019,Q4,7,F,201902.0,20191210.0,20190423,20191213,EXP,,US-PFIZER INC-2016573618,PFIZER,,50.0,YR,,M,Y,95.0,KG,20191213.0,,OT,US,US,2019,Q4,Adult
162277367,16227736,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, DAILY",,,,,,,,300.0,MG,TABLET,,2019,Q4,Osteonecrosis,,2019,Q4,7,F,201902.0,20191210.0,20190423,20191213,EXP,,US-PFIZER INC-2016573618,PFIZER,,50.0,YR,,M,Y,95.0,KG,20191213.0,,OT,US,US,2019,Q4,Adult
162277367,16227736,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, DAILY",,,,,,,,300.0,MG,TABLET,,2019,Q4,Sleep disorder,,2019,Q4,7,F,201902.0,20191210.0,20190423,20191213,EXP,,US-PFIZER INC-2016573618,PFIZER,,50.0,YR,,M,Y,95.0,KG,20191213.0,,OT,US,US,2019,Q4,Adult
162569152,16256915,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Myocardial infarction,,2019,Q4,2,F,20160514.0,20191115.0,20190430,20191125,EXP,,JP-JNJFOC-20160724067,JOHNSON AND JOHNSON,,40.0,YR,,M,Y,68.0,KG,20191125.0,,MD,JP,JP,2019,Q4,Adult
162569152,16256915,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Pollakiuria,,2019,Q4,2,F,20160514.0,20191115.0,20190430,20191125,EXP,,JP-JNJFOC-20160724067,JOHNSON AND JOHNSON,,40.0,YR,,M,Y,68.0,KG,20191125.0,,MD,JP,JP,2019,Q4,Adult
163263072,16326307,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Diarrhoea,,2019,Q4,2,F,20180301.0,20191120.0,20190517,20191203,EXP,,JP-JNJFOC-20190345062,JOHNSON AND JOHNSON,,59.0,YR,,M,Y,,,20191203.0,,MD,JP,JP,2019,Q4,Adult
163263072,16326307,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Gastroenteritis eosinophilic,,2019,Q4,2,F,20180301.0,20191120.0,20190517,20191203,EXP,,JP-JNJFOC-20190345062,JOHNSON AND JOHNSON,,59.0,YR,,M,Y,,,20191203.0,,MD,JP,JP,2019,Q4,Adult
163263072,16326307,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Pneumonia influenzal,,2019,Q4,2,F,20180301.0,20191120.0,20190517,20191203,EXP,,JP-JNJFOC-20190345062,JOHNSON AND JOHNSON,,59.0,YR,,M,Y,,,20191203.0,,MD,JP,JP,2019,Q4,Adult
163263072,16326307,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Diarrhoea,,2019,Q4,2,F,20180301.0,20191120.0,20190517,20191203,EXP,,JP-JNJFOC-20190345062,JOHNSON AND JOHNSON,,59.0,YR,,M,Y,,,20191203.0,,MD,JP,JP,2019,Q4,Adult
163263072,16326307,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Gastroenteritis eosinophilic,,2019,Q4,2,F,20180301.0,20191120.0,20190517,20191203,EXP,,JP-JNJFOC-20190345062,JOHNSON AND JOHNSON,,59.0,YR,,M,Y,,,20191203.0,,MD,JP,JP,2019,Q4,Adult
163263072,16326307,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Pneumonia influenzal,,2019,Q4,2,F,20180301.0,20191120.0,20190517,20191203,EXP,,JP-JNJFOC-20190345062,JOHNSON AND JOHNSON,,59.0,YR,,M,Y,,,20191203.0,,MD,JP,JP,2019,Q4,Adult
163371833,16337183,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Off label use,,2019,Q4,3,F,20180418.0,20191129.0,20190521,20191211,EXP,,JP-JNJFOC-20190523455,JOHNSON AND JOHNSON,,71.0,YR,,M,Y,74.6,KG,20191211.0,,MD,JP,JP,2019,Q4,Elderly
163371833,16337183,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Polyarteritis nodosa,,2019,Q4,3,F,20180418.0,20191129.0,20190521,20191211,EXP,,JP-JNJFOC-20190523455,JOHNSON AND JOHNSON,,71.0,YR,,M,Y,74.6,KG,20191211.0,,MD,JP,JP,2019,Q4,Elderly
163371833,16337183,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Product use in unapproved indication,,2019,Q4,3,F,20180418.0,20191129.0,20190521,20191211,EXP,,JP-JNJFOC-20190523455,JOHNSON AND JOHNSON,,71.0,YR,,M,Y,74.6,KG,20191211.0,,MD,JP,JP,2019,Q4,Elderly
163371833,16337183,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,N,,,,204042.0,,,,,2019,Q4,Off label use,,2019,Q4,3,F,20180418.0,20191129.0,20190521,20191211,EXP,,JP-JNJFOC-20190523455,JOHNSON AND JOHNSON,,71.0,YR,,M,Y,74.6,KG,20191211.0,,MD,JP,JP,2019,Q4,Elderly
163371833,16337183,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,N,,,,204042.0,,,,,2019,Q4,Polyarteritis nodosa,,2019,Q4,3,F,20180418.0,20191129.0,20190521,20191211,EXP,,JP-JNJFOC-20190523455,JOHNSON AND JOHNSON,,71.0,YR,,M,Y,74.6,KG,20191211.0,,MD,JP,JP,2019,Q4,Elderly
163371833,16337183,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,N,,,,204042.0,,,,,2019,Q4,Product use in unapproved indication,,2019,Q4,3,F,20180418.0,20191129.0,20190521,20191211,EXP,,JP-JNJFOC-20190523455,JOHNSON AND JOHNSON,,71.0,YR,,M,Y,74.6,KG,20191211.0,,MD,JP,JP,2019,Q4,Elderly
163653083,16365308,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM,,,U,,,,,100.0,MG,,,2019,Q4,Abdominal pain upper,,2019,Q4,3,F,,20191015.0,20190529,20191031,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050380,BRISTOL MYERS SQUIBB,,71.0,YR,,F,Y,55.0,KG,20191031.0,,OT,JP,JP,2019,Q4,Elderly
163653083,16365308,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM,,,U,,,,,100.0,MG,,,2019,Q4,Cholecystitis acute,,2019,Q4,3,F,,20191015.0,20190529,20191031,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050380,BRISTOL MYERS SQUIBB,,71.0,YR,,F,Y,55.0,KG,20191031.0,,OT,JP,JP,2019,Q4,Elderly
163653083,16365308,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM,,,U,,,,,100.0,MG,,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,3,F,,20191015.0,20190529,20191031,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050380,BRISTOL MYERS SQUIBB,,71.0,YR,,F,Y,55.0,KG,20191031.0,,OT,JP,JP,2019,Q4,Elderly
163653083,16365308,6,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,Y,,,,,100.0,MG,TABLET,,2019,Q4,Abdominal pain upper,,2019,Q4,3,F,,20191015.0,20190529,20191031,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050380,BRISTOL MYERS SQUIBB,,71.0,YR,,F,Y,55.0,KG,20191031.0,,OT,JP,JP,2019,Q4,Elderly
163653083,16365308,6,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,Y,,,,,100.0,MG,TABLET,,2019,Q4,Cholecystitis acute,,2019,Q4,3,F,,20191015.0,20190529,20191031,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050380,BRISTOL MYERS SQUIBB,,71.0,YR,,F,Y,55.0,KG,20191031.0,,OT,JP,JP,2019,Q4,Elderly
163653083,16365308,6,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,Y,,,,,100.0,MG,TABLET,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,3,F,,20191015.0,20190529,20191031,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-050380,BRISTOL MYERS SQUIBB,,71.0,YR,,F,Y,55.0,KG,20191031.0,,OT,JP,JP,2019,Q4,Elderly
164146002,16414600,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Chronic hepatic failure,,2019,Q4,2,F,2017.0,20191129.0,20190611,20191211,EXP,,JP-JNJFOC-20190612408,JOHNSON AND JOHNSON,,71.0,YR,,F,Y,,,20191211.0,,MD,JP,JP,2019,Q4,Elderly
164167604,16416760,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Carotid artery stenosis,,2019,Q4,4,F,20171104.0,20191008.0,20190611,20191017,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20191017.0,,MD,JP,JP,2019,Q4,Adult
164167604,16416760,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Cellulitis,,2019,Q4,4,F,20171104.0,20191008.0,20190611,20191017,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20191017.0,,MD,JP,JP,2019,Q4,Adult
164167604,16416760,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Transient ischaemic attack,,2019,Q4,4,F,20171104.0,20191008.0,20190611,20191017,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20191017.0,,MD,JP,JP,2019,Q4,Adult
164167604,16416760,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Carotid artery stenosis,,2019,Q4,4,F,20171104.0,20191008.0,20190611,20191017,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20191017.0,,MD,JP,JP,2019,Q4,Adult
164167604,16416760,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Cellulitis,,2019,Q4,4,F,20171104.0,20191008.0,20190611,20191017,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20191017.0,,MD,JP,JP,2019,Q4,Adult
164167604,16416760,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Transient ischaemic attack,,2019,Q4,4,F,20171104.0,20191008.0,20190611,20191017,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20191017.0,,MD,JP,JP,2019,Q4,Adult
164167604,16416760,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Carotid artery stenosis,,2019,Q4,4,F,20171104.0,20191008.0,20190611,20191017,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20191017.0,,MD,JP,JP,2019,Q4,Adult
164167604,16416760,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Cellulitis,,2019,Q4,4,F,20171104.0,20191008.0,20190611,20191017,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20191017.0,,MD,JP,JP,2019,Q4,Adult
164167604,16416760,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Transient ischaemic attack,,2019,Q4,4,F,20171104.0,20191008.0,20190611,20191017,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20191017.0,,MD,JP,JP,2019,Q4,Adult
164167604,16416760,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Carotid artery stenosis,,2019,Q4,4,F,20171104.0,20191008.0,20190611,20191017,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20191017.0,,MD,JP,JP,2019,Q4,Adult
164167604,16416760,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Cellulitis,,2019,Q4,4,F,20171104.0,20191008.0,20190611,20191017,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20191017.0,,MD,JP,JP,2019,Q4,Adult
164167604,16416760,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Transient ischaemic attack,,2019,Q4,4,F,20171104.0,20191008.0,20190611,20191017,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20191017.0,,MD,JP,JP,2019,Q4,Adult
164167604,16416760,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Carotid artery stenosis,,2019,Q4,4,F,20171104.0,20191008.0,20190611,20191017,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20191017.0,,MD,JP,JP,2019,Q4,Adult
164167604,16416760,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Cellulitis,,2019,Q4,4,F,20171104.0,20191008.0,20190611,20191017,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20191017.0,,MD,JP,JP,2019,Q4,Adult
164167604,16416760,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Transient ischaemic attack,,2019,Q4,4,F,20171104.0,20191008.0,20190611,20191017,EXP,,JP-JNJFOC-20190610490,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,,,20191017.0,,MD,JP,JP,2019,Q4,Adult
164811113,16481111,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Asthma,,2019,Q4,3,F,201908.0,20191007.0,20190626,20191011,EXP,,US-JAZZ-2019-US-008758,JAZZ,,48.0,YR,,F,Y,,,20191011.0,,,US,US,2019,Q4,Adult
164811113,16481111,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Cystitis,,2019,Q4,3,F,201908.0,20191007.0,20190626,20191011,EXP,,US-JAZZ-2019-US-008758,JAZZ,,48.0,YR,,F,Y,,,20191011.0,,,US,US,2019,Q4,Adult
164811113,16481111,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Electroconvulsive therapy,,2019,Q4,3,F,201908.0,20191007.0,20190626,20191011,EXP,,US-JAZZ-2019-US-008758,JAZZ,,48.0,YR,,F,Y,,,20191011.0,,,US,US,2019,Q4,Adult
164811113,16481111,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Hospitalisation,,2019,Q4,3,F,201908.0,20191007.0,20190626,20191011,EXP,,US-JAZZ-2019-US-008758,JAZZ,,48.0,YR,,F,Y,,,20191011.0,,,US,US,2019,Q4,Adult
164811113,16481111,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Memory impairment,,2019,Q4,3,F,201908.0,20191007.0,20190626,20191011,EXP,,US-JAZZ-2019-US-008758,JAZZ,,48.0,YR,,F,Y,,,20191011.0,,,US,US,2019,Q4,Adult
164811113,16481111,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,TABLET,,2019,Q4,Spinal fusion surgery,,2019,Q4,3,F,201908.0,20191007.0,20190626,20191011,EXP,,US-JAZZ-2019-US-008758,JAZZ,,48.0,YR,,F,Y,,,20191011.0,,,US,US,2019,Q4,Adult
164833102,16483310,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Peripheral arterial occlusive disease,,2019,Q4,2,F,,20191025.0,20190627,20191104,EXP,,JP-JNJFOC-20190632144,JOHNSON AND JOHNSON,,69.0,YR,,M,Y,,,20191104.0,,MD,JP,JP,2019,Q4,Elderly
164833192,16483319,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Atrial fibrillation,,2019,Q4,2,F,20171204.0,20191018.0,20190627,20191030,EXP,,JP-JNJFOC-20190629283,JOHNSON AND JOHNSON,,59.0,YR,,M,Y,,,20191030.0,,MD,JP,JP,2019,Q4,Adult
165390843,16539084,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Pemphigoid,,2019,Q4,3,F,201808.0,20190924.0,20190708,20191007,EXP,,JP-JNJFOC-20190633016,JOHNSON AND JOHNSON,,70.0,YR,,M,Y,,,20191007.0,,MD,JP,JP,2019,Q4,Elderly
165590722,16559072,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Dizziness,,2019,Q4,2,F,20170910.0,20191129.0,20190711,20191211,EXP,,JP-JNJFOC-20190708063,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,,,20191211.0,,MD,JP,JP,2019,Q4,Elderly
165590722,16559072,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Epiglottitis,,2019,Q4,2,F,20170910.0,20191129.0,20190711,20191211,EXP,,JP-JNJFOC-20190708063,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,,,20191211.0,,MD,JP,JP,2019,Q4,Elderly
165590722,16559072,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Internal haemorrhage,,2019,Q4,2,F,20170910.0,20191129.0,20190711,20191211,EXP,,JP-JNJFOC-20190708063,JOHNSON AND JOHNSON,,81.0,YR,,M,Y,,,20191211.0,,MD,JP,JP,2019,Q4,Elderly
166015603,16601560,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Diarrhoea,,2019,Q4,3,F,20190509.0,20191202.0,20190719,20191213,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Adult
166015603,16601560,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Hyperglycaemia,,2019,Q4,3,F,20190509.0,20191202.0,20190719,20191213,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Adult
166015603,16601560,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Pyrexia,,2019,Q4,3,F,20190509.0,20191202.0,20190719,20191213,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Adult
166015603,16601560,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Shock,,2019,Q4,3,F,20190509.0,20191202.0,20190719,20191213,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Adult
166015603,16601560,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Vomiting,,2019,Q4,3,F,20190509.0,20191202.0,20190719,20191213,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Adult
166015603,16601560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Diarrhoea,,2019,Q4,3,F,20190509.0,20191202.0,20190719,20191213,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Adult
166015603,16601560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Hyperglycaemia,,2019,Q4,3,F,20190509.0,20191202.0,20190719,20191213,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Adult
166015603,16601560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Pyrexia,,2019,Q4,3,F,20190509.0,20191202.0,20190719,20191213,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Adult
166015603,16601560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Shock,,2019,Q4,3,F,20190509.0,20191202.0,20190719,20191213,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Adult
166015603,16601560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Vomiting,,2019,Q4,3,F,20190509.0,20191202.0,20190719,20191213,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Adult
166015603,16601560,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Diarrhoea,,2019,Q4,3,F,20190509.0,20191202.0,20190719,20191213,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Adult
166015603,16601560,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Hyperglycaemia,,2019,Q4,3,F,20190509.0,20191202.0,20190719,20191213,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Adult
166015603,16601560,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Pyrexia,,2019,Q4,3,F,20190509.0,20191202.0,20190719,20191213,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Adult
166015603,16601560,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Shock,,2019,Q4,3,F,20190509.0,20191202.0,20190719,20191213,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Adult
166015603,16601560,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Vomiting,,2019,Q4,3,F,20190509.0,20191202.0,20190719,20191213,EXP,,JP-JNJFOC-20190724801,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Adult
166432292,16643229,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Diabetic ketoacidosis,,2019,Q4,2,F,20170623.0,20191202.0,20190729,20191213,EXP,,JP-JNJFOC-20171121181,JOHNSON AND JOHNSON,TOYOOKA I. 2H-25 A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS DURING ORAL TREATMENT WITH SGLT2 INHIBITORS. 2017 OCT;207.,67.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Elderly
166432292,16643229,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Gastroenteritis,,2019,Q4,2,F,20170623.0,20191202.0,20190729,20191213,EXP,,JP-JNJFOC-20171121181,JOHNSON AND JOHNSON,TOYOOKA I. 2H-25 A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS DURING ORAL TREATMENT WITH SGLT2 INHIBITORS. 2017 OCT;207.,67.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Elderly
166432292,16643229,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Laboratory test abnormal,,2019,Q4,2,F,20170623.0,20191202.0,20190729,20191213,EXP,,JP-JNJFOC-20171121181,JOHNSON AND JOHNSON,TOYOOKA I. 2H-25 A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS DURING ORAL TREATMENT WITH SGLT2 INHIBITORS. 2017 OCT;207.,67.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Elderly
166432292,16643229,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Weight decreased,,2019,Q4,2,F,20170623.0,20191202.0,20190729,20191213,EXP,,JP-JNJFOC-20171121181,JOHNSON AND JOHNSON,TOYOOKA I. 2H-25 A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS DURING ORAL TREATMENT WITH SGLT2 INHIBITORS. 2017 OCT;207.,67.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Elderly
166432292,16643229,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,204042.0,,,,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,2,F,20170623.0,20191202.0,20190729,20191213,EXP,,JP-JNJFOC-20171121181,JOHNSON AND JOHNSON,TOYOOKA I. 2H-25 A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS DURING ORAL TREATMENT WITH SGLT2 INHIBITORS. 2017 OCT;207.,67.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Elderly
166432292,16643229,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,204042.0,,,,,2019,Q4,Gastroenteritis,,2019,Q4,2,F,20170623.0,20191202.0,20190729,20191213,EXP,,JP-JNJFOC-20171121181,JOHNSON AND JOHNSON,TOYOOKA I. 2H-25 A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS DURING ORAL TREATMENT WITH SGLT2 INHIBITORS. 2017 OCT;207.,67.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Elderly
166432292,16643229,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,204042.0,,,,,2019,Q4,Laboratory test abnormal,,2019,Q4,2,F,20170623.0,20191202.0,20190729,20191213,EXP,,JP-JNJFOC-20171121181,JOHNSON AND JOHNSON,TOYOOKA I. 2H-25 A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS DURING ORAL TREATMENT WITH SGLT2 INHIBITORS. 2017 OCT;207.,67.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Elderly
166432292,16643229,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,204042.0,,,,,2019,Q4,Weight decreased,,2019,Q4,2,F,20170623.0,20191202.0,20190729,20191213,EXP,,JP-JNJFOC-20171121181,JOHNSON AND JOHNSON,TOYOOKA I. 2H-25 A CASE OF EUGLYCEMIC DIABETIC KETOACIDOSIS DURING ORAL TREATMENT WITH SGLT2 INHIBITORS. 2017 OCT;207.,67.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Elderly
166996242,16699624,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Hepatic function abnormal,,2019,Q4,2,F,,20191004.0,20190813,20191015,EXP,,JP-JNJFOC-20190812932,JOHNSON AND JOHNSON,,73.0,YR,,F,Y,,,20191015.0,,MD,JP,JP,2019,Q4,Elderly
167213802,16721380,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Herpes zoster,,2019,Q4,2,F,20180809.0,20191017.0,20190820,20191029,EXP,,JP-JNJFOC-20190820939,JOHNSON AND JOHNSON,,73.0,YR,,F,Y,55.0,KG,20191029.0,,MD,JP,JP,2019,Q4,Elderly
167986972,16798697,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Myocardial infarction,,2019,Q4,2,F,,20191030.0,20190912,20191107,EXP,,JP-JNJFOC-20190912100,JOHNSON AND JOHNSON,,46.0,YR,,M,Y,89.0,KG,20191107.0,,MD,JP,JP,2019,Q4,Adult
168021612,16802161,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Cardiac ventricular thrombosis,,2019,Q4,2,F,20180719.0,20191004.0,20190912,20191015,EXP,,JP-JNJFOC-20190912334,JOHNSON AND JOHNSON,,61.0,YR,,M,Y,,,20191015.0,,MD,JP,JP,2019,Q4,Adult
168067963,16806796,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Dehydration,,2019,Q4,3,F,20190831.0,20191115.0,20190913,20191129,EXP,,ES-NOVOPROD-684111,NOVO NORDISK,,50.0,YR,,F,Y,112.0,KG,20191129.0,,MD,ES,ES,2019,Q4,Adult
168067963,16806796,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Gastroenteritis,,2019,Q4,3,F,20190831.0,20191115.0,20190913,20191129,EXP,,ES-NOVOPROD-684111,NOVO NORDISK,,50.0,YR,,F,Y,112.0,KG,20191129.0,,MD,ES,ES,2019,Q4,Adult
168067963,16806796,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Renal failure,,2019,Q4,3,F,20190831.0,20191115.0,20190913,20191129,EXP,,ES-NOVOPROD-684111,NOVO NORDISK,,50.0,YR,,F,Y,112.0,KG,20191129.0,,MD,ES,ES,2019,Q4,Adult
168345722,16834572,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Osteoarthritis,,2019,Q4,2,F,2018.0,20191029.0,20190920,20191107,EXP,,JP-JNJFOC-20190925204,JOHNSON AND JOHNSON,,73.0,YR,,M,Y,,,20191107.0,,MD,JP,JP,2019,Q4,Elderly
168577642,16857764,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q4,Pemphigoid,,2019,Q4,2,F,201907.0,20191202.0,20190926,20191211,EXP,,JP-JNJFOC-20190933572,JOHNSON AND JOHNSON,,85.0,YR,,M,Y,,,20191211.0,,PH,JP,JP,2019,Q4,Elderly
168686302,16868630,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Toxic skin eruption,,2019,Q4,2,F,20190913.0,20191011.0,20190930,20191024,EXP,,JP-JNJFOC-20190936839,JOHNSON AND JOHNSON,,69.0,YR,,M,Y,,,20191024.0,,PH,JP,JP,2019,Q4,Elderly
168919221,16891922,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",85600.0,MG,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Cardiac death,,2019,Q4,1,I,,20190927.0,20191007,20191007,EXP,,JP-JNJFOC-20191007574,JOHNSON AND JOHNSON,,55.0,YR,,F,Y,106.1,KG,20191007.0,,MD,JP,JP,2019,Q4,Adult
168919611,16891961,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Diarrhoea,,2019,Q4,1,I,20160415.0,20160624.0,20191007,20191007,EXP,,JP-JNJFOC-20160700829,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,82.0,KG,20191007.0,,MD,JP,JP,2019,Q4,Adult
168919611,16891961,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Inguinal hernia,,2019,Q4,1,I,20160415.0,20160624.0,20191007,20191007,EXP,,JP-JNJFOC-20160700829,JOHNSON AND JOHNSON,,51.0,YR,,M,Y,82.0,KG,20191007.0,,MD,JP,JP,2019,Q4,Adult
169089722,16908972,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, QD",32900.0,MG,,,,,204042.0,50.0,MG,FILM-COATED TABLET,QD,2019,Q4,Aphthous ulcer,,2019,Q4,2,F,20160928.0,20191028.0,20191011,20191106,EXP,,JP-JNJFOC-20191012109,JOHNSON AND JOHNSON,,76.0,YR,,F,Y,,,20191106.0,,MD,JP,JP,2019,Q4,Elderly
169089722,16908972,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, QD",32900.0,MG,,,,,204042.0,50.0,MG,FILM-COATED TABLET,QD,2019,Q4,Foot fracture,,2019,Q4,2,F,20160928.0,20191028.0,20191011,20191106,EXP,,JP-JNJFOC-20191012109,JOHNSON AND JOHNSON,,76.0,YR,,F,Y,,,20191106.0,,MD,JP,JP,2019,Q4,Elderly
169089722,16908972,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, QD",32900.0,MG,,,,,204042.0,50.0,MG,FILM-COATED TABLET,QD,2019,Q4,Herpes zoster,,2019,Q4,2,F,20160928.0,20191028.0,20191011,20191106,EXP,,JP-JNJFOC-20191012109,JOHNSON AND JOHNSON,,76.0,YR,,F,Y,,,20191106.0,,MD,JP,JP,2019,Q4,Elderly
169089722,16908972,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, QD",32900.0,MG,,,,,204042.0,50.0,MG,FILM-COATED TABLET,QD,2019,Q4,Hypertension,,2019,Q4,2,F,20160928.0,20191028.0,20191011,20191106,EXP,,JP-JNJFOC-20191012109,JOHNSON AND JOHNSON,,76.0,YR,,F,Y,,,20191106.0,,MD,JP,JP,2019,Q4,Elderly
169089722,16908972,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, QD",32900.0,MG,,,,,204042.0,50.0,MG,FILM-COATED TABLET,QD,2019,Q4,Incorrect dose administered,,2019,Q4,2,F,20160928.0,20191028.0,20191011,20191106,EXP,,JP-JNJFOC-20191012109,JOHNSON AND JOHNSON,,76.0,YR,,F,Y,,,20191106.0,,MD,JP,JP,2019,Q4,Elderly
169089722,16908972,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, QD",32900.0,MG,,,,,204042.0,50.0,MG,FILM-COATED TABLET,QD,2019,Q4,Off label use,,2019,Q4,2,F,20160928.0,20191028.0,20191011,20191106,EXP,,JP-JNJFOC-20191012109,JOHNSON AND JOHNSON,,76.0,YR,,F,Y,,,20191106.0,,MD,JP,JP,2019,Q4,Elderly
169089722,16908972,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, QD",32900.0,MG,,,,,204042.0,50.0,MG,FILM-COATED TABLET,QD,2019,Q4,Aphthous ulcer,,2019,Q4,2,F,20160928.0,20191028.0,20191011,20191106,EXP,,JP-JNJFOC-20191012109,JOHNSON AND JOHNSON,,76.0,YR,,F,Y,,,20191106.0,,MD,JP,JP,2019,Q4,Elderly
169089722,16908972,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, QD",32900.0,MG,,,,,204042.0,50.0,MG,FILM-COATED TABLET,QD,2019,Q4,Foot fracture,,2019,Q4,2,F,20160928.0,20191028.0,20191011,20191106,EXP,,JP-JNJFOC-20191012109,JOHNSON AND JOHNSON,,76.0,YR,,F,Y,,,20191106.0,,MD,JP,JP,2019,Q4,Elderly
169089722,16908972,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, QD",32900.0,MG,,,,,204042.0,50.0,MG,FILM-COATED TABLET,QD,2019,Q4,Herpes zoster,,2019,Q4,2,F,20160928.0,20191028.0,20191011,20191106,EXP,,JP-JNJFOC-20191012109,JOHNSON AND JOHNSON,,76.0,YR,,F,Y,,,20191106.0,,MD,JP,JP,2019,Q4,Elderly
169089722,16908972,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, QD",32900.0,MG,,,,,204042.0,50.0,MG,FILM-COATED TABLET,QD,2019,Q4,Hypertension,,2019,Q4,2,F,20160928.0,20191028.0,20191011,20191106,EXP,,JP-JNJFOC-20191012109,JOHNSON AND JOHNSON,,76.0,YR,,F,Y,,,20191106.0,,MD,JP,JP,2019,Q4,Elderly
169089722,16908972,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, QD",32900.0,MG,,,,,204042.0,50.0,MG,FILM-COATED TABLET,QD,2019,Q4,Incorrect dose administered,,2019,Q4,2,F,20160928.0,20191028.0,20191011,20191106,EXP,,JP-JNJFOC-20191012109,JOHNSON AND JOHNSON,,76.0,YR,,F,Y,,,20191106.0,,MD,JP,JP,2019,Q4,Elderly
169089722,16908972,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, QD",32900.0,MG,,,,,204042.0,50.0,MG,FILM-COATED TABLET,QD,2019,Q4,Off label use,,2019,Q4,2,F,20160928.0,20191028.0,20191011,20191106,EXP,,JP-JNJFOC-20191012109,JOHNSON AND JOHNSON,,76.0,YR,,F,Y,,,20191106.0,,MD,JP,JP,2019,Q4,Elderly
169100291,16910029,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MG ID,,,U,,,,,100.0,MG,,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,,20191010.0,20191011,20191011,EXP,,PT-BAUSCH-BL-2019-057654,BAUSCH AND LOMB,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. ACIDOSE LACTICA ASSOCIADA A METFORMINA, COM LESAO RENAL AGUDA POR HIPOTENSAO IATROGENICA. 25TH CONGRESSO NACIONAL DE MEDICINA INTERNA: DOENCAS ENDOCRINAS E METABOLICAS. 2019 MAY;.",76.0,YR,,M,Y,,,20191011.0,,MD,PT,PT,2019,Q4,Elderly
169100291,16910029,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MG ID,,,U,,,,,100.0,MG,,,2019,Q4,Hypotension,,2019,Q4,1,I,,20191010.0,20191011,20191011,EXP,,PT-BAUSCH-BL-2019-057654,BAUSCH AND LOMB,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. ACIDOSE LACTICA ASSOCIADA A METFORMINA, COM LESAO RENAL AGUDA POR HIPOTENSAO IATROGENICA. 25TH CONGRESSO NACIONAL DE MEDICINA INTERNA: DOENCAS ENDOCRINAS E METABOLICAS. 2019 MAY;.",76.0,YR,,M,Y,,,20191011.0,,MD,PT,PT,2019,Q4,Elderly
169100291,16910029,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MG ID,,,U,,,,,100.0,MG,,,2019,Q4,Lactic acidosis,,2019,Q4,1,I,,20191010.0,20191011,20191011,EXP,,PT-BAUSCH-BL-2019-057654,BAUSCH AND LOMB,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. ACIDOSE LACTICA ASSOCIADA A METFORMINA, COM LESAO RENAL AGUDA POR HIPOTENSAO IATROGENICA. 25TH CONGRESSO NACIONAL DE MEDICINA INTERNA: DOENCAS ENDOCRINAS E METABOLICAS. 2019 MAY;.",76.0,YR,,M,Y,,,20191011.0,,MD,PT,PT,2019,Q4,Elderly
169182181,16918218,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204042.0,300.0,MG,FILM-COATED TABLET,,2019,Q4,Dyspnoea,,2019,Q4,1,I,20190917.0,20191007.0,20191015,20191015,EXP,GB-MHRA-EYC 00208303,GB-JNJFOC-20191010698,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,,,20191015.0,,MD,GB,GB,2019,Q4,Adult
169182181,16918218,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204042.0,300.0,MG,FILM-COATED TABLET,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,20190917.0,20191007.0,20191015,20191015,EXP,GB-MHRA-EYC 00208303,GB-JNJFOC-20191010698,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,,,20191015.0,,MD,GB,GB,2019,Q4,Adult
169182181,16918218,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204042.0,300.0,MG,FILM-COATED TABLET,,2019,Q4,Metabolic acidosis,,2019,Q4,1,I,20190917.0,20191007.0,20191015,20191015,EXP,GB-MHRA-EYC 00208303,GB-JNJFOC-20191010698,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,,,20191015.0,,MD,GB,GB,2019,Q4,Adult
169182251,16918225,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,10.0,MG,FILM-COATED TABLET,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,20190917.0,20191007.0,20191015,20191015,EXP,GB-MHRA-EYC 00208388,GB-JNJFOC-20191011199,JOHNSON AND JOHNSON,,55.0,YR,,M,Y,99.0,KG,20191015.0,,MD,GB,GB,2019,Q4,Adult
169269891,16926989,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",91600.0,MG,Y,,,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Embolic stroke,,2019,Q4,1,I,20190313.0,20191007.0,20191016,20191016,EXP,,JP-JNJFOC-20191022023,JOHNSON AND JOHNSON,,66.0,YR,,M,Y,,,20191016.0,,MD,JP,JP,2019,Q4,Elderly
169302571,16930257,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,INVOKANA 100 MG,,,N,, 1KL3Z01,,204042.0,0.5,DF,FILM-COATED TABLET,,2019,Q4,Balance disorder,,2019,Q4,1,I,20190901.0,20191009.0,20191017,20191017,EXP,BE-FAMHP-DHH-N2019-73341,BE-JNJFOC-20191013344,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,80.0,KG,20191017.0,,CN,BE,BE,2019,Q4,Elderly
169302571,16930257,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,INVOKANA 100 MG,,,N,, 1KL3Z01,,204042.0,0.5,DF,FILM-COATED TABLET,,2019,Q4,Constipation,,2019,Q4,1,I,20190901.0,20191009.0,20191017,20191017,EXP,BE-FAMHP-DHH-N2019-73341,BE-JNJFOC-20191013344,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,80.0,KG,20191017.0,,CN,BE,BE,2019,Q4,Elderly
169302571,16930257,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,INVOKANA 100 MG,,,N,, 1KL3Z01,,204042.0,0.5,DF,FILM-COATED TABLET,,2019,Q4,Dry mouth,,2019,Q4,1,I,20190901.0,20191009.0,20191017,20191017,EXP,BE-FAMHP-DHH-N2019-73341,BE-JNJFOC-20191013344,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,80.0,KG,20191017.0,,CN,BE,BE,2019,Q4,Elderly
169302571,16930257,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,INVOKANA 100 MG,,,N,, 1KL3Z01,,204042.0,0.5,DF,FILM-COATED TABLET,,2019,Q4,Ear pain,,2019,Q4,1,I,20190901.0,20191009.0,20191017,20191017,EXP,BE-FAMHP-DHH-N2019-73341,BE-JNJFOC-20191013344,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,80.0,KG,20191017.0,,CN,BE,BE,2019,Q4,Elderly
169302571,16930257,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,INVOKANA 100 MG,,,N,, 1KL3Z01,,204042.0,0.5,DF,FILM-COATED TABLET,,2019,Q4,Hypersomnia,,2019,Q4,1,I,20190901.0,20191009.0,20191017,20191017,EXP,BE-FAMHP-DHH-N2019-73341,BE-JNJFOC-20191013344,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,80.0,KG,20191017.0,,CN,BE,BE,2019,Q4,Elderly
169302571,16930257,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,INVOKANA 100 MG,,,N,, 1KL3Z01,,204042.0,0.5,DF,FILM-COATED TABLET,,2019,Q4,Penile erythema,,2019,Q4,1,I,20190901.0,20191009.0,20191017,20191017,EXP,BE-FAMHP-DHH-N2019-73341,BE-JNJFOC-20191013344,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,80.0,KG,20191017.0,,CN,BE,BE,2019,Q4,Elderly
169302571,16930257,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,INVOKANA 100 MG,,,N,, 1KL3Z01,,204042.0,0.5,DF,FILM-COATED TABLET,,2019,Q4,Phimosis,,2019,Q4,1,I,20190901.0,20191009.0,20191017,20191017,EXP,BE-FAMHP-DHH-N2019-73341,BE-JNJFOC-20191013344,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,80.0,KG,20191017.0,,CN,BE,BE,2019,Q4,Elderly
169302571,16930257,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,INVOKANA 100 MG,,,N,, 1KL3Z01,,204042.0,0.5,DF,FILM-COATED TABLET,,2019,Q4,Rash,,2019,Q4,1,I,20190901.0,20191009.0,20191017,20191017,EXP,BE-FAMHP-DHH-N2019-73341,BE-JNJFOC-20191013344,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,80.0,KG,20191017.0,,CN,BE,BE,2019,Q4,Elderly
169302571,16930257,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,INVOKANA 100 MG,,,N,, 1KL3Z01,,204042.0,0.5,DF,FILM-COATED TABLET,,2019,Q4,Swollen tongue,,2019,Q4,1,I,20190901.0,20191009.0,20191017,20191017,EXP,BE-FAMHP-DHH-N2019-73341,BE-JNJFOC-20191013344,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,80.0,KG,20191017.0,,CN,BE,BE,2019,Q4,Elderly
169302571,16930257,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,INVOKANA 100 MG,,,N,, 1KL3Z01,,204042.0,0.5,DF,FILM-COATED TABLET,,2019,Q4,Thirst,,2019,Q4,1,I,20190901.0,20191009.0,20191017,20191017,EXP,BE-FAMHP-DHH-N2019-73341,BE-JNJFOC-20191013344,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,80.0,KG,20191017.0,,CN,BE,BE,2019,Q4,Elderly
169302571,16930257,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,INVOKANA 100 MG,,,N,, 1KL3Z01,,204042.0,0.5,DF,FILM-COATED TABLET,,2019,Q4,Tongue injury,,2019,Q4,1,I,20190901.0,20191009.0,20191017,20191017,EXP,BE-FAMHP-DHH-N2019-73341,BE-JNJFOC-20191013344,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,80.0,KG,20191017.0,,CN,BE,BE,2019,Q4,Elderly
169371153,16937115,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Colitis ischaemic,,2019,Q4,3,F,20190107.0,20191204.0,20191018,20191213,EXP,,JP-JNJFOC-20191027354,JOHNSON AND JOHNSON,,68.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Elderly
169371153,16937115,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Colitis ischaemic,,2019,Q4,3,F,20190107.0,20191204.0,20191018,20191213,EXP,,JP-JNJFOC-20191027354,JOHNSON AND JOHNSON,,68.0,YR,,M,Y,,,20191213.0,,MD,JP,JP,2019,Q4,Elderly
169390671,16939067,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,,20191016.0,20191020,20191020,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-108533",BOEHRINGER INGELHEIM,"NAIMARK D, MAHMOOD T, PUCKRIN R, SUGAR L. STAPHYLOCOCCUS-ASSOCIATED GLOMERULONEPHRITIS MIMICKING HENOCH-SCH?NLEIN PURPURA AND CRYOGLOBULINEMIC VASCULITIS IN A PATIENT WITH AN EPIDURAL ABSCESS: A CASE REPORT AND BRIEF REVIEW OF THE LITERATURE. CANADIAN JOURNAL OF KIDNEY HEALTH AND DISEASE. 2018;5:.",64.0,YR,,M,Y,,,20191021.0,,OT,CA,CA,2019,Q4,Adult
169390671,16939067,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q4,Extradural abscess,,2019,Q4,1,I,,20191016.0,20191020,20191020,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-108533",BOEHRINGER INGELHEIM,"NAIMARK D, MAHMOOD T, PUCKRIN R, SUGAR L. STAPHYLOCOCCUS-ASSOCIATED GLOMERULONEPHRITIS MIMICKING HENOCH-SCH?NLEIN PURPURA AND CRYOGLOBULINEMIC VASCULITIS IN A PATIENT WITH AN EPIDURAL ABSCESS: A CASE REPORT AND BRIEF REVIEW OF THE LITERATURE. CANADIAN JOURNAL OF KIDNEY HEALTH AND DISEASE. 2018;5:.",64.0,YR,,M,Y,,,20191021.0,,OT,CA,CA,2019,Q4,Adult
169390671,16939067,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2019,Q4,Post streptococcal glomerulonephritis,,2019,Q4,1,I,,20191016.0,20191020,20191020,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-108533",BOEHRINGER INGELHEIM,"NAIMARK D, MAHMOOD T, PUCKRIN R, SUGAR L. STAPHYLOCOCCUS-ASSOCIATED GLOMERULONEPHRITIS MIMICKING HENOCH-SCH?NLEIN PURPURA AND CRYOGLOBULINEMIC VASCULITIS IN A PATIENT WITH AN EPIDURAL ABSCESS: A CASE REPORT AND BRIEF REVIEW OF THE LITERATURE. CANADIAN JOURNAL OF KIDNEY HEALTH AND DISEASE. 2018;5:.",64.0,YR,,M,Y,,,20191021.0,,OT,CA,CA,2019,Q4,Adult
169430551,16943055,8,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Cataract,,2019,Q4,1,I,,20191021.0,20191021,20191021,EXP,,US-ANIPHARMA-2019-US-019734,ANI,"CHOU TY, BRICEL S, YAZDANIE M.RAPID FORMATION OF CATARACT AFTER STARTING ZIPRASIDONE WITH SPONTANEOUS REGRESSION AFTER THERAPY WAS DISCONTINUED..JCRS ONLINE CASE REPORTS.2019;7(3):48-51.",48.0,YR,,F,Y,112.0,KG,20191021.0,,MD,US,US,2019,Q4,Adult
169575381,16957538,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Atrial fibrillation,,2019,Q4,1,I,20190405.0,20191015.0,20191024,20191024,EXP,,JP-JNJFOC-20191032113,JOHNSON AND JOHNSON,,74.0,YR,,M,Y,,,20191024.0,,MD,JP,JP,2019,Q4,Elderly
169579601,16957960,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,74800.0,MG,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Cholecystitis,,2019,Q4,1,I,20170821.0,20191015.0,20191024,20191024,EXP,,JP-JNJFOC-20191029519,JOHNSON AND JOHNSON,,67.0,YR,,F,Y,,,20191024.0,,MD,JP,JP,2019,Q4,Elderly
169608761,16960876,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, QD",,,,,,,,300.0,MG,,QD,2019,Q4,Alcoholic seizure,,2019,Q4,1,I,20190715.0,20191015.0,20191025,20191025,EXP,,GB-NOVOPROD-691427,NOVO NORDISK,,55.0,YR,,M,Y,70.3,KG,20191025.0,,MD,GB,GB,2019,Q4,Adult
169702731,16970273,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,1 TABLET EVERY 12 HOURS,,,,,,,204353.0,1.0,DF,TABLET,,2019,Q4,Cellulitis,,2019,Q4,1,I,20190913.0,20191021.0,20191029,20191029,EXP,ES-AEMPS-553232,ES-JNJFOC-20191031745,JOHNSON AND JOHNSON,,60.0,YR,,M,Y,126.0,KG,20191029.0,,PH,ES,ES,2019,Q4,Adult
169756071,16975607,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2019,Q4,Blood creatinine increased,,2019,Q4,1,I,20191001.0,20191024.0,20191030,20191030,EXP,,CA-TAKEDA-2019TUS060721,TAKEDA,,67.0,YR,,M,Y,,,20191030.0,,CN,CA,CA,2019,Q4,Elderly
169758391,16975839,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Diarrhoea,,2019,Q4,1,I,201907.0,20191025.0,20191030,20191030,EXP,GB-MHRA-EYC 00210136,GB-MYLANLABS-2019M1102832,MYLAN,,66.0,YR,,M,Y,,,20191030.0,,MD,GB,GB,2019,Q4,Elderly
169765351,16976535,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Sarcoidosis,,2019,Q4,1,I,,20191021.0,20191030,20191030,EXP,,JP-JNJFOC-20191042071,JOHNSON AND JOHNSON,,71.0,YR,,F,Y,,,20191030.0,,MD,JP,JP,2019,Q4,Elderly
169832701,16983270,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204042.0,300.0,MG,TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20191006.0,20191023.0,20191101,20191101,EXP,GB-MHRA-EYC 00209741,GB-JNJFOC-20191036957,JOHNSON AND JOHNSON,,61.0,YR,,M,Y,86.5,KG,20191101.0,,MD,GB,GB,2019,Q4,Adult
169835701,16983570,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Intradermal,,,,,,,,,100.0,MG,,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,PT-EMD SERONO-9125420,EMD SERONO INC,"MARIA B, MAGDA G, PEDRO C, PAULO A, ADRIANA S. LACTIC ACIDOSIS ASSOCIATED WITH METFORMIN IN A PATIENT WITH ACUTE RENAL LESION CAUSED BY IATROGENIC HYPOTENSION.. ENDOCRINE AND METABOLIC DISORDERS - E-POSTER.",76.0,YR,,M,Y,,,20191101.0,,MD,PT,PT,2019,Q4,Elderly
169835701,16983570,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Intradermal,,,,,,,,,100.0,MG,,,2019,Q4,Lactic acidosis,,2019,Q4,1,I,,20191024.0,20191101,20191101,EXP,,PT-EMD SERONO-9125420,EMD SERONO INC,"MARIA B, MAGDA G, PEDRO C, PAULO A, ADRIANA S. LACTIC ACIDOSIS ASSOCIATED WITH METFORMIN IN A PATIENT WITH ACUTE RENAL LESION CAUSED BY IATROGENIC HYPOTENSION.. ENDOCRINE AND METABOLIC DISORDERS - E-POSTER.",76.0,YR,,M,Y,,,20191101.0,,MD,PT,PT,2019,Q4,Elderly
169912101,16991210,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,,,FILM-COATED TABLET,,2019,Q4,Priapism,,2019,Q4,1,I,,20191023.0,20191104,20191104,EXP,,JP-JNJFOC-20191100273,JOHNSON AND JOHNSON,"MITSUI Y, NATSUYAMA T, OTA S, HISASUE S, UETANI M. HISTOLOGIC EVALUATION OF PROLONGED ISCHEMIC PRIAPISM USING WINTER PROCEDURE WITH PERCUTANEOUS DISTAL SHUNT CONSTRUCTION-REPORT OF TWO CASES. ACTA UROLOGICA JAPONICA. 2019 SEP 30;65(9):385-388.",51.0,YR,,M,Y,,,20191104.0,,MD,JP,JP,2019,Q4,Adult
169945342,16994534,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Angina pectoris,,2019,Q4,2,F,20181216.0,20191120.0,20191105,20191202,EXP,,JP-JNJFOC-20191102116,JOHNSON AND JOHNSON,,47.0,YR,,M,Y,,,20191202.0,,MD,JP,JP,2019,Q4,Adult
169990081,16999008,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Breast cancer,,2019,Q4,1,I,,20191025.0,20191106,20191106,EXP,,JP-JNJFOC-20191102148,JOHNSON AND JOHNSON,,59.0,YR,,F,Y,,,20191106.0,,MD,JP,JP,2019,Q4,Adult
170033901,17003390,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,,,2019,Q4,Bile duct stone,Bile duct stone,2019,Q4,1,I,2003.0,20191024.0,20191107,20191107,EXP,,US-ALVOGEN-2019-ALVOGEN-101822,ALVOGEN,,52.0,YR,,M,Y,97.07,KG,20191107.0,,MD,COUNTRY NOT SPECIFIED,US,2019,Q4,Adult
170033901,17003390,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,,,2019,Q4,Cholecystectomy,Cholecystectomy,2019,Q4,1,I,2003.0,20191024.0,20191107,20191107,EXP,,US-ALVOGEN-2019-ALVOGEN-101822,ALVOGEN,,52.0,YR,,M,Y,97.07,KG,20191107.0,,MD,COUNTRY NOT SPECIFIED,US,2019,Q4,Adult
170033901,17003390,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,,,2019,Q4,Dental caries,Dental caries,2019,Q4,1,I,2003.0,20191024.0,20191107,20191107,EXP,,US-ALVOGEN-2019-ALVOGEN-101822,ALVOGEN,,52.0,YR,,M,Y,97.07,KG,20191107.0,,MD,COUNTRY NOT SPECIFIED,US,2019,Q4,Adult
170033901,17003390,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,,,2019,Q4,Irritable bowel syndrome,Irritable bowel syndrome,2019,Q4,1,I,2003.0,20191024.0,20191107,20191107,EXP,,US-ALVOGEN-2019-ALVOGEN-101822,ALVOGEN,,52.0,YR,,M,Y,97.07,KG,20191107.0,,MD,COUNTRY NOT SPECIFIED,US,2019,Q4,Adult
170033901,17003390,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,,,2019,Q4,Type 2 diabetes mellitus,Type 2 diabetes mellitus,2019,Q4,1,I,2003.0,20191024.0,20191107,20191107,EXP,,US-ALVOGEN-2019-ALVOGEN-101822,ALVOGEN,,52.0,YR,,M,Y,97.07,KG,20191107.0,,MD,COUNTRY NOT SPECIFIED,US,2019,Q4,Adult
170033901,17003390,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,,,2019,Q4,Weight fluctuation,Weight fluctuation,2019,Q4,1,I,2003.0,20191024.0,20191107,20191107,EXP,,US-ALVOGEN-2019-ALVOGEN-101822,ALVOGEN,,52.0,YR,,M,Y,97.07,KG,20191107.0,,MD,COUNTRY NOT SPECIFIED,US,2019,Q4,Adult
170042631,17004263,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,,20191029.0,20191107,20191107,EXP,,US-EMD SERONO-9126091,EMD SERONO INC,"SIT A, YU R. SOUR WITHOUT THE SWEET: A SUBTLE PRESENTATION OF EUGLYCEMIC DIABETIC KETOACIDOSIS... JOURNAL OF HOSPITAL MEDICINE. 2018 JAN 01;13(4):.",48.0,YR,,M,Y,,,20191107.0,,OT,US,US,2019,Q4,Adult
170042631,17004263,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,,20191029.0,20191107,20191107,EXP,,US-EMD SERONO-9126091,EMD SERONO INC,"SIT A, YU R. SOUR WITHOUT THE SWEET: A SUBTLE PRESENTATION OF EUGLYCEMIC DIABETIC KETOACIDOSIS... JOURNAL OF HOSPITAL MEDICINE. 2018 JAN 01;13(4):.",48.0,YR,,M,Y,,,20191107.0,,OT,US,US,2019,Q4,Adult
170042631,17004263,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q4,Pyelonephritis,,2019,Q4,1,I,,20191029.0,20191107,20191107,EXP,,US-EMD SERONO-9126091,EMD SERONO INC,"SIT A, YU R. SOUR WITHOUT THE SWEET: A SUBTLE PRESENTATION OF EUGLYCEMIC DIABETIC KETOACIDOSIS... JOURNAL OF HOSPITAL MEDICINE. 2018 JAN 01;13(4):.",48.0,YR,,M,Y,,,20191107.0,,OT,US,US,2019,Q4,Adult
170066651,17006665,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q4,Drug resistance,,2019,Q4,1,I,20160909.0,20191030.0,20191107,20191107,EXP,GB-MHRA-EYC 00179543,GB-JNJFOC-20191046468,JOHNSON AND JOHNSON,,69.0,YR,,F,Y,109.6,KG,20191107.0,,MD,GB,GB,2019,Q4,Elderly
170066651,17006665,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q4,Urinary tract infection,,2019,Q4,1,I,20160909.0,20191030.0,20191107,20191107,EXP,GB-MHRA-EYC 00179543,GB-JNJFOC-20191046468,JOHNSON AND JOHNSON,,69.0,YR,,F,Y,109.6,KG,20191107.0,,MD,GB,GB,2019,Q4,Elderly
170094301,17009430,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,, UNKNOWN,,,300.0,MG,,QD,2019,Q4,Acute kidney injury,,2019,Q4,1,I,2019.0,20190909.0,20191108,20191108,EXP,,US-NOVOPROD-684734,NOVO NORDISK,,62.0,YR,,M,Y,81.63,KG,20191108.0,,OT,US,US,2019,Q4,Adult
170094301,17009430,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,, UNKNOWN,,,300.0,MG,,QD,2019,Q4,Glycosylated haemoglobin increased,,2019,Q4,1,I,2019.0,20190909.0,20191108,20191108,EXP,,US-NOVOPROD-684734,NOVO NORDISK,,62.0,YR,,M,Y,81.63,KG,20191108.0,,OT,US,US,2019,Q4,Adult
170094301,17009430,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,, UNKNOWN,,,300.0,MG,,QD,2019,Q4,Hypoglycaemia,,2019,Q4,1,I,2019.0,20190909.0,20191108,20191108,EXP,,US-NOVOPROD-684734,NOVO NORDISK,,62.0,YR,,M,Y,81.63,KG,20191108.0,,OT,US,US,2019,Q4,Adult
170094301,17009430,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,, UNKNOWN,,,300.0,MG,,QD,2019,Q4,Hyponatraemia,,2019,Q4,1,I,2019.0,20190909.0,20191108,20191108,EXP,,US-NOVOPROD-684734,NOVO NORDISK,,62.0,YR,,M,Y,81.63,KG,20191108.0,,OT,US,US,2019,Q4,Adult
170094301,17009430,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,, UNKNOWN,,,300.0,MG,,QD,2019,Q4,Hypotension,,2019,Q4,1,I,2019.0,20190909.0,20191108,20191108,EXP,,US-NOVOPROD-684734,NOVO NORDISK,,62.0,YR,,M,Y,81.63,KG,20191108.0,,OT,US,US,2019,Q4,Adult
170094301,17009430,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,, UNKNOWN,,,300.0,MG,,QD,2019,Q4,Pancreatitis acute,,2019,Q4,1,I,2019.0,20190909.0,20191108,20191108,EXP,,US-NOVOPROD-684734,NOVO NORDISK,,62.0,YR,,M,Y,81.63,KG,20191108.0,,OT,US,US,2019,Q4,Adult
170094301,17009430,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,, UNKNOWN,,,300.0,MG,,QD,2019,Q4,Product prescribing error,,2019,Q4,1,I,2019.0,20190909.0,20191108,20191108,EXP,,US-NOVOPROD-684734,NOVO NORDISK,,62.0,YR,,M,Y,81.63,KG,20191108.0,,OT,US,US,2019,Q4,Adult
170165221,17016522,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Ketoacidosis,,2019,Q4,1,I,,20191030.0,20191111,20191111,EXP,,US-JNJFOC-20191101071,JOHNSON AND JOHNSON,"PONGRACZ B, THEODORE D, TITUS B, DUBE K. EUGLYCEMIC KETOACIDOSIS IN A POSTOPERATIVE DEFORMITY CORRECTION SPINE SURGERY PATIENT: A CASE REPORT. CRITICAL CARE MEDICINE 48TH CRITICAL CARE CONGRESS OF THE SOCIETY OF CRITICAL CARE MEDICINE, SCCM 2019. 2019;VOLUME 47:.",79.0,YR,,M,Y,,,20191111.0,,OT,US,US,2019,Q4,Elderly
170298451,17029845,4,C,Canagliflozin,CANAGLIFLOZIN,1,Intradermal,100 MILLIGRAM,,,U,U,,,,100.0,MG,,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,,20191102.0,20191114,20191114,EXP,,PT-AUROBINDO-AUR-APL-2019-072733,AUROBINDO,,76.0,YR,,M,Y,,,20191114.0,,OT,PT,PT,2019,Q4,Elderly
170298451,17029845,4,C,Canagliflozin,CANAGLIFLOZIN,1,Intradermal,100 MILLIGRAM,,,U,U,,,,100.0,MG,,,2019,Q4,Lactic acidosis,,2019,Q4,1,I,,20191102.0,20191114,20191114,EXP,,PT-AUROBINDO-AUR-APL-2019-072733,AUROBINDO,,76.0,YR,,M,Y,,,20191114.0,,OT,PT,PT,2019,Q4,Elderly
170383741,17038374,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Intradermal,,,,,,,,,100.0,MG,,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,,20191104.0,20191115,20191115,EXP,,PT-BAUSCH-BL-2019-060716,BAUSCH AND LOMB,"MARIA B, MAGDA G, PEDRO C, PAULO A, ADRIANA S. LACTIC ACIDOSIS ASSOCIATED WITH METFORMIN IN A PATIENT WITH ACUTE RENAL LESION CAUSED BY IATROGENIC HYPOTENSION. ENDOCRINE AND METABOLIC DISORDERS- E-POSTE.",76.0,YR,,M,Y,,,20191115.0,,MD,PT,PT,2019,Q4,Elderly
170383741,17038374,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Intradermal,,,,,,,,,100.0,MG,,,2019,Q4,Lactic acidosis,,2019,Q4,1,I,,20191104.0,20191115,20191115,EXP,,PT-BAUSCH-BL-2019-060716,BAUSCH AND LOMB,"MARIA B, MAGDA G, PEDRO C, PAULO A, ADRIANA S. LACTIC ACIDOSIS ASSOCIATED WITH METFORMIN IN A PATIENT WITH ACUTE RENAL LESION CAUSED BY IATROGENIC HYPOTENSION. ENDOCRINE AND METABOLIC DISORDERS- E-POSTE.",76.0,YR,,M,Y,,,20191115.0,,MD,PT,PT,2019,Q4,Elderly
170441412,17044141,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",106500.0,MG,Y,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Cerebral infarction,,2019,Q4,2,F,20181214.0,20191216.0,20191118,20191227,EXP,,JP-JNJFOC-20191122947,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,,,20191227.0,,MD,JP,JP,2019,Q4,Elderly
170446221,17044622,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,,,FILM-COATED TABLET,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,,20191104.0,20191118,20191118,EXP,,US-JNJFOC-20191110340,JOHNSON AND JOHNSON,"OSMAN N, RUNCIE K. A CASE OF CANAGLIFLOZIN INDUCED EUGLYCEMIC DIABETIC KETOACIDOSIS: RARE BUT SIGNIFICANT. J HOSP MED. 2018;13 (4 SUPPLEMENT 1):.",54.0,YR,,F,Y,,,20191118.0,,MD,US,US,2019,Q4,Adult
170446221,17044622,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,204042.0,,,,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,,20191104.0,20191118,20191118,EXP,,US-JNJFOC-20191110340,JOHNSON AND JOHNSON,"OSMAN N, RUNCIE K. A CASE OF CANAGLIFLOZIN INDUCED EUGLYCEMIC DIABETIC KETOACIDOSIS: RARE BUT SIGNIFICANT. J HOSP MED. 2018;13 (4 SUPPLEMENT 1):.",54.0,YR,,F,Y,,,20191118.0,,MD,US,US,2019,Q4,Adult
170446951,17044695,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q4,Acute kidney injury,,2019,Q4,1,I,,20191104.0,20191118,20191118,EXP,,PT-JNJFOC-20191104904,JOHNSON AND JOHNSON,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. ACIDOSE LATICA A METFORMINAS, COM LESAO RENAL AGUDA POR HIPOTENSAO IATROGANICA. MEDICINA INTERNA - CONGRESSOS NACIONAIS 25CNMI19.",76.0,YR,,M,Y,,,20191118.0,,MD,PT,PT,2019,Q4,Elderly
170446951,17044695,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q4,Lactic acidosis,,2019,Q4,1,I,,20191104.0,20191118,20191118,EXP,,PT-JNJFOC-20191104904,JOHNSON AND JOHNSON,"SANTOS M, GARCA M, COTA P, AVILA P, SANTOS A. ACIDOSE LATICA A METFORMINAS, COM LESAO RENAL AGUDA POR HIPOTENSAO IATROGANICA. MEDICINA INTERNA - CONGRESSOS NACIONAIS 25CNMI19.",76.0,YR,,M,Y,,,20191118.0,,MD,PT,PT,2019,Q4,Elderly
170447601,17044760,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Haemothorax,,2019,Q4,1,I,20180423.0,20191107.0,20191118,20191118,EXP,,JP-JNJFOC-20191116067,JOHNSON AND JOHNSON,,62.0,YR,,M,Y,,,20191118.0,,MD,JP,JP,2019,Q4,Adult
170447601,17044760,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Rib fracture,,2019,Q4,1,I,20180423.0,20191107.0,20191118,20191118,EXP,,JP-JNJFOC-20191116067,JOHNSON AND JOHNSON,,62.0,YR,,M,Y,,,20191118.0,,MD,JP,JP,2019,Q4,Adult
170488101,17048810,4,C,canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Angioedema,,2019,Q4,1,I,20191112.0,,20191118,20191118,DIR,,,FDA-CTU,,52.0,YR,,M,N,91.6,KG,20191118.0,N,OT,US,US,2019,Q4,Adult
170488101,17048810,4,C,canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Dyspnoea,,2019,Q4,1,I,20191112.0,,20191118,20191118,DIR,,,FDA-CTU,,52.0,YR,,M,N,91.6,KG,20191118.0,N,OT,US,US,2019,Q4,Adult
170501841,17050184,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",86900.0,MG,U,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Angina pectoris,,2019,Q4,1,I,20190119.0,20191107.0,20191119,20191119,EXP,,JP-JNJFOC-20191120412,JOHNSON AND JOHNSON,,64.0,YR,,F,Y,,,20191119.0,,MD,JP,JP,2019,Q4,Adult
170546821,17054682,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,,,FILM-COATED TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,2019.0,20191111.0,20191120,20191120,EXP,,IE-JNJFOC-20191120273,JOHNSON AND JOHNSON,,4.0,DEC,,F,Y,,,20191120.0,,OT,IE,IE,2019,Q4,Child
170546821,17054682,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,,,FILM-COATED TABLET,,2019,Q4,Gastroenteritis,,2019,Q4,1,I,2019.0,20191111.0,20191120,20191120,EXP,,IE-JNJFOC-20191120273,JOHNSON AND JOHNSON,,4.0,DEC,,F,Y,,,20191120.0,,OT,IE,IE,2019,Q4,Child
170609341,17060934,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Diabetic nephropathy,,2019,Q4,1,I,,20191114.0,20191121,20191121,EXP,,CZ-MYLANLABS-2019M1110883,MYLAN,PSOTTOV? J.. POZITIVN? TERAPEUTICK? ??INEK KANAGLIFLOZINU NA ZLEP?EN? DLOUHODOB? KOMPENZACE A CHRONICK?HO REN?LN?HO SELH?N? U PACIENTKY S DIAGN?ZOU DIABETES MELLITUS 2.TYPU.. KAZUISTIKY V DIABETOLOGII. 2019;17 (3):27-9,63.0,YR,,F,Y,,,20191121.0,,MD,CZ,CZ,2019,Q4,Adult
170609341,17060934,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Drug ineffective,,2019,Q4,1,I,,20191114.0,20191121,20191121,EXP,,CZ-MYLANLABS-2019M1110883,MYLAN,PSOTTOV? J.. POZITIVN? TERAPEUTICK? ??INEK KANAGLIFLOZINU NA ZLEP?EN? DLOUHODOB? KOMPENZACE A CHRONICK?HO REN?LN?HO SELH?N? U PACIENTKY S DIAGN?ZOU DIABETES MELLITUS 2.TYPU.. KAZUISTIKY V DIABETOLOGII. 2019;17 (3):27-9,63.0,YR,,F,Y,,,20191121.0,,MD,CZ,CZ,2019,Q4,Adult
170609341,17060934,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2019,Q4,Treatment noncompliance,,2019,Q4,1,I,,20191114.0,20191121,20191121,EXP,,CZ-MYLANLABS-2019M1110883,MYLAN,PSOTTOV? J.. POZITIVN? TERAPEUTICK? ??INEK KANAGLIFLOZINU NA ZLEP?EN? DLOUHODOB? KOMPENZACE A CHRONICK?HO REN?LN?HO SELH?N? U PACIENTKY S DIAGN?ZOU DIABETES MELLITUS 2.TYPU.. KAZUISTIKY V DIABETOLOGII. 2019;17 (3):27-9,63.0,YR,,F,Y,,,20191121.0,,MD,CZ,CZ,2019,Q4,Adult
170632531,17063253,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2019,Q4,Gastritis,,2019,Q4,1,I,20180730.0,20191114.0,20191122,20191122,EXP,GB-MHRA-MIDB-9840F50A-8ED2-487A-8463-C217FA45EC8F,GB-TEVA-2019-GB-1139575,TEVA,,54.0,YR,,M,Y,,,20191122.0,,PH,GB,GB,2019,Q4,Adult
170656501,17065650,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Diabetic nephropathy,,2019,Q4,1,I,2016.0,20191113.0,20191122,20191122,EXP,,CZ-EMD SERONO-9129863,EMD SERONO INC,UNKNOWN. THE POSITIVE EFFECT OF CANAGLIFLOZIN ON THE IMPROVEMENT OF DIABETES AND CHRONIC. KAZUISTIKY V DIABETOLOGII. 2019;17(3):27-29.,38.0,YR,,F,Y,111.0,KG,20191122.0,,MD,CZ,CZ,2019,Q4,Adult
170656501,17065650,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Therapy non-responder,,2019,Q4,1,I,2016.0,20191113.0,20191122,20191122,EXP,,CZ-EMD SERONO-9129863,EMD SERONO INC,UNKNOWN. THE POSITIVE EFFECT OF CANAGLIFLOZIN ON THE IMPROVEMENT OF DIABETES AND CHRONIC. KAZUISTIKY V DIABETOLOGII. 2019;17(3):27-29.,38.0,YR,,F,Y,111.0,KG,20191122.0,,MD,CZ,CZ,2019,Q4,Adult
170679741,17067974,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,,20191118.0,20191122,20191122,EXP,GB-MHRA-EYC 00211414,GB-JNJFOC-20191128309,JOHNSON AND JOHNSON,,90.0,YR,,M,Y,,,20191122.0,,PH,GB,GB,2019,Q4,Elderly
170738821,17073882,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Pancreatitis acute,,2019,Q4,1,I,20180928.0,20181019.0,20191126,20191126,PER,,US-ALVOGEN-2019-ALVOGEN-098541,ALVOGEN,,72.0,YR,,M,Y,,,20191125.0,,MD,US,US,2019,Q4,Elderly
170949971,17094997,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q4,Drug interaction,,2019,Q4,1,I,,20191120.0,20191130,20191130,EXP,,PL-ACCORD-163426,ACCORD,"WORON J, SIWEK M, GOROSTOWICZ A, ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTI-DEPRESSANTS AND MEDICATIONS USED IN TREATMENT OF CARDIOVASCULAR DISORDERS, PSYCHIATR. POL. 2019; 53(5): 977-995.",48.0,YR,,M,Y,,,20191130.0,,OT,PL,PL,2019,Q4,Adult
170949971,17094997,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q4,Drug level increased,,2019,Q4,1,I,,20191120.0,20191130,20191130,EXP,,PL-ACCORD-163426,ACCORD,"WORON J, SIWEK M, GOROSTOWICZ A, ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTI-DEPRESSANTS AND MEDICATIONS USED IN TREATMENT OF CARDIOVASCULAR DISORDERS, PSYCHIATR. POL. 2019; 53(5): 977-995.",48.0,YR,,M,Y,,,20191130.0,,OT,PL,PL,2019,Q4,Adult
170949971,17094997,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q4,Headache,,2019,Q4,1,I,,20191120.0,20191130,20191130,EXP,,PL-ACCORD-163426,ACCORD,"WORON J, SIWEK M, GOROSTOWICZ A, ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTI-DEPRESSANTS AND MEDICATIONS USED IN TREATMENT OF CARDIOVASCULAR DISORDERS, PSYCHIATR. POL. 2019; 53(5): 977-995.",48.0,YR,,M,Y,,,20191130.0,,OT,PL,PL,2019,Q4,Adult
170949971,17094997,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,,,2019,Q4,Peripheral swelling,,2019,Q4,1,I,,20191120.0,20191130,20191130,EXP,,PL-ACCORD-163426,ACCORD,"WORON J, SIWEK M, GOROSTOWICZ A, ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTI-DEPRESSANTS AND MEDICATIONS USED IN TREATMENT OF CARDIOVASCULAR DISORDERS, PSYCHIATR. POL. 2019; 53(5): 977-995.",48.0,YR,,M,Y,,,20191130.0,,OT,PL,PL,2019,Q4,Adult
171018202,17101820,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Cerebral infarction,,2019,Q4,2,F,201712.0,20191225.0,20191202,20191231,EXP,,JP-JNJFOC-20191142584,JOHNSON AND JOHNSON,,45.0,YR,,M,Y,,,20191231.0,,MD,JP,JP,2019,Q4,Adult
171035201,17103520,7,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Drug interaction,,2019,Q4,1,I,,20191121.0,20191203,20191203,EXP,,PL-UNICHEM PHARMACEUTICALS (USA) INC-UCM201911-000794,UNICHEM,"SIWEK M, WORON J, GOROSTOWICZ A. ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTIDEPRESSANTS AND MEDICATIONS USED  IN TREATMENT OF CARDIOVASCULAR DISORDERS. PSYCHIATR POL. 2019;VOLUME 53:ISSUE 5:977-95. DOI:10.12740/PP/ONLINEFIRST/96286",48.0,YR,,M,Y,,,20191203.0,,,COUNTRY NOT SPECIFIED,PL,2019,Q4,Adult
171035201,17103520,7,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Headache,,2019,Q4,1,I,,20191121.0,20191203,20191203,EXP,,PL-UNICHEM PHARMACEUTICALS (USA) INC-UCM201911-000794,UNICHEM,"SIWEK M, WORON J, GOROSTOWICZ A. ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTIDEPRESSANTS AND MEDICATIONS USED  IN TREATMENT OF CARDIOVASCULAR DISORDERS. PSYCHIATR POL. 2019;VOLUME 53:ISSUE 5:977-95. DOI:10.12740/PP/ONLINEFIRST/96286",48.0,YR,,M,Y,,,20191203.0,,,COUNTRY NOT SPECIFIED,PL,2019,Q4,Adult
171035201,17103520,7,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2019,Q4,Peripheral swelling,,2019,Q4,1,I,,20191121.0,20191203,20191203,EXP,,PL-UNICHEM PHARMACEUTICALS (USA) INC-UCM201911-000794,UNICHEM,"SIWEK M, WORON J, GOROSTOWICZ A. ADVERSE EFFECTS OF INTERACTIONS BETWEEN ANTIDEPRESSANTS AND MEDICATIONS USED  IN TREATMENT OF CARDIOVASCULAR DISORDERS. PSYCHIATR POL. 2019;VOLUME 53:ISSUE 5:977-95. DOI:10.12740/PP/ONLINEFIRST/96286",48.0,YR,,M,Y,,,20191203.0,,,COUNTRY NOT SPECIFIED,PL,2019,Q4,Adult
171036391,17103639,5,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Diabetic nephropathy,,2019,Q4,1,I,,20191121.0,20191203,20191203,EXP,,CZ-AUROBINDO-AUR-APL-2019-076273,AUROBINDO,PSOTTOV? J. POZITIVN? TERAPEUTICK? ??INEK KANAGLIFLOZINU NA ZLEP?EN? DLOUHODOB? KOMPENZACE A CHRONICK?HO REN?LN?HO SELH?N? U PACIENTKY S DIAGN?ZOU DIABETES MELLITUS 2.TYPU. KAZUISTIKY V DIABETOLOGII. 2019;17 (3):27-9,63.0,YR,,F,Y,,,20191203.0,,MD,CZ,CZ,2019,Q4,Adult
171036391,17103639,5,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Drug ineffective,,2019,Q4,1,I,,20191121.0,20191203,20191203,EXP,,CZ-AUROBINDO-AUR-APL-2019-076273,AUROBINDO,PSOTTOV? J. POZITIVN? TERAPEUTICK? ??INEK KANAGLIFLOZINU NA ZLEP?EN? DLOUHODOB? KOMPENZACE A CHRONICK?HO REN?LN?HO SELH?N? U PACIENTKY S DIAGN?ZOU DIABETES MELLITUS 2.TYPU. KAZUISTIKY V DIABETOLOGII. 2019;17 (3):27-9,63.0,YR,,F,Y,,,20191203.0,,MD,CZ,CZ,2019,Q4,Adult
171036391,17103639,5,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Treatment noncompliance,,2019,Q4,1,I,,20191121.0,20191203,20191203,EXP,,CZ-AUROBINDO-AUR-APL-2019-076273,AUROBINDO,PSOTTOV? J. POZITIVN? TERAPEUTICK? ??INEK KANAGLIFLOZINU NA ZLEP?EN? DLOUHODOB? KOMPENZACE A CHRONICK?HO REN?LN?HO SELH?N? U PACIENTKY S DIAGN?ZOU DIABETES MELLITUS 2.TYPU. KAZUISTIKY V DIABETOLOGII. 2019;17 (3):27-9,63.0,YR,,F,Y,,,20191203.0,,MD,CZ,CZ,2019,Q4,Adult
171163872,17116387,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Anaplastic astrocytoma,,2019,Q4,2,F,201812.0,20191223.0,20191205,20191231,EXP,,JP-JNJFOC-20191205242,JOHNSON AND JOHNSON,,61.0,YR,,M,Y,,,20191231.0,,MD,JP,JP,2019,Q4,Adult
171163872,17116387,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Hepatic steatosis,,2019,Q4,2,F,201812.0,20191223.0,20191205,20191231,EXP,,JP-JNJFOC-20191205242,JOHNSON AND JOHNSON,,61.0,YR,,M,Y,,,20191231.0,,MD,JP,JP,2019,Q4,Adult
171190231,17119023,4,C,Canagliflozin,CANAGLIFLOZIN,1,,100 MG,,,U,U,,,,,,TABLET,,2019,Q4,Abdominal distension,,2019,Q4,1,I,2017.0,20170808.0,20191206,20191206,PER,,US-UCBSA-2017032095,UCB,,36.0,YR,,M,Y,,,20191206.0,,PH,US,US,2019,Q4,Adult
171190231,17119023,4,C,Canagliflozin,CANAGLIFLOZIN,1,,100 MG,,,U,U,,,,,,TABLET,,2019,Q4,Constipation,,2019,Q4,1,I,2017.0,20170808.0,20191206,20191206,PER,,US-UCBSA-2017032095,UCB,,36.0,YR,,M,Y,,,20191206.0,,PH,US,US,2019,Q4,Adult
171190231,17119023,4,C,Canagliflozin,CANAGLIFLOZIN,1,,100 MG,,,U,U,,,,,,TABLET,,2019,Q4,Crohn's disease,,2019,Q4,1,I,2017.0,20170808.0,20191206,20191206,PER,,US-UCBSA-2017032095,UCB,,36.0,YR,,M,Y,,,20191206.0,,PH,US,US,2019,Q4,Adult
171190231,17119023,4,C,Canagliflozin,CANAGLIFLOZIN,1,,100 MG,,,U,U,,,,,,TABLET,,2019,Q4,Diarrhoea,,2019,Q4,1,I,2017.0,20170808.0,20191206,20191206,PER,,US-UCBSA-2017032095,UCB,,36.0,YR,,M,Y,,,20191206.0,,PH,US,US,2019,Q4,Adult
171190231,17119023,4,C,Canagliflozin,CANAGLIFLOZIN,1,,100 MG,,,U,U,,,,,,TABLET,,2019,Q4,Pain,,2019,Q4,1,I,2017.0,20170808.0,20191206,20191206,PER,,US-UCBSA-2017032095,UCB,,36.0,YR,,M,Y,,,20191206.0,,PH,US,US,2019,Q4,Adult
171412822,17141282,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Haematemesis,,2019,Q4,2,F,,20191217.0,20191211,20191230,EXP,,JP-JNJFOC-20191211794,JOHNSON AND JOHNSON,,4.0,DEC,,M,Y,,,20191230.0,,MD,JP,JP,2019,Q4,Child
171412832,17141283,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Bradycardia,,2019,Q4,2,F,20191129.0,20191220.0,20191211,20191230,EXP,,JP-JNJFOC-20191212644,JOHNSON AND JOHNSON,,88.0,YR,,M,Y,,,20191230.0,,PH,JP,JP,2019,Q4,Elderly
171418331,17141833,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Interstitial lung disease,,2019,Q4,1,I,,20191127.0,20191211,20191211,EXP,,JP-JNJFOC-20191210697,JOHNSON AND JOHNSON,,69.0,YR,,M,Y,,,20191211.0,,PH,JP,JP,2019,Q4,Elderly
171423861,17142386,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,20191106.0,20191203.0,20191211,20191211,EXP,GB-MHRA-EYC 00212672,GB-JNJFOC-20191207095,JOHNSON AND JOHNSON,,63.0,YR,,F,Y,63.0,KG,20191211.0,,OT,GB,GB,2019,Q4,Adult
171426541,17142654,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",101600.0,MG,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Haemorrhagic cerebral infarction,,2019,Q4,1,I,20190620.0,20191202.0,20191211,20191211,EXP,,JP-JNJFOC-20191215135,JOHNSON AND JOHNSON,,56.0,YR,,M,Y,,,20191211.0,,MD,JP,JP,2019,Q4,Adult
171427571,17142757,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2019,Q4,Acute kidney injury,,2019,Q4,1,I,,20191202.0,20191211,20191211,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20191211.0,,OT,PT,PT,2019,Q4,Elderly
171427571,17142757,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2019,Q4,Blood bicarbonate decreased,,2019,Q4,1,I,,20191202.0,20191211,20191211,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20191211.0,,OT,PT,PT,2019,Q4,Elderly
171427571,17142757,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2019,Q4,Blood lactic acid increased,,2019,Q4,1,I,,20191202.0,20191211,20191211,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20191211.0,,OT,PT,PT,2019,Q4,Elderly
171427571,17142757,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2019,Q4,Dyspnoea,,2019,Q4,1,I,,20191202.0,20191211,20191211,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20191211.0,,OT,PT,PT,2019,Q4,Elderly
171427571,17142757,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2019,Q4,Emotional distress,,2019,Q4,1,I,,20191202.0,20191211,20191211,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20191211.0,,OT,PT,PT,2019,Q4,Elderly
171427571,17142757,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2019,Q4,Fatigue,,2019,Q4,1,I,,20191202.0,20191211,20191211,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20191211.0,,OT,PT,PT,2019,Q4,Elderly
171427571,17142757,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2019,Q4,Hyperhidrosis,,2019,Q4,1,I,,20191202.0,20191211,20191211,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20191211.0,,OT,PT,PT,2019,Q4,Elderly
171427571,17142757,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2019,Q4,Hypotension,,2019,Q4,1,I,,20191202.0,20191211,20191211,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20191211.0,,OT,PT,PT,2019,Q4,Elderly
171427571,17142757,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2019,Q4,Lactic acidosis,,2019,Q4,1,I,,20191202.0,20191211,20191211,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20191211.0,,OT,PT,PT,2019,Q4,Elderly
171427571,17142757,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2019,Q4,Metabolic acidosis,,2019,Q4,1,I,,20191202.0,20191211,20191211,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20191211.0,,OT,PT,PT,2019,Q4,Elderly
171427571,17142757,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2019,Q4,Pallor,,2019,Q4,1,I,,20191202.0,20191211,20191211,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20191211.0,,OT,PT,PT,2019,Q4,Elderly
171427571,17142757,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2019,Q4,Palpitations,,2019,Q4,1,I,,20191202.0,20191211,20191211,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20191211.0,,OT,PT,PT,2019,Q4,Elderly
171427571,17142757,4,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,,,,,100.0,MG,,QD,2019,Q4,Vomiting,,2019,Q4,1,I,,20191202.0,20191211,20191211,EXP,,NVSC2019PT057912,NOVARTIS,,76.0,YR,,M,Y,,,20191211.0,,OT,PT,PT,2019,Q4,Elderly
171466401,17146640,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Atrial fibrillation,,2019,Q4,1,I,,20191203.0,20191212,20191212,EXP,,JP-JNJFOC-20191217373,JOHNSON AND JOHNSON,,58.0,YR,,M,Y,,,20191212.0,,MD,JP,JP,2019,Q4,Adult
171601381,17160138,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Abdominal discomfort,,2019,Q4,1,I,20160928.0,20170123.0,20191216,20191216,EXP,,JP-JNJFOC-20170128197,JOHNSON AND JOHNSON,,67.0,YR,,F,Y,72.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Elderly
171601381,17160138,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Angina pectoris,,2019,Q4,1,I,20160928.0,20170123.0,20191216,20191216,EXP,,JP-JNJFOC-20170128197,JOHNSON AND JOHNSON,,67.0,YR,,F,Y,72.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Elderly
171601381,17160138,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Blood creatinine increased,,2019,Q4,1,I,20160928.0,20170123.0,20191216,20191216,EXP,,JP-JNJFOC-20170128197,JOHNSON AND JOHNSON,,67.0,YR,,F,Y,72.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Elderly
171601381,17160138,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Blood urea increased,,2019,Q4,1,I,20160928.0,20170123.0,20191216,20191216,EXP,,JP-JNJFOC-20170128197,JOHNSON AND JOHNSON,,67.0,YR,,F,Y,72.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Elderly
171601381,17160138,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Blood uric acid increased,,2019,Q4,1,I,20160928.0,20170123.0,20191216,20191216,EXP,,JP-JNJFOC-20170128197,JOHNSON AND JOHNSON,,67.0,YR,,F,Y,72.0,KG,20191216.0,,MD,JP,JP,2019,Q4,Elderly
171603251,17160325,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",25.0,DF,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Pemphigoid,,2019,Q4,1,I,20190716.0,20191205.0,20191216,20191216,EXP,,JP-JNJFOC-20191223732,JOHNSON AND JOHNSON,,49.0,YR,,M,Y,,,20191216.0,,PH,JP,JP,2019,Q4,Adult
171603251,17160325,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,25.0,DF,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Pemphigoid,,2019,Q4,1,I,20190716.0,20191205.0,20191216,20191216,EXP,,JP-JNJFOC-20191223732,JOHNSON AND JOHNSON,,49.0,YR,,M,Y,,,20191216.0,,PH,JP,JP,2019,Q4,Adult
171649222,17164922,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q4,Peripheral ischaemia,,2019,Q4,2,F,20191116.0,20191216.0,20191217,20191226,EXP,IE-HPRA-2019-053624,IE-JNJFOC-20191223637,JOHNSON AND JOHNSON,,49.0,YR,,F,Y,98.0,KG,20191226.0,,MD,IE,IE,2019,Q4,Adult
171695791,17169579,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",48300.0,MG,U,U,,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Anxiety disorder,,2019,Q4,1,I,20171106.0,20191205.0,20191218,20191218,EXP,,JP-JNJFOC-20191226571,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,,,20191218.0,,MD,JP,JP,2019,Q4,Adult
171695791,17169579,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",48300.0,MG,U,U,,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Gastric ulcer,,2019,Q4,1,I,20171106.0,20191205.0,20191218,20191218,EXP,,JP-JNJFOC-20191226571,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,,,20191218.0,,MD,JP,JP,2019,Q4,Adult
171695791,17169579,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",48300.0,MG,U,U,,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Insomnia,,2019,Q4,1,I,20171106.0,20191205.0,20191218,20191218,EXP,,JP-JNJFOC-20191226571,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,,,20191218.0,,MD,JP,JP,2019,Q4,Adult
171695791,17169579,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,48300.0,MG,U,U,,,204042.0,1.0,DF,TABLET,QD,2019,Q4,Anxiety disorder,,2019,Q4,1,I,20171106.0,20191205.0,20191218,20191218,EXP,,JP-JNJFOC-20191226571,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,,,20191218.0,,MD,JP,JP,2019,Q4,Adult
171695791,17169579,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,48300.0,MG,U,U,,,204042.0,1.0,DF,TABLET,QD,2019,Q4,Gastric ulcer,,2019,Q4,1,I,20171106.0,20191205.0,20191218,20191218,EXP,,JP-JNJFOC-20191226571,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,,,20191218.0,,MD,JP,JP,2019,Q4,Adult
171695791,17169579,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,48300.0,MG,U,U,,,204042.0,1.0,DF,TABLET,QD,2019,Q4,Insomnia,,2019,Q4,1,I,20171106.0,20191205.0,20191218,20191218,EXP,,JP-JNJFOC-20191226571,JOHNSON AND JOHNSON,,42.0,YR,,F,Y,,,20191218.0,,MD,JP,JP,2019,Q4,Adult
171749161,17174916,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,20191123.0,20191209.0,20191219,20191219,EXP,GB-MHRA-EYC 00213231,GB-JNJFOC-20191215074,JOHNSON AND JOHNSON,,70.0,YR,,F,Y,50.0,KG,20191219.0,,MD,GB,GB,2019,Q4,Elderly
171762841,17176284,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, DAILY",,,U,,,,,100.0,MG,,QD,2019,Q4,Abdominal discomfort,,2019,Q4,1,I,,20191209.0,20191219,20191219,EXP,,ES-ELI_LILLY_AND_COMPANY-ES201912004619,ELI LILLY AND CO,,59.0,YR,,M,Y,,,20191219.0,,CN,ES,ES,2019,Q4,Adult
171762841,17176284,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, DAILY",,,U,,,,,100.0,MG,,QD,2019,Q4,Asthenia,,2019,Q4,1,I,,20191209.0,20191219,20191219,EXP,,ES-ELI_LILLY_AND_COMPANY-ES201912004619,ELI LILLY AND CO,,59.0,YR,,M,Y,,,20191219.0,,CN,ES,ES,2019,Q4,Adult
171762841,17176284,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, DAILY",,,U,,,,,100.0,MG,,QD,2019,Q4,Blood glucose increased,,2019,Q4,1,I,,20191209.0,20191219,20191219,EXP,,ES-ELI_LILLY_AND_COMPANY-ES201912004619,ELI LILLY AND CO,,59.0,YR,,M,Y,,,20191219.0,,CN,ES,ES,2019,Q4,Adult
171762841,17176284,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, DAILY",,,U,,,,,100.0,MG,,QD,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,,20191209.0,20191219,20191219,EXP,,ES-ELI_LILLY_AND_COMPANY-ES201912004619,ELI LILLY AND CO,,59.0,YR,,M,Y,,,20191219.0,,CN,ES,ES,2019,Q4,Adult
171762841,17176284,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, DAILY",,,U,,,,,100.0,MG,,QD,2019,Q4,Glycosylated haemoglobin increased,,2019,Q4,1,I,,20191209.0,20191219,20191219,EXP,,ES-ELI_LILLY_AND_COMPANY-ES201912004619,ELI LILLY AND CO,,59.0,YR,,M,Y,,,20191219.0,,CN,ES,ES,2019,Q4,Adult
171762841,17176284,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, DAILY",,,U,,,,,100.0,MG,,QD,2019,Q4,Ketonuria,,2019,Q4,1,I,,20191209.0,20191219,20191219,EXP,,ES-ELI_LILLY_AND_COMPANY-ES201912004619,ELI LILLY AND CO,,59.0,YR,,M,Y,,,20191219.0,,CN,ES,ES,2019,Q4,Adult
171762841,17176284,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, DAILY",,,U,,,,,100.0,MG,,QD,2019,Q4,Metabolic acidosis,,2019,Q4,1,I,,20191209.0,20191219,20191219,EXP,,ES-ELI_LILLY_AND_COMPANY-ES201912004619,ELI LILLY AND CO,,59.0,YR,,M,Y,,,20191219.0,,CN,ES,ES,2019,Q4,Adult
171762841,17176284,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, DAILY",,,U,,,,,100.0,MG,,QD,2019,Q4,Metabolic disorder,,2019,Q4,1,I,,20191209.0,20191219,20191219,EXP,,ES-ELI_LILLY_AND_COMPANY-ES201912004619,ELI LILLY AND CO,,59.0,YR,,M,Y,,,20191219.0,,CN,ES,ES,2019,Q4,Adult
171762841,17176284,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, DAILY",,,U,,,,,100.0,MG,,QD,2019,Q4,Nausea,,2019,Q4,1,I,,20191209.0,20191219,20191219,EXP,,ES-ELI_LILLY_AND_COMPANY-ES201912004619,ELI LILLY AND CO,,59.0,YR,,M,Y,,,20191219.0,,CN,ES,ES,2019,Q4,Adult
171762841,17176284,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, DAILY",,,U,,,,,100.0,MG,,QD,2019,Q4,Vomiting,,2019,Q4,1,I,,20191209.0,20191219,20191219,EXP,,ES-ELI_LILLY_AND_COMPANY-ES201912004619,ELI LILLY AND CO,,59.0,YR,,M,Y,,,20191219.0,,CN,ES,ES,2019,Q4,Adult
171825561,17182556,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,300.0,MG,FILM-COATED TABLET,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,,20191210.0,20191219,20191219,EXP,GB-MHRA-EYC 00213318,GB-JNJFOC-20191219285,JOHNSON AND JOHNSON,,45.0,YR,,M,Y,85.0,KG,20191219.0,,MD,GB,GB,2019,Q4,Adult
171837301,17183730,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2019,Q4,Abdominal discomfort,,2019,Q4,1,I,,20191216.0,20191220,20191220,EXP,,ES-009507513-1912ESP007207,MERCK,,59.0,YR,,M,Y,,,20191220.0,,CN,ES,ES,2019,Q4,Adult
171837301,17183730,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2019,Q4,Asthenia,,2019,Q4,1,I,,20191216.0,20191220,20191220,EXP,,ES-009507513-1912ESP007207,MERCK,,59.0,YR,,M,Y,,,20191220.0,,CN,ES,ES,2019,Q4,Adult
171837301,17183730,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2019,Q4,Blood glucose increased,,2019,Q4,1,I,,20191216.0,20191220,20191220,EXP,,ES-009507513-1912ESP007207,MERCK,,59.0,YR,,M,Y,,,20191220.0,,CN,ES,ES,2019,Q4,Adult
171837301,17183730,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,,20191216.0,20191220,20191220,EXP,,ES-009507513-1912ESP007207,MERCK,,59.0,YR,,M,Y,,,20191220.0,,CN,ES,ES,2019,Q4,Adult
171837301,17183730,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2019,Q4,Glycosylated haemoglobin increased,,2019,Q4,1,I,,20191216.0,20191220,20191220,EXP,,ES-009507513-1912ESP007207,MERCK,,59.0,YR,,M,Y,,,20191220.0,,CN,ES,ES,2019,Q4,Adult
171837301,17183730,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2019,Q4,Ketonuria,,2019,Q4,1,I,,20191216.0,20191220,20191220,EXP,,ES-009507513-1912ESP007207,MERCK,,59.0,YR,,M,Y,,,20191220.0,,CN,ES,ES,2019,Q4,Adult
171837301,17183730,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2019,Q4,Metabolic acidosis,,2019,Q4,1,I,,20191216.0,20191220,20191220,EXP,,ES-009507513-1912ESP007207,MERCK,,59.0,YR,,M,Y,,,20191220.0,,CN,ES,ES,2019,Q4,Adult
171837301,17183730,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2019,Q4,Metabolic disorder,,2019,Q4,1,I,,20191216.0,20191220,20191220,EXP,,ES-009507513-1912ESP007207,MERCK,,59.0,YR,,M,Y,,,20191220.0,,CN,ES,ES,2019,Q4,Adult
171837301,17183730,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2019,Q4,Nausea,,2019,Q4,1,I,,20191216.0,20191220,20191220,EXP,,ES-009507513-1912ESP007207,MERCK,,59.0,YR,,M,Y,,,20191220.0,,CN,ES,ES,2019,Q4,Adult
171837301,17183730,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2019,Q4,Vomiting,,2019,Q4,1,I,,20191216.0,20191220,20191220,EXP,,ES-009507513-1912ESP007207,MERCK,,59.0,YR,,M,Y,,,20191220.0,,CN,ES,ES,2019,Q4,Adult
171870281,17187028,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,,20191211.0,20191220,20191220,EXP,GB-MHRA-EYC 00211637,GB-JNJFOC-20191221709,JOHNSON AND JOHNSON,,52.0,YR,,M,Y,88.3,KG,20191220.0,,PH,GB,GB,2019,Q4,Adult
171898142,17189814,3,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2019,Q4,Abdominal discomfort,,2019,Q4,2,F,,20191209.0,20191223,20191224,EXP,,ES-AUROBINDO-AUR-APL-2019-106398,AUROBINDO,,59.0,YR,,M,Y,,,20191224.0,,CN,ES,ES,2019,Q4,Adult
171898142,17189814,3,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2019,Q4,Asthenia,,2019,Q4,2,F,,20191209.0,20191223,20191224,EXP,,ES-AUROBINDO-AUR-APL-2019-106398,AUROBINDO,,59.0,YR,,M,Y,,,20191224.0,,CN,ES,ES,2019,Q4,Adult
171898142,17189814,3,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2019,Q4,Blood glucose increased,,2019,Q4,2,F,,20191209.0,20191223,20191224,EXP,,ES-AUROBINDO-AUR-APL-2019-106398,AUROBINDO,,59.0,YR,,M,Y,,,20191224.0,,CN,ES,ES,2019,Q4,Adult
171898142,17189814,3,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2019,Q4,Diabetic ketoacidosis,,2019,Q4,2,F,,20191209.0,20191223,20191224,EXP,,ES-AUROBINDO-AUR-APL-2019-106398,AUROBINDO,,59.0,YR,,M,Y,,,20191224.0,,CN,ES,ES,2019,Q4,Adult
171898142,17189814,3,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2019,Q4,Glycosylated haemoglobin increased,,2019,Q4,2,F,,20191209.0,20191223,20191224,EXP,,ES-AUROBINDO-AUR-APL-2019-106398,AUROBINDO,,59.0,YR,,M,Y,,,20191224.0,,CN,ES,ES,2019,Q4,Adult
171898142,17189814,3,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2019,Q4,Ketonuria,,2019,Q4,2,F,,20191209.0,20191223,20191224,EXP,,ES-AUROBINDO-AUR-APL-2019-106398,AUROBINDO,,59.0,YR,,M,Y,,,20191224.0,,CN,ES,ES,2019,Q4,Adult
171898142,17189814,3,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2019,Q4,Metabolic acidosis,,2019,Q4,2,F,,20191209.0,20191223,20191224,EXP,,ES-AUROBINDO-AUR-APL-2019-106398,AUROBINDO,,59.0,YR,,M,Y,,,20191224.0,,CN,ES,ES,2019,Q4,Adult
171898142,17189814,3,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2019,Q4,Metabolic disorder,,2019,Q4,2,F,,20191209.0,20191223,20191224,EXP,,ES-AUROBINDO-AUR-APL-2019-106398,AUROBINDO,,59.0,YR,,M,Y,,,20191224.0,,CN,ES,ES,2019,Q4,Adult
171898142,17189814,3,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2019,Q4,Nausea,,2019,Q4,2,F,,20191209.0,20191223,20191224,EXP,,ES-AUROBINDO-AUR-APL-2019-106398,AUROBINDO,,59.0,YR,,M,Y,,,20191224.0,,CN,ES,ES,2019,Q4,Adult
171898142,17189814,3,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2019,Q4,Vomiting,,2019,Q4,2,F,,20191209.0,20191223,20191224,EXP,,ES-AUROBINDO-AUR-APL-2019-106398,AUROBINDO,,59.0,YR,,M,Y,,,20191224.0,,CN,ES,ES,2019,Q4,Adult
171922521,17192252,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,,20191211.0,20191223,20191223,EXP,GB-MHRA-EYC 00211731,GB-JNJFOC-20191221090,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,,,20191223.0,,PH,GB,GB,2019,Q4,Elderly
171922521,17192252,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q4,Nausea,,2019,Q4,1,I,,20191211.0,20191223,20191223,EXP,GB-MHRA-EYC 00211731,GB-JNJFOC-20191221090,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,,,20191223.0,,PH,GB,GB,2019,Q4,Elderly
171922521,17192252,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q4,Vomiting,,2019,Q4,1,I,,20191211.0,20191223,20191223,EXP,GB-MHRA-EYC 00211731,GB-JNJFOC-20191221090,JOHNSON AND JOHNSON,,72.0,YR,,M,Y,,,20191223.0,,PH,GB,GB,2019,Q4,Elderly
171933251,17193325,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q4,Urinary retention,,2019,Q4,1,I,,20191212.0,20191223,20191223,EXP,,JP-JNJFOC-20191235857,JOHNSON AND JOHNSON,,73.0,YR,,M,Y,,,20191223.0,,PH,JP,JP,2019,Q4,Elderly
171934401,17193440,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q4,Euglycaemic diabetic ketoacidosis,,2019,Q4,1,I,,20191212.0,20191223,20191223,EXP,,GB-JNJFOC-20191221846,JOHNSON AND JOHNSON,,66.0,YR,,M,Y,,,20191223.0,,OT,GB,GB,2019,Q4,Elderly
171935311,17193531,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2019,Q4,Abdominal discomfort,,2019,Q4,1,I,,20191211.0,20191223,20191223,EXP,,ES-BAUSCH-BL-2019-065191,BAUSCH AND LOMB,,59.0,YR,,M,Y,,,20191223.0,,CN,ES,ES,2019,Q4,Adult
171935311,17193531,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2019,Q4,Asthenia,,2019,Q4,1,I,,20191211.0,20191223,20191223,EXP,,ES-BAUSCH-BL-2019-065191,BAUSCH AND LOMB,,59.0,YR,,M,Y,,,20191223.0,,CN,ES,ES,2019,Q4,Adult
171935311,17193531,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2019,Q4,Blood glucose increased,,2019,Q4,1,I,,20191211.0,20191223,20191223,EXP,,ES-BAUSCH-BL-2019-065191,BAUSCH AND LOMB,,59.0,YR,,M,Y,,,20191223.0,,CN,ES,ES,2019,Q4,Adult
171935311,17193531,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2019,Q4,Diabetic ketoacidosis,,2019,Q4,1,I,,20191211.0,20191223,20191223,EXP,,ES-BAUSCH-BL-2019-065191,BAUSCH AND LOMB,,59.0,YR,,M,Y,,,20191223.0,,CN,ES,ES,2019,Q4,Adult
171935311,17193531,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2019,Q4,Glycosylated haemoglobin increased,,2019,Q4,1,I,,20191211.0,20191223,20191223,EXP,,ES-BAUSCH-BL-2019-065191,BAUSCH AND LOMB,,59.0,YR,,M,Y,,,20191223.0,,CN,ES,ES,2019,Q4,Adult
171935311,17193531,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2019,Q4,Ketonuria,,2019,Q4,1,I,,20191211.0,20191223,20191223,EXP,,ES-BAUSCH-BL-2019-065191,BAUSCH AND LOMB,,59.0,YR,,M,Y,,,20191223.0,,CN,ES,ES,2019,Q4,Adult
171935311,17193531,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2019,Q4,Metabolic acidosis,,2019,Q4,1,I,,20191211.0,20191223,20191223,EXP,,ES-BAUSCH-BL-2019-065191,BAUSCH AND LOMB,,59.0,YR,,M,Y,,,20191223.0,,CN,ES,ES,2019,Q4,Adult
171935311,17193531,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2019,Q4,Metabolic disorder,,2019,Q4,1,I,,20191211.0,20191223,20191223,EXP,,ES-BAUSCH-BL-2019-065191,BAUSCH AND LOMB,,59.0,YR,,M,Y,,,20191223.0,,CN,ES,ES,2019,Q4,Adult
171935311,17193531,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2019,Q4,Nausea,,2019,Q4,1,I,,20191211.0,20191223,20191223,EXP,,ES-BAUSCH-BL-2019-065191,BAUSCH AND LOMB,,59.0,YR,,M,Y,,,20191223.0,,CN,ES,ES,2019,Q4,Adult
171935311,17193531,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2019,Q4,Vomiting,,2019,Q4,1,I,,20191211.0,20191223,20191223,EXP,,ES-BAUSCH-BL-2019-065191,BAUSCH AND LOMB,,59.0,YR,,M,Y,,,20191223.0,,CN,ES,ES,2019,Q4,Adult
172038831,17203883,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"UNK, UNKNOWN",,,,,,,,,,,,2019,Q4,Diarrhoea,,2019,Q4,1,I,201912.0,20191223.0,20191226,20191226,EXP,PT-INFARMED-J201912-641,PT-ELI_LILLY_AND_COMPANY-PT201912011483,ELI LILLY AND CO,,68.0,YR,,M,Y,90.0,KG,20191226.0,,CN,PT,PT,2019,Q4,Elderly
172038831,17203883,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"UNK, UNKNOWN",,,,,,,,,,,,2019,Q4,Hypovolaemic shock,,2019,Q4,1,I,201912.0,20191223.0,20191226,20191226,EXP,PT-INFARMED-J201912-641,PT-ELI_LILLY_AND_COMPANY-PT201912011483,ELI LILLY AND CO,,68.0,YR,,M,Y,90.0,KG,20191226.0,,CN,PT,PT,2019,Q4,Elderly
172073301,17207330,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,, IJZOXOO,,204042.0,100.0,MG,TABLET,QD,2019,Q4,Urine ketone body present,,2019,Q4,1,I,20191201.0,20191213.0,20191227,20191227,EXP,,CN-JNJFOC-20191225472,JOHNSON AND JOHNSON,,33.0,YR,,F,Y,33.0,KG,20191227.0,,OT,CN,CN,2019,Q4,Young Adult
172162861,17216286,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",51800.0,MG,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Atrial fibrillation,,2019,Q4,1,I,20161026.0,20191219.0,20191230,20191230,EXP,,JP-JNJFOC-20191246449,JOHNSON AND JOHNSON,,41.0,YR,,M,Y,,,20191230.0,,MD,JP,JP,2019,Q4,Adult
172162861,17216286,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",51800.0,MG,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Hepatic function abnormal,,2019,Q4,1,I,20161026.0,20191219.0,20191230,20191230,EXP,,JP-JNJFOC-20191246449,JOHNSON AND JOHNSON,,41.0,YR,,M,Y,,,20191230.0,,MD,JP,JP,2019,Q4,Adult
172162861,17216286,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",51800.0,MG,D,,,,204042.0,100.0,MG,FILM-COATED TABLET,QD,2019,Q4,Hypoglycaemia,,2019,Q4,1,I,20161026.0,20191219.0,20191230,20191230,EXP,,JP-JNJFOC-20191246449,JOHNSON AND JOHNSON,,41.0,YR,,M,Y,,,20191230.0,,MD,JP,JP,2019,Q4,Adult
172164551,17216455,6,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Bradycardia,,2019,Q4,1,I,,20191216.0,20191230,20191230,EXP,,PL-AUROBINDO-AUR-APL-2019-108573,AUROBINDO,,74.0,YR,,F,Y,,,20191231.0,,OT,PL,PL,2019,Q4,Elderly
172164551,17216455,6,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Drug interaction,,2019,Q4,1,I,,20191216.0,20191230,20191230,EXP,,PL-AUROBINDO-AUR-APL-2019-108573,AUROBINDO,,74.0,YR,,F,Y,,,20191231.0,,OT,PL,PL,2019,Q4,Elderly
172164551,17216455,6,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2019,Q4,Hypotension,,2019,Q4,1,I,,20191216.0,20191230,20191230,EXP,,PL-AUROBINDO-AUR-APL-2019-108573,AUROBINDO,,74.0,YR,,F,Y,,,20191231.0,,OT,PL,PL,2019,Q4,Elderly
172204041,17220404,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,100.0,MG,FILM-COATED TABLET,,2019,Q4,Prostatitis,,2019,Q4,1,I,,20191223.0,20191231,20191231,EXP,,JP-JNJFOC-20191246322,JOHNSON AND JOHNSON,,64.0,YR,,M,Y,,,20191231.0,,MD,JP,JP,2019,Q4,Adult
